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Abstract 
 
Katherine N. Theken: Cytochrome P450-derived eicosanoids, inflammation, and 
atherosclerotic cardiovascular disease 
(Under the direction of Craig R. Lee, J. Herbert Patterson, Howard L. McLeod, Samuel 
M. Poloyac, and Jo Ellen Rodgers) 
 
Inflammation contributes to the pathogenesis of atherosclerosis from the initiation of 
plaque formation to progression to acute coronary syndrome clinical events.  Due to the 
divergent effects of cytochrome P450 (CYP)-derived epoxyeicosatrienoic acids (EETs) 
and 20-hydroxyeicosatetraenoic acid (20-HETE) in the regulation of vascular tone and 
inflammation, alterations in the functional balance between the CYP epoxygenase and 
!-hydroxylase pathways may contribute to the pathophysiology of cardiovascular 
disease.  The objectives of the work described in this doctoral dissertation were to 
characterize the effect of inflammation, metabolic dysfunction, and cardiovascular 
disease on the functional balance between the CYP epoxygenase and !-hydroxylase 
pathways, and explore the potential of modulating CYP-mediated eicosanoid metabolism 
as an anti-inflammatory therapeutic strategy for atherosclerotic cardiovascular disease.  
Acute activation of the innate immune response altered CYP-mediated eicosanoid 
metabolism in a tissue- and time-dependent manner.  High fat diet feeding shifted the 
functional balance between the pathways in favor of the CYP !-hydroxylase pathway, 
suggesting that dysregulation of CYP-mediated eicosanoid metabolism contributes to 
the pathophysiologic consequences of the metabolic syndrome.  Enalapril treatment 
restored the functional balance between the pathways, implicating the renin-angiotensin 
system in mediating high fat diet-induced alterations in CYP-mediated eicosanoid 
metabolism.  Although 20-HETE does not contribute to the acute inflammatory response 
to lipopolysaccharide, inhibition of the CYP !-hydroxylase pathway may have 
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therapeutic utility for the treatment of chronic vascular inflammation.  CYP epoxygenase 
and !-hydroxylase pathway function differed between healthy volunteers and patients 
with established atherosclerosis, and several clinical factors were associated with 
plasma levels of CYP-derived eicosanoids.  Functional genetic variation in the CYP 
epoxygenase and !-hydroxylase pathways was associated with survival in patients 
following an acute coronary syndrome, suggesting that therapies that specifically 
modulate CYP-mediated eicosanoid metabolism may represent a novel treatment 
strategy for atherosclerotic cardiovascular disease.  
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Chapter I :   Introduction 
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in 
the United States, accounting for more than 810,000 deaths in 2007.  Nearly half of 
these deaths are attributable to coronary artery disease (CAD) and acute coronary 
syndromes (ACS) associated with progressive atherosclerosis [1].   Despite advances in 
the diagnosis, prevention, and treatment of atherosclerotic CVD, it remains a significant 
public health concern, and novel therapies are needed to improve outcomes. 
Inflammation is integral to the development and progression of atherosclerotic 
CVD.  Cellular adhesion molecules (CAMs) (i.e. E-selectin), chemokines (i.e. monocyte 
chemoattractant protein-1 (MCP-1)), and cytokines (i.e. interleukin-6 (IL-6), tumor 
necrosis factor-! (TNF-!)), have been detected in atherosclerotic lesions of humans and 
experimental animals [2].  Moreover, animals deficient in these pro-inflammatory 
mediators are resistant to lesion development [2].  In patients, elevated plasma levels of 
inflammatory biomarkers, including C-reactive protein (CRP) [3], E-selectin [4], MCP-1 
[5,6], and TNF-! [7], have been associated with poor outcomes.  Consequently, novel 
pharmacologic agents that specifically modulate vascular inflammation may offer 
therapeutic potential for the treatment of atherosclerotic CVD.   
Cytochrome P450-mediated arachidonic acid metabolism 
The role of cytochrome P450 (CYP) enzymes in drug metabolism is well-
recognized; however, various CYPs also metabolize numerous endogenous substrates, 
including steroids, hormones, and fatty acids, to biologically active mediators.  One such 
example is the oxidative metabolism of arachidonic acid to epoxyeicosatrienoic acids 
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(EETs) and hydroxyeicosatetraenoic acids (HETEs).  Olefin epoxidation of arachidonic 
acid to four EET regioisomers (5,6-, 8,9-, 11,12-, 14,15-EET) is primarily catalyzed by 
CYP2J and CYP2C isoforms.  Soluble epoxide hydrolase (sEH) rapidly hydrolyzes EETs 
to the corresponding dihydroxyeicosatrienoic acids (DHETs), which, in general, are 
much less biologically active.  In contrast, CYP4A and CYP4F isoforms catalyze the !-
hydroxylation of arachidonic acid to 20-HETE [8,9,10] (Figure 1.1). 
EETs function as endothelium-derived hyperpolarizing factors and are 
vasodilatory via activation of calcium-sensitive potassium (BKCa++) channels [11,12].  
Potentiation of the CYP epoxygenase pathway, via enhanced CYP-mediated EET 
biosynthesis or inhibition of sEH-mediated EET hydrolysis, lowers blood pressure in 
rodent models of hypertension [13,14,15,16], and improves functional recovery following 
myocardial ischemia/reperfusion injury [17,18,19].  In contrast to EETs, 20-HETE is a 
potent vasoconstrictor [20], and promotes hypertension and endothelial dysfunction in 
rodents [21,22,23,24].  Furthermore, inhibition of 20-HETE formation is cardioprotective 
[25,26,27,28] and neuroprotective [29] following ischemic injury. 
Accumulating evidence suggests that the CYP epoxygenase and !-hydroxylase 
pathways are involved in the regulation of inflammation.  EETs possess potent anti-
inflammatory properties by attenuating cytokine-induced leukocyte adhesion to the 
vascular wall via inhibition of nuclear factor-"B (NF-"B) activation [30], a well-
characterized initiating event of pro-inflammatory signaling and atherosclerotic lesion 
development [31].  EETs also activate peroxisome proliferator-activated receptor-# 
(PPAR-#)) [32] and PPAR-$ [33], transcription factors which inhibit NF-"B activation.  
Conversely, 20-HETE induces expression of CAMs and cytokines via NF-"B activation, 
thereby promoting inflammation [34].  20-HETE also stimulates production of reactive 
oxygen species in endothelial cells via activation of NADPH oxidase [35] and promotes 
endothelial nitric oxide synthase uncoupling [36,37].  These observations suggest that 
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modulating CYP-mediated eicosanoid metabolism may be a novel anti-inflammatory 
therapeutic strategy, but the functional role of the CYP epoxygenase and !-hydroxylase 
pathways in the regulation of vascular inflammation in vivo has not been investigated.  
CYP expression and metabolic act iv i ty in the presence of inf lammation and 
metabolic dysfunction 
It is well-established that acute inflammatory stimuli alter hepatic CYP expression 
in vitro and in vivo.  Cytokines suppress hepatic CYP expression via a pretranslational 
mechanism, thereby decreasing xenobiotic metabolism and clearance in preclinical 
models and humans [38,39,40].  In human hepatocyte culture, direct administration of IL-
6, interleukin-1% (IL-1%), and TNF-! significantly decreases CYP1A2, CYP2C, CYP2E1, 
and CYP3A mRNA and metabolic activity [41].  Similarly, systemic lipopolysaccharide 
(LPS) treatment induces cytokine expression and significantly suppresses hepatic 
CYP2A, CYP2C, CYP2E, and CYP3A expression in rodents in vivo [42,43].  Although 
the effect of inflammation has not been rigorously characterized in extrahepatic tissues, 
studies to date suggest that pulmonary CYP2C and CYP2J expression and activity are 
suppressed in rat models of sepsis [44] and Pseudomonas pneumonia [45,46].   
In contrast to other CYPs, CYP4A and CYP4F isoforms can be induced in the 
presence of inflammation, although the effects are isoform- and tissue-specific.  In rats, 
systemic administration of LPS significantly induced hepatic [42] and renal [47] CYP4A 
expression.  However, LPS treatment suppressed hepatic Cyp4a, but significantly 
induced renal Cyp4a10 in mice [43].  Direct cytokine administration and systemic LPS 
treatment significantly induced CYP4F5 mRNA expression in cultured rat hepatocytes 
[48] and in rat liver tissue [49], respectively.  In contrast, hepatic CYP4F4 expression 
was suppressed by LPS treatment in vivo, and no alterations in renal CYP4F expression 
were observed [49].  Pulmonary CYP4A mRNA expression was markedly induced in a 
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rat model of sepsis [44] and in mice following systemic IL-1% administration [50].  
Similarly, pulmonary CYP4F expression was induced in the presence of inflammation 
secondary to traumatic brain injury in rats [51].  
CYP expression and metabolic activity is also altered in preclinical models of 
obesity and metabolic syndrome.  Hepatic CYP2C is suppressed in obese Zucker rats 
[52] and in high fat diet-fed mice [53], while db/db mice exhibit higher hepatic Cyp2c29 
mRNA levels and metabolic activity [54,55], relative to lean controls.  In kidney, CYP 
epoxygenase expression and metabolic activity was suppressed in high fat diet-fed rats 
[56,57], obese Zucker rats [58,59] and heme oxygenase-2-deficient mice [60].  In 
contrast, hepatic CYP4A expression was significantly higher in both obese Zucker rats 
[61] and db/db mice [54,55], relative to lean controls.  Hepatic Cyp4a protein expression 
was induced in mice continuously fed a high fat diet [62], but renal tubular CYP !-
hydroxylase expression and metabolic activity were suppressed in high fat diet-fed rats 
[56,57].  Collectively, these studies demonstrate that inflammation and metabolic 
dysfunction alter CYP expression and metabolic activity.  However, the effects of these 
stimuli on CYP epoxygenase and !-hydroxylase pathway function have not been 
rigorously characterized.  
CYP-mediated eicosanoid metabolism in humans 
Although numerous preclinical studies have demonstrated that CYP-mediated 
eicosanoid metabolism is important in the maintenance of cardiovascular homeostasis 
following a pathologic insult, few studies have directly assessed CYP epoxygenase and 
!-hydroxylase pathway function in humans.  One small study found that plasma 20-
HETE concentrations correlated with plasma renin activity and were significantly higher 
in individuals with renovascular disease, compared to healthy controls.  Plasma EET 
levels tended to be lower in renovascular disease patients, but this finding was not 
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statistically significant [63].  Urinary 20-HETE levels have been shown to correlate with 
body mass index [64,65], and higher plasma and urinary 20-HETE concentrations have 
been reported in individuals with metabolic syndrome compared to healthy controls [66].  
These studies suggest that CYP-mediated eicosanoid metabolism may be altered in the 
presence of cardiovascular and metabolic disease in humans, but CYP epoxygenase 
and !-hydroxylase pathway function in CAD patients has not been characterized.   
Pharmacologic agents that specifically modulate CYP-mediated eicosanoid 
metabolism are not approved for use in humans; thus, the therapeutic utility of directly 
manipulating the CYP epoxygenase and !-hydroxylase pathways in patients with 
atherosclerotic CVD has not been investigated.  Epidemiologic studies have been 
conducted to initially characterize the relationship between functional genetic variants in 
the CYP epoxygenases (CYP2J2, CYP2C8), sEH (EPHX2), and the CYP !-
hydroxylases (CYP4A11, CYP4F2) and cardiovascular disease susceptibility in humans.  
A CYP2J2 proximal promoter polymorphism (-50G>T), which decreases CYP2J2 mRNA 
expression and plasma EET levels, has been associated with significantly greater risk of 
CAD [67] and prevalent myocardial infarction (MI) [68].  Genetic variation in CYP2J2 and 
CYP2C8 has also been shown to influence risk of incident CAD events [69].  The 
EPHX2 Arg287Gln variant has been associated with coronary artery calcification [70], an 
established measure of subclinical atherosclerotic burden.  Another EPHX2 variant, 
Lys55Arg, has been associated with higher apparent sEH activity in vivo and increased 
risk of incident CAD [71] and ischemic stroke [72].  Nonsynonymous polymorphisms in 
CYP4A11 (Phe434Ser) and CYP4F2 (Val433Met) have been associated with increased 
risk of hypertension [73,74,75,76,77,78], and the CYP4F2 Val433Met polymorphism has 
been associated with ischemic stroke [79].  However, the relationship between genetic 
variation in CYP4A11 and CYP4F2 and CAD has not been evaluated to date.  These 
results suggest that alterations in CYP-mediated eicosanoid metabolism may influence 
!!
&!
cardiovascular disease risk in humans, but some inconsistent relationships have been 
observed across studies.  Of note, all studies to date have evaluated the relationship 
between these polymorphisms and CVD susceptibility.  Because the CYP epoxygenase 
pathway is believed to function as a reserve system to nitric oxide, functional genetic 
variants in the CYP epoxygenases or EPHX2 may be most influential in individuals with 
endothelial dysfunction, a key process in the pathophysiology of CVD that has been 
ascribed to impaired nitric oxide biosynthesis [80].  Moreover, numerous preclinical 
studies have demonstrated that the CYP epoxygenase and !-hydroxylase pathways are 
important in the maintenance of cardiovascular homeostasis following pathologic insult 
[8,9,10].  Therefore, the clinical impact of polymorphisms that result in altered EET or 20-
HETE levels may be most pronounced in individuals with underlying atherosclerotic 
CVD.  However, the relationship between genetic variation in the CYP epoxygenase and 
!-hydroxylase pathways and prognosis in patients with established CAD has not been 
evaluated to date. 
Perspective 
Atherosclerotic CVD is a leading cause of death in the United States, and novel 
therapies are needed to decrease morbidity and mortality.  Inflammation contributes to 
the pathogenesis of atherosclerosis from the initiation of plaque formation to progression 
to ACS clinical events.  Due to the divergent effects of CYP-derived EETs and 20-HETE 
in the regulation of vascular tone and inflammation, alterations in the functional balance 
between the CYP epoxygenase and !-hydroxylase pathways may contribute to the 
pathophysiology of cardiovascular disease.  However, studies investigating the effects of 
inflammation and metabolic dysfunction on CYP-mediated eicosanoid metabolism 
remain necessary.  Moreover, EETs and 20-HETE regulate inflammation in vitro, but 
additional studies are necessary to demonstrate that potentiation of the CYP 
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epoxygenase pathway and/or inhibition of the CYP !-hydroxylase pathway attenuates 
vascular inflammation in vivo.  Few studies have evaluated CYP epoxygenase and !-
hydroxylase pathway function in humans, and CYP-mediated eicosanoid metabolism 
has not been characterized in CAD patients.  Furthermore, additional studies are needed 
to evaluate the association between genetic variation in the CYP epoxygenase and !-
hydroxylase pathways and CVD prognosis, and potentially identify subsets of the 
population who will most benefit from therapies that modulate these pathways. 
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Specif ic Aims 
Aim #1:  Characterize the effect of acute inf lammation and high fat diet-
induced metabolic dysfunction on the expression and function of the CYP 
epoxygenase and ! -hydroxylase pathways in vivo .  
Hypothesis:  Acute inflammation and metabolic dysfunction will result in lower levels of 
EETs and higher levels of 20-HETE due to suppression of CYP epoxygenase (CYP2J, 
CYP2C) and induction of CYP !-hydroxylase (CYP4A, CYP4F) expression via a 
pretranslational mechanism. 
Aim #2:  Determine the therapeutic effect of pharmacologic inhibit ion of  
the CYP !-hydroxylase pathway on acute vascular inf lammation in vivo .   
Hypothesis:  Inhibition of CYP-mediated 20-HETE biosynthesis or the putative 20-HETE 
receptor will attenuate the acute inflammatory response to LPS in vivo by inhibiting NF-
"B activation.  
Aim #3:  Evaluate the contr ibution of phenotypic and genotypic variat ion in 
the CYP epoxygenase and ! -hydroxylase pathways to the pathogenesis of 
cardiovascular disease in humans.  
Hypothesis:  Patients with established atherosclerotic CVD will have lower levels of 
EETs and higher levels of 20-HETE in plasma compared to healthy controls.  Genetic 
variation in the CYP epoxygenase and !-hydroxylase pathways will be associated with 
5-year survival in patients with acute coronary syndromes.     
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Figure 1.1:  The CYP epoxygenase and !-hydroxylase pathways 
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Chapter I I :   Activation of the acute inf lammatory response alters 
cytochrome P450 expression and eicosanoid metabolism 
 In addition to their role in xenobiotic metabolism, cytochromes P450 (CYP) 
metabolize numerous endogenous substrates, including steroids, hormones, and fatty 
acids, to biologically active mediators [1].  One such example is the oxidative 
metabolism of arachidonic acid to epoxyeicosatrienoic acids (EETs) and 
hydroxyeicosatetraenoic acids (HETEs).  Olefin epoxidation of arachidonic acid to four 
EET regioisomers (5,6-EET, 8,9-EET, 11,12-EET, 14,15-EET) is primarily catalyzed by 
CYP2C and CYP2J isoforms [2].  Soluble epoxide hydrolase (sEH, Ephx2) rapidly 
hydrolyzes EETs to dihydroxyeicosatrienoic acids (DHETs), which, in general, are less 
biologically active.  In contrast, !-hydroxylation of arachidonic acid by CYP4A and 
CYP4F isoforms produces 20-HETE [1].   
 EETs and 20-HETE regulate numerous biological processes, including vascular 
tone, angiogenesis, and the response to ischemia/reperfusion injury [1,2,3].  
Accumulating evidence has demonstrated that the CYP epoxygenase and !-
hydroxylase pathways also regulate inflammation.  The EETs possess potent anti-
inflammatory properties by attenuating cytokine-induced nuclear factor-"B (NF-"B) 
activation and leukocyte adhesion to the vascular wall [4].  Conversely, 20-HETE 
activates NF-"B signaling and induces expression of cellular adhesion molecules and 
cytokines, thereby promoting inflammation [5].  
 Due to the divergent effects of the CYP epoxygenase and !-hydroxylase 
pathways in the regulation of inflammation, alterations in the functional balance between 
these parallel pathways may contribute to the pathogenesis and progression of 
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inflammatory diseases, such as sepsis, cancer, and cardiovascular disease.  Although it 
is well-established that acute inflammatory stimuli suppress hepatic CYP expression via 
a pretranslational mechanism, thereby decreasing xenobiotic metabolism and clearance 
in preclinical models and humans [6,7,8], the effect on CYP-mediated eicosanoid 
metabolism in hepatic and extra-hepatic tissue has not been rigorously evaluated.  
Moreover, the biological properties of the CYP epoxygenase and !-hydroxylase 
pathways in vivo are most commonly investigated in mouse models; however, the 
relative expression and function of each pathway across tissues in mice has not been 
well described to date.  Therefore, we sought to characterize the (1) relative expression 
and metabolic activity of the CYP epoxygenase and !-hydroxylase pathways across 
liver, kidney, lung, and heart in mice, and (2) impact of acute inflammation induced by 
systemic lipopolysaccharide (LPS) administration on CYP epoxygenase and !-
hydroxylase expression and metabolic activity in each tissue. 
Methods 
Reagents 
All reagents were purchased from Fisher Scientific (Pittsburgh, PA, USA) unless 
otherwise noted. 
Experimental Protocol 
 Male C57Bl/6 mice (4-5 months of age) were treated with E. coli LPS (1 mg/kg; 
serotype O111:B4, 1,000,000 EU/mg; Sigma, St. Louis, MO) or endotoxin-free saline by 
intraperitoneal injection and were euthanized by CO2 inhalation 3, 6, 24, or 48 hours 
after treatment.  Liver, kidney, lung, heart and aorta were harvested and flash frozen in 
liquid nitrogen.  Blood was collected in heparinized tubes, and plasma was separated by 
centrifugation.  Tissue and plasma were stored at -80ºC pending analysis.  All studies 
were in accordance with principles outlined in the NIH Guide for the Care and Use of 
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Laboratory Animals and were approved by the Institutional Animal Care and Use 
Committee at the University of North Carolina at Chapel Hill. 
RNA isolation, reverse transcription, and qRT-PCR 
 Total RNA was isolated from whole tissue homogenates using the RNeasy 
Miniprep Kit (QIAGEN, Valencia, CA) per the manufacturer’s instructions.  Total RNA 
was reverse transcribed to cDNA using the ABI High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems, Foster City, CA) with a reaction temperature of 
25ºC for 10 minutes then 37ºC for 120 minutes.  Expression of murine Cyp2c29, 
Cyp2c44, Cyp2j5, Cyp2j9, Cyp4a12a, Cyp4a12b, Cyp4f13, Cyp4f16, Ephx2, and 
GAPDH were quantified by quantitative RT-PCR using commercially available Taqman® 
Assays on Demand (Applied Biosystems) (Table 2.1).  CYP isoforms were selected 
based on known epoxygenase or !-hydroxylase activity and/or expression in several of 
the tissues examined in an initial expression screen [9,10,11,12,13,14].  The metabolic 
activity of murine Cyp4f isoforms has not been characterized, but these isoforms were 
included as CYP4F isoforms in other species have been shown to catalyze 20-HETE 
formation [15,16,17].  Each reaction was carried out in a 20 µL volume with 50 ng cDNA, 
20X Assay on Demand, and 2X Taqman® Universal PCR Master Mix.  All reactions were 
performed in triplicate using the ABI Prism 7300 Sequence Detection System.  The 
cycling conditions were as follows:  2 minutes at 50ºC, 10 minutes at 95ºC, and 40 
cycles of 15 seconds at 95ºC followed by 60 seconds at 60ºC.  The efficiency of each 
RT-PCR probe was calculated over a range of cDNA amounts (1-100 ng), as previously 
described [18], and was equivalent for all probes (data not shown).  CYP mRNA levels 
were normalized to GAPDH and expressed relative to the saline-treated controls using 
the 2-""Ct method [19].  
Microsome isolation 
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 Microsomal fractions from liver, kidney, lung, and heart were isolated as 
previously described [20].  Briefly, frozen tissue was homogenized in 0.25 M 
sucrose/10mM Tris-HCl buffer (pH 7.5) containing protease inhibitors.  Liver and kidney 
homogenates were prepared from individual mice. Lung and heart homogenates were 
prepared from tissue pooled from 2-4 mice, due to the tissue size and low levels of CYP 
expression.  Homogenates were centrifuged at 4ºC at 2570 x g for 20 minutes, then at 
10300 x g for 20 minutes to remove cellular debris.  The supernatants were then 
centrifuged at 100000 x g at 4ºC for 90 minutes.  The resulting microsomal pellets were 
resuspended in 50 mM Tris/1 mM DTT/1 mM EDTA buffer (pH 7.5) containing 20% 
glycerol.  Protein concentrations were quantified using the Bio-Rad protein assay (Bio-
Rad, Hercules, CA), per the manufacturer’s instructions. 
Microsomal incubations  
 Incubations contained 300 µg (liver, kidney) or 350 µg (lung, heart) microsomal 
protein and 50 µM (liver, kidney, heart) or 150 µM (lung) arachidonic acid in a 1 mL 
volume of 0.12 M potassium phosphate incubation buffer containing 5 mM magnesium 
chloride, as previously described [21].  In the presence of these saturating substrate 
concentrations, formation rates reflect the amount of metabolically active protein [21]. 
The limited amount of tissue precluded assessment of CYP epoxygenase and !-
hydroxylase activity in aorta.  Reactions were initiated by the addition of 1 mM NADPH 
and were carried out at 37ºC for 20 minutes (liver, kidney) or 60 minutes (lung, heart).  In 
lung and heart incubations, an additional 1 mM NADPH was added after 30 minutes.  
Incubations were carried out at saturating concentrations of substrate, and metabolite 
formation was linear with respect to incubation time and microsomal protein, as 
determined from preliminary incubations.  The reactions were stopped by placing the 
samples on ice, and 12.5 ng 20-HETE-d6 was added as an internal standard.  Due to 
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high metabolite formation, liver incubations were diluted 20-fold in incubation buffer prior 
to addition of internal standard.  Metabolites were extracted with diethyl ether, 
evaporated to dryness under nitrogen gas, and reconstituted in 80% methanol in 
deionized water for analysis.  
Immunoblotting 
Immunoblotting was performed as previously described [20]. Briefly, hepatic 
microsomes (20µg) were separated by electrophoresis using 4-12% NuPAGE Bis-Tris 
gels (Invitrogen, Carlsbad, CA) and were transferred to nitrocellulose membranes. 
Membranes were blocked with 5% non-fat milk in Tris-buffered saline (TBS) for 2 hours 
at room temperature. Membranes were incubated with anti-CYP2C (1:2000 in 5% non-
fat milk; kindly provided Dr. Darryl Zeldin, NIH/NIEHS, Research Triangle Park, NC, 
USA), anti-CYP2J2 pep3 (1:2000 in 5% non-fat milk; kindly provided by Dr. Darryl 
Zeldin), anti-CYP4A1/2/3 (1:2000 in 5% non-fat milk; Santa Cruz Biotechnology, Santa 
Cruz, CA), anti-CYP4F2 (1:2000 in 5% BSA, Fitzgerald, Concord, MA), or anti-!-actin 
(1:1000 in 3% milk, Cell Signaling Technology, Danvers, MA) at 4ºC overnight. The anti-
CYP2C antibody was developed against a CYP2C-specific peptide (RGKLPPGPTPLPII) 
and recognizes multiple murine CYP2C isoforms [22]. The anti-CYP2J2pep3 antibody 
was developed against a polypeptide (RESMPYTNAVIHEVQRMGNIIPLN) of human 
CYP2J2 and cross-reacts with murine CYP2J isoforms [23]. The anti-CYP4A1/2/3 and 
anti-CYP4F2 antibodies are commercially available polyclonal antibodies that recognize 
rat CYP4A isoforms and human CYP4F2, respectively. After washing in 0.05% Tween 
20-TBS, membranes were incubated with the appropriate horseradish peroxidase-
conjugated secondary antibody (1:5000 in 5% non-fat milk; Santa Cruz Biotechnology) 
for 1.5 hours at room temperature. Immunoreactive bands were detected by 
chemiluminescence using SuperSignal chemiluminescent substrate (Pierce, Rockford, 
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IL) and visualized with a VersaDoc Imager (Bio-Rad). Densitometry of each 
immunoreactive band was evaluated using Quantity One software (v.4.4, Bio-Rad). 
Plasma Extractions 
 Plasma (125-200µL) was diluted in 0.12 M potassium phosphate buffer 
containing 0.113 mM butylated hydroxytoluene, and 12.5 ng 20-HETE-d6 was added as 
an internal standard.  Samples were loaded onto Oasis HLB (30 mg) SPE cartridges 
(Waters, Milford, MA) that were conditioned and equilibrated with 1 mL of methanol and 
1 mL of water, respectively. Columns were washed with three 1 mL volumes of 5% 
methanol and were eluted with 100% methanol. Extracts were dried under nitrogen gas 
at 37 °C and reconstituted in 125 µL of 80:20 methanol:deionized water. 
UPLC-MS/MS 
 Arachidonic acid metabolites (14,15-EET, 11,12-EET, 8,9-EET, 14,15-DHET, 
11,12-DHET, 8,9-DHET, 5,6-DHET, and 20-HETE) in microsomal incubations and 
plasma were quantified by UPLC-MS/MS as previously described [24].  Analytes were 
separated on a UPLC BEH C-18, 1.7 µm (2.1 mm x 100 mm) reversed-phase column 
(Waters, Milford, MA) protected by a guard column (2.1 mm x 5 mm; Waters).  Mobile 
phases consisted of 0.005% acetic acid/5% acetonitrile in deionized water (A) and 
0.005% acetic acid in acetonitrile (B) at an initial mixture of 65% A and 35% B.  Mobile 
phase B increased from 35% to 70% in a linear gradient over 4 minutes, then increased 
to 95% over 0.5 minute where it remained for 0.3 minute.  This was followed by a linear 
return to the initial conditions over 0.1 minute with a 1.5 minute pre-equilibration period 
prior to the next sample run. 
 Mass spectrometric analysis was performed with a TSQ Quantum Ultra (Thermo 
Fisher Scientific, San Jose, CA) triple quadrupole mass spectrometer coupled with 
heated electrospray ionization (HESI) operated in negative selective reaction monitoring 
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(SRM) mode.  Unit resolutions at both Q1 and Q3 were set at 0.70 full width at half 
maximum.  Quantitation by SRM analysis on EETs, DHETs, and HETEs was performed 
by monitoring their m/z transitions.  Parameters were optimized to obtain the highest [M-
H]- ion abundance and were as follows:  capillary temperature 400ºC, spray voltage 
3000V, and a source collision-induced dissociation set at 0V.  Sheath gas, auxiliary gas, 
and ion sweep gas pressures were set at 65, 55, and 3, respectively.  Scan time was set 
at 0.01 seconds and collision gas pressure was set at 1.3 mTorr.  Analytical data was 
acquired and analyzed using Xcaliber software version 2.0.6 (ThermoFinnigan, San 
Jose, CA).  Metabolite concentrations were calculated from a standard curve and 
expressed as formation rates (pmol/mg protein/min).  
Statistical analysis 
 All data are expressed as mean ± standard error of the mean (SEM).  The sum 
formation rate of all EET and DHET regioisomers was calculated and used as an index 
of total CYP epoxygenase metabolic activity.  The functional balance between the CYP 
!-hydroxylase and epoxygenase pathways was assessed by the ratio of 20-HETE to 
total EET+DHET formation.  Because the data were not normally distributed, mRNA and 
protein levels were transformed to ranks and metabolite formation rates were log-
transformed prior to statistical analysis.  Data from saline-treated mice at each time point 
were pooled to create a single control group for statistical comparisons.  Data were 
analyzed by one-way ANOVA followed by post-hoc Dunnett’s test for comparison to the 
pooled saline control group.  The relationship between CYP mRNA and protein levels 
and EET+DHET or 20-HETE formation was evaluated by Spearman rank correlation.  
Statistical analysis was performed using SAS software (v.9.1.3, SAS Institute, Cary, 
NC).  P<0.05 was considered statistically significant. 
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Results 
Induction of cytokine expression 
 Systemic LPS administration induced tumor necrosis factor-! (TNF-!) expression 
in a time-dependent manner in all tissues examined, consistent with acute activation of 
the innate immune response (Figure 2.1).  The most substantial increase was observed 
3 and 6 hours after LPS administration.  TNF-! expression decreased over time, but 
remained significantly elevated compared to saline-treated mice in most tissues at 48 
hours.  
Liver 
 All CYP isoforms examined were expressed at high levels in liver, with Cyp2c29 
and Cyp4a12a being the most abundant CYP epoxygenase and "-hydroxylase, 
respectively (Figure 2.2A).  Hepatic Cyp2c29 (0.06±0.02), Cyp2c44 (0.18±0.03), and 
Cyp2j5 (0.34±0.06) mRNA levels were markedly suppressed 24 hours after LPS 
administration (Figure 2.2B), with partial (Cyp2c29: 0.62±0.16; Cyp2c44: 0.69±0.22) or 
full (Cyp2j5: 1.00±0.25) restoration of expression to basal levels at 48 hours.  Hepatic 
CYP2C and CYP2J protein expression was also significantly suppressed 24 hours after 
LPS administration (Figure 2.3, P<0.05 versus saline).  At 48 hours, CYP2C remained 
significantly suppressed, but CYP2J expression recovered to near-basal levels.  Hepatic 
Cyp4a12a (0.47±0.06), Cyp4a12b (0.67±0.06), and Cyp4f13 (0.59±0.08) mRNA levels 
were also significantly suppressed, but to a lesser degree, 24 hours after LPS 
administration, and returned to basal levels by 48 hours (Cyp4a12a: 0.79±0.22; 
Cyp4a12b: 1.21±0.37; Cyp4f13: 1.02±0.33).  In contrast, Cyp4f16 mRNA levels were 
significantly higher 24 (4.56±0.62) and 48 hours (2.82±0.81) after LPS administration 
compared to saline controls (Figure 2.2C).  No significant alterations in CYP4A or 
CYP4F protein expression were observed (Figure 2.3). 
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 Total hepatic CYP epoxygenase metabolic activity was significantly lower 24 
(173.9±15.7 pmol/mg protein/min) and 48 (295.4±18.8 pmol/mg protein/min) hours after 
LPS administration, compared to the saline control group (458.2±24.0 pmol/mg 
protein/min), while no differences were observed at 3 and 6 hours (Figure 2.2D).  Similar 
results were observed when each EET+DHET regioisomer was evaluated individually 
(Figure 2.4A).  Total CYP epoxygenase metabolic activity was strongly correlated with 
hepatic Cyp2c29 (r=0.74, P<0.001), Cyp2c44 (r=0.65, P<0.001), and Cyp2j5 (r=0.56, 
P<0.001) mRNA levels, as well as CYP2C (r=0.50, P=0.006) and CYP2J (r=0.37, 
P=0.056) protein levels.  Compared to saline-treated mice (286.7±11.2 pmol/mg 
protein/min), 20-HETE formation was also significantly lower 24 hours (180.8±17.8 
pmol/mg protein/min) after LPS administration, but returned to basal levels at 48 hours 
(305.5±11.7 pmol/mg protein/min) (Figure 2.2D).  No significant differences in hepatic 
20-HETE formation were observed 3 or 6 hours after LPS administration.  20-HETE 
formation was significantly correlated with hepatic Cyp4a12b mRNA levels (r=0.51, 
P=0.002).   
Kidney 
 Cyp2j5 and Cyp4a12a were the most abundant CYP epoxygenase and !-
hydroxylase in kidney, respectively, while Cyp2c29 mRNA was undetectable (Figure 
2.5A).  Renal Cyp2c44 mRNA levels were significantly suppressed 3 (0.64±0.06), 6 
(0.56±0.03), and 24 hours (0.26±0.03) after LPS administration, but returned to baseline 
at 48 hours (1.04±0.11).  A similar profile was observed for Cyp2j5, but Cyp2j5 was 
suppressed to a lesser degree (Figure 2.5B).  Cyp4a12a expression was also 
significantly suppressed at 24 hours (0.63±0.06).  In contrast, Cyp4a12b and Cyp4f16 
mRNA levels were significantly lower at 6 hours, but were significantly higher 24 and 48 
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hours after LPS administration (Figure 2.5C, P<0.05 versus saline).  Significant changes 
in Cyp4f13 mRNA levels were observed only at 24 hours. 
 Total CYP epoxygenase metabolic activity was significantly lower in kidney 
microsomes 24 hours (13.2±0.7 pmol/mg protein/min) after LPS administration, 
compared to the saline control group (18.7±1.6 pmol/mg protein/min).  Formation of the 
14,15- and 11,12-, but not the 8,9- or 5,6-, regioisomers was significantly lower 24 hours 
after LPS administration (Figure 2.4B).  At 48 hours, total EET+DHET formation was 
returning to basal levels (14.7±1.4 pmol/mg protein/min; P=0.12 vs. saline) (Figure 
2.5D).  Similarly, renal 20-HETE formation was significantly lower in LPS-treated mice at 
24 hours (15.3±1.9 pmol/mg protein/min), compared to saline (32.5±6.7 pmol/mg 
protein/min), but was recovering toward baseline at 48 hours (22.2±4.9 pmol/mg 
protein/min; P=0.45 vs. saline) (Figure 2.5D).  No significant differences in renal 
EET+DHET, or 20-HETE formation were observed 3 or 6 hours after LPS administration.  
A significant correlation between total CYP epoxygenase and !-hydroxylase metabolic 
activity, and renal Cyp2j5 (r=0.42, P=0.012) and Cyp4a12a mRNA levels (r=0.55, 
P<0.001), respectively, was observed.  
Lung 
 Cyp2j9 was the most abundant CYP epoxygenase isoform expressed in lung 
(Figure 2.6A).  Cyp2j9 and Cyp2c44 mRNA levels were significantly lower in LPS-treated 
mice at 3, 6, 24, and 48 hours (Figure 2.6B, P<0.05 versus saline).  Cyp2j5 also 
appeared to be suppressed at 24 hours (0.20±0.05; P=0.11); however, due to 
substantial inter-animal variability, these differences were not statistically significant 
(Figure 2.6B).  Following LPS administration, Cyp4a12a, Cyp4a12b, Cyp4f13, and 
Cyp4f16 mRNA levels were significantly lower at almost every time point, although 
Cyp4f16 returned to basal levels at 48 hours (Figure 2.6C). 
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 Compared to saline-treated mice (54.1±5.2 pmol/mg protein/min), total CYP 
epoxygenase metabolic activity in lung microsomes was lower, but not statistically 
significant, 3 (35.8±3.0 pmol/mg protein/min, P=0.063), 6 (38.4±7.3 pmol/mg protein/min, 
P=0.171), and 24 (38.7±3.7 pmol/mg protein/min, P=0.094) hours after LPS treatment, 
while EET+DHET formation was significantly lower at the 48 hour time point (28.9±2.2 
pmol/mg protein/min, P=0.008) (Figure 2.6D).  Similar time-dependent changes in 
metabolism were observed for each regioisomer (Figure 2.4C).  20-HETE formation was 
significantly lower 6 (12.8±5.9 pmol/mg protein/min) and 24 (9.4±1.5 pmol/mg 
protein/min) hours after LPS administration, compared to the saline control group 
(23.1±1.4 pmol/mg protein/min), whereas no differences were observed at 3 or 48 hours 
(Figure 2.6D).  No significant correlations between total CYP epoxygenase metabolic 
activity and Cyp2c44, Cyp2j5, or Cyp2j9 mRNA levels were observed.  However, 20-
HETE formation significantly correlated with pulmonary Cyp4a12a (r=0.47, P=0.026), 
Cyp4a12b (r=0.46, P=0.030), and Cyp4f13 (r=0.46, P=0.033) mRNA levels.   
Heart/Aorta  
 Overall, myocardial CYP mRNA levels were low, with Cyp4f13 and Cyp4f16 
being the most abundant isoforms.  Of the CYP epoxygenases examined, only Cyp2c44 
was expressed at detectable levels (Figure 2.7A).  The CYP expression profile in aorta 
was similar; however, Cyp2c29 mRNA was expressed at detectable levels, and Cyp2c44 
and Cyp4f13 mRNA levels were approximately 10-fold higher in aorta compared to heart 
(Table 2.1).  Myocardial Cyp2c44 mRNA levels were significantly lower 3 and 6 hours 
after LPS administration (Figure 2.7B, P<0.05 versus saline).  Although it remained 
significantly suppressed at 24 hours (0.51±0.14), Cyp2c44 appeared to be returning to 
basal levels, with full recovery observed at 48 hours (0.78 ±0.13).  In aorta, Cyp2c29 
(0.38±0.12, P=0.128) and Cyp2c44 (0.26±0.06, P=0.128) mRNA appeared to be 
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suppressed 24 hours after LPS administration, relative to saline-treated mice, but this 
difference was not statistically significant due to substantial inter-animal variability.  In 
heart, both Cyp4f13 and Cyp4f16 mRNA levels were significantly lower in LPS-treated 
mice at 3 hours, but significantly higher at 24 and 48 hours (Figure 2.7C, P<0.05 versus 
saline).  Similarly, Cyp4f13 and Cyp4f16 mRNA levels in aorta were significantly higher 
in LPS-treated mice at 24 (Cyp4f13: 1.48±0.12; Cyp4f16: 3.65±0.44; P<0.05 vs. saline) 
and 48 hours (Cyp4f13: 1.93±0.18; Cyp4f16: 3.30±0.61; P<0.05 vs. saline).     
  Total CYP epoxygenase metabolic activity (3.97±0.44 pmol/mg protein/min) was 
approximately 8-fold higher than CYP !-hydroxylase activity (0.51±0.04 pmol/mg 
protein/min) in heart microsomes under basal conditions (Figure 2.7D).  Compared to 
saline, no significant differences in EET+DHET or 20-HETE formation were observed 24 
hours after LPS administration. Although EET+DHET formation appeared to be lower 
and 20-HETE formation appeared to be higher 48 hours after LPS administration, the 
limited sample size (N=2 incubations) at 48 hours precluded statistical comparisons. 
Ephx2 expression 
 Ephx2 was abundantly expressed in all tissues examined.  In liver, kidney, and 
lung, Ephx2 mRNA levels were similar to the CYP isoforms examined.  In contrast, 
Ephx2 was approximately 100- and 10-fold more abundant than Cyp4f13 in heart and 
aorta, respectively (Table 2.1).  Tissue-specific alterations in Ephx2 expression were 
observed following LPS administration (Figure 2.8).  In liver, kidney, and lung, Ephx2 
expression was suppressed by 30-80% 6 to 48 hours following LPS administration, 
relative to saline control.  In contrast, no differences were observed in heart, and Ephx2 
mRNA levels were significantly higher in aorta at 48 hours (2.57±0.49, P<0.05 vs. 
saline). 
  
 
29 
Functional balance between CYP epoxygenase and !-hydroxylase pathways across 
tissues 
Under basal conditions, hepatic EET+DHET formation was higher than 20-HETE 
formation, resulting in a 20-HETE: EET+DHET formation rate ratio of 0.64±0.03 in 
saline-treated mice (Figure 2.9A). A similar 20-HETE: EET+DHET formation rate ratio 
was observed in lung (0.45±0.06, Figure 2.9C) and heart (0.13±0.02, Figure 2.9D), 
indicative of higher CYP epoxygenase metabolic activity relative to CYP !-hydroxylase 
metabolic activity. In contrast, the renal ratio of CYP !-hydroxylase to CYP 
epoxygenase metabolic activity was 1.69±0.25 (Figure 2.9B), due to higher 20-HETE 
compared to EET+DHET formation under basal conditions in kidney. 
Following LPS stimulation, the hepatic 20-HETE: EET+DHET formation rate ratio 
was significantly greater at 24 (1.02±0.06) and 48 (1.05±0.06) hours compared to saline-
treated mice (Figure 2.9A).  Although the ratio of CYP !-hydroxylase to CYP 
epoxygenase metabolic activity in heart appeared higher 48 hours after LPS treatment 
(0.23±0.06), the limited sample size precluded formal statistical comparisons (Figure 
2.9D).  In contrast, the pulmonary 20-HETE: EET+DHET formation rate ratio was 
significantly lower at 24 hours (0.24±0.02) compared to saline-treated mice (Figure 
2.9C).  In kidney, no significant differences in the ratio of CYP !-hydroxylase to CYP 
epoxygenase metabolic activity were observed after LPS treatment (Figure 2.9B), which 
remained greater than 1.0 at all time-points. 
Compared to saline-treated mice, plasma 14,15-DHET levels were significantly 
higher 6 hours after LPS administration; however, no differences in DHET levels were 
observed at 3, 24 or 48 hours (Figure 2.4E).  Plasma EETs and 20-HETE were below 
the limit of detection in the majority of mice (data not shown). 
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Discussion 
 Although it is well established that acute inflammatory stimuli suppress hepatic 
CYP expression and xenobiotic metabolism, the effect on CYP-mediated eicosanoid 
metabolism in hepatic and extra-hepatic tissues has not been characterized to date.  To 
our knowledge, this is the first study demonstrating that acute activation of the innate 
immune response alters CYP epoxygenase and !-hydroxylase metabolic activity in 
mice, through pretranslational regulation of CYP expression, and disrupts the functional 
balance between these parallel pathways in a tissue- and time-dependent manner.  
Collectively, these findings suggest that alteration of CYP-mediated eicosanoid 
metabolism is an important consequence of the acute inflammatory response in vivo. 
Under basal conditions, CYP epoxygenase and !-hydroxylase metabolic activity 
in liver was approximately 10-20-fold greater than kidney and lung, and 100-fold greater 
than heart.  In contrast to the other tissues examined, CYP mRNA levels in heart and 
aorta were low, with Cyp4f13 and Cyp4f16 being the most abundant isoforms.  
Myocardial EET+DHET formation was approximately 8-fold higher than 20-HETE 
formation despite the high levels of Cyp4f13 and Cyp4f16, suggesting that these 
isoforms play a minor role in 20-HETE biosynthesis.   
Consistent with previous studies in human hepatocyte culture [25] and in rodents 
[26,27], hepatic CYP epoxygenase mRNA, protein, and metabolic activity was 
suppressed 24 hours after LPS treatment, with partial (CYP2C) or full (CYP2J) 
restoration to basal levels at 48 hours.  The correlation between time-dependent 
changes in hepatic Cyp2c29, Cyp2c44, and Cyp2j5 mRNA levels and epoxygenase 
metabolic activity support the hypothesis that inflammation-mediated alterations in CYP 
metabolism are mediated primarily via pretranslational regulation of CYP expression [7].  
Although Cyp2c29, Cyp2c44, and Cyp2j5 catalyze the formation of individual EET 
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regioisomers in different proportions [9,10,11], the collective suppression of all 
EET+DHET regioisomers is consistent with the regioisomer profiles for these isoforms.   
In contrast to the majority of CYPs, hepatic CYP4A and CYP4F isoforms may be 
induced by inflammation, although this appears to be isoform- and species-specific 
[26,27,28,29].  The temporal profiles of hepatic Cyp4a12a, Cyp4a12b, and Cyp4f13 
mRNA levels were similar to 20-HETE formation, which was also suppressed at 24 
hours, but to a lesser degree than EET+DHET formation. The significantly higher 20-
HETE:EET+DHET formation rate ratio at 24 and 48 hours suggests that following 
systemic activation of the innate immune response, the functional balance in liver is 
tipped in favor of the pro-inflammatory CYP !-hydroxylase pathway.   
Consistent with previous findings in rats [28], LPS suppressed renal Cyp2c44 
and Cyp2j5 expression and epoxygenase metabolic activity, which correlated with 
Cyp2j5 mRNA levels.  This suggests a pretranslational mechanism and that Cyp2j5 is 
primarily responsible for renal EET formation. We observed lower Cyp4a12a, but higher 
Cyp4a12b, Cyp4f13, and Cyp4f16 mRNA levels in kidney following LPS administration.  
Renal Cyp4a10 mRNA levels were also higher 24 and 48 hours after LPS administration 
(data not shown), which is consistent with previous reports [26]. However, Cyp4a10 
does not readily catalyze 20-HETE formation [13]. Renal CYP !-hydroxylase activity 
was suppressed at 24 hours and significantly correlated with Cyp4a12a mRNA levels, 
suggesting that Cyp4a12a is primarily responsible for renal 20-HETE formation.  In 
contrast to the other tissues examined, CYP !-hydroxylase metabolic activity 
predominated under both basal and LPS-stimulated conditions, indicating that inhibition 
of 20-HETE biosynthesis may be a rational therapeutic strategy to attenuate renal 
inflammation.  
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In lung, our findings are consistent with studies demonstrating lower pulmonary 
CYP2C and CYP2J expression and epoxygenase metabolic activity in rat models of 
sepsis [30] and Pseudomonas pneumonia [31,32], providing further evidence that 
suppression of pulmonary EET formation is a key component of the pathological 
response to inflammation. Compared to basal conditions, 20-HETE formation and the 
20-HETE:EET+DHET formation rate ratio were significantly lower 24 hours after LPS 
administration, suggesting that the functional balance was shifted in favor of the anti-
inflammatory CYP epoxygenase pathway.  Although this could serve as a compensatory 
mechanism to facilitate resolution of the inflammatory response, additional studies are 
necessary to dissect the role of CYP-mediated EET and 20-HETE biosynthesis in the 
regulation of pulmonary inflammation. 
A recent study demonstrated that myocardial CYP epoxygenase activity was 
significantly suppressed, while CYP !-hydroxylase activity was induced following LPS 
administration in rats [28].  Although we observed no significant changes in CYP 
epoxygenase or !-hydroxylase metabolic activity, the low arachidonic acid-metabolizing 
capacity of mouse heart limited our sample size.  Future studies remain necessary to 
characterize the effect of inflammation on myocardial CYP epoxygenase and !-
hydroxylase metabolic activity.  
Plasma EETs and 20-HETE were below the limit of detection in the majority of 
mice, consistent with previous reports [33,34].  Plasma DHET levels appeared modestly 
elevated 6 hours after LPS administration, consistent with previous studies [33,34,35]; 
however, only 14,15-DHET was statistically significant. Importantly, the primary source 
of circulating EET, DHET, and 20-HETE levels in plasma has not been determined.  A 
recent study demonstrated that LPS-induced elevations in plasma DHETs were 
attenuated in myeloperoxidase-deficient (Mpo-/-) mice, suggesting that lipid peroxidation 
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by reactive oxygen species may serve as a CYP-independent source of circulating 
eicosanoids [33].  Furthermore, since EETs and 20-HETE circulate at levels <1.0 ng/mL, 
it has been hypothesized that these mediators act predominantly in a paracrine manner 
[1].  Our data demonstrate that systemic activation of the innate immune response 
significantly alters the formation of EETs and 20-HETE in tissue. Future studies 
characterizing the functional consequences of these local effects remain necessary. 
It is believed that the primary mechanism by which CYP expression is down-
regulated in response to LPS is cytokine-mediated suppression of gene transcription.  
However, identification of the specific nuclear receptors that mediate these effects has 
remained elusive [6,7,8].  For example, an initial study suggested that LPS-mediated 
alteration of hepatic and renal CYP expression was mediated by peroxisome proliferator-
activated receptor-! (PPAR-!) [26].  However, subsequent experiments have 
demonstrated that LPS-mediated down-regulation of hepatic CYP expression is 
independent of PPAR-!, pregnane X receptor (PXR), and signal transducer and 
activator of transcription (Stat)-1 [36,37].  Although we did not directly investigate the 
mechanism by which LPS alters CYP expression and metabolic activity, the observed 
isoform- and tissue-specific response suggests that the mechanism is complex, and 
most likely involves multiple transcription factors that vary across isoforms and tissues.  
Moreover, the time-dependent changes observed further suggest a multi-factorial 
mechanism.  In addition, multiple murine CYP isoforms catalyze EET and 20-HETE 
formation, further complicating the ability to identify a single factor that underlies the net 
impact of the inflammatory response on CYP-mediated eicosanoid metabolism in each 
tissue.  Future studies remain necessary to dissect these complex mechanisms. 
CYP-derived EETs possess anti-inflammatory properties via inhibition of NF-"B 
activation [4], while 20-HETE activates NF-"B signaling and elicits pro-inflammatory 
effects [5].  These opposing effects on the regulation of inflammation suggest that 
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inflammation-induced alterations in the functional balance between these parallel 
pathways may contribute to the pathologic consequences of the inflammatory response.  
A limitation of the current work is that we did not directly demonstrate that potentiation of 
the CYP epoxygenase pathway and/or inhibition of the CYP !-hydroxylase pathway 
attenuates the acute inflammatory response to LPS in each tissue. However, our 
findings provide an important foundation to guide future studies evaluating these 
therapeutic strategies, particularly in tissues where inflammatory stimuli tip the functional 
balance in favor of CYP-mediated 20-HETE biosynthesis, such as liver.  Indeed, the liver 
is the predominant source of cytokine production and drives the systemic inflammatory 
response, as observed during sepsis, via subsequent activation of extra-hepatic 
inflammation and multi-organ dysfunction [38]. Inhibition of sEH-mediated EET 
hydrolysis has potent anti-inflammatory effects, including attenuation of endotoxemia-
induced hypotension and mortality [34,39,40].  In contrast, a recent study demonstrated 
that LPS-induced hepatic inflammation was not attenuated in Ephx2-/- mice or by sEH 
inhibition [35].  Although the mechanisms underlying these conflicting findings remain 
unclear, our data suggest that dual inhibition of 20-HETE biosynthesis and sEH-
mediated EET hydrolysis may be a more effective means to attenuate hepatic 
inflammation.  Future studies remain necessary to evaluate these therapeutic strategies 
in disease models of local and systemic inflammation. 
In conclusion, our findings demonstrate that acute activation of the inflammatory 
response with LPS alters CYP epoxygenase and !-hydroxylase expression and 
metabolic activity in a tissue-, isoform-, and time-dependent manner.  These results 
highlight the relative differences in CYP-mediated eicosanoid metabolism across tissues 
under basal and inflammatory conditions, and lay an important foundation to guide future 
studies that seek to determine whether therapeutic restoration of the functional balance 
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between the CYP epoxygenase and !-hydroxylase pathways is an effective anti-
inflammatory strategy in vivo. 
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Table 2.1:  Basal CYP mRNA levels relative to GAPDH across tissues.  
 Liver Kidney Lung Heart Aorta 
Cyp2c29 
Mm00725580_s1 
 
0.89 ± 0.10 N.D. N.D. N.D. 0.0002 ± 
0.0001 
Cyp2c44 
Mm01197184_m1 
 
0.16 ± 0.01 0.007 ± 
0.0003 
0.0009 ± 
8.3x10-5 
1.3x10-5 ± 
4.2x10-6 
7.4x10-5 ±  
3.9x10-5 
Cyp2c50 
Mm00663066_gH 
 
0.17 ± 0.03 N.D. N.D. N.D. 3x10-5 ± 
2x10-5 
Cyp2c55 
Mm00472168_m1 
 
0.004 ± 
0.0002 
1.6x10-5 ± 
1.2x10-5 
N.D. N.D. N.D. 
Cyp2j5 
Mm00487292_m1 
 
0.28 ± 0.03 0.35 ± 0.01 0.0003 ± 
7.7x10-5 
N.D. N.D. 
Cyp2j9 
Mm00466423_m1 
 
0.0003 ± 
2.3x10-5 
0.0006 ± 
7.5x10-5 
0.017 ± 
0.001 
0.0009 ± 
0.0002 
0.0009 ± 
8.4x10-5 
Cyp4a10 
Mm02601690_gH 
 
0.04 ± 0.02 0.06 ± 0.01 N.D. N.D. 1.3x10-5 ± 
8.6x10-6 
Cyp4a12a 
Mm00514494_m1 
 
0.21 ± 0.02 0.05 ± 
0.002 
0.007 ± 
0.002 
N.D. N.D. 
Cyp4a12b 
Mm00655431_gH 
 
0.05 ± 
0.009 
0.003 ± 
0.0002 
0.005 ± 
0.001 
N.D. N.D. 
Cyp4f13 
Mm00504576_m1 
 
0.02 ± 
0.001 
0.006 ± 
0.0003 
0.02 ± 
0.0007 
0.0003 ± 
2.2x10-5 
0.003 ± 
0.0002 
Cyp4f16 
Mm00775893_m1 
 
0.0002 ± 
2.9x10-5 
0.0007 ± 
4.5x10-5 
0.007 ± 
0.0009 
0.0002 ± 
2.3x10-5 
0.0003 ± 
2x10-5 
Ephx2 
Mm01313813_m1 
 
0.16 ± 0.02 0.06 ± 
0.002 
0.004 ± 
0.0005 
0.02 ± 
0.001 
0.03 ± 
0.002 
The commercially available Taqman® Assay on Demand product ID for each gene is 
provided (Applied Biosystems). Data were generated by quantitative RT-PCR, and are 
expressed relative to GAPDH using the 2-!Ct method as mean ± SEM.  N=18-24 for all 
detectable isoforms in each tissue. N.D.= not detected (N=3). 
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Figure Legends 
Figure 2.1:  Effect of LPS administration (1 mg/kg, IP) on TNF-! mRNA levels over 48 
hours in liver, kidney, lung, heart, and aorta.  Data are expressed as mean ± SEM-fold 
change in expression, relative to the saline control group, using the 2-!!Ct method. N=5-6 
per time point. * P<0.05 versus saline control group. 
Figure 2.2:  (A) The relative abundance of hepatic CYP mRNA was quantified in 
saline-treated mice (N=20) and normalized to GAPDH.  The time-dependent effect of 
LPS administration (1 mg/kg, IP) on hepatic (B) Cyp2c29, Cyp2c44, and Cyp2j5 and (C) 
Cyp4a12a, Cyp4a12b, Cyp4f13, and Cyp4f16 mRNA levels were quantified by qRT-PCR 
and expressed relative to the saline control group [Saline (pooled): N=20; LPS 3 hours: 
N=6, 6 hours: N=6, 24 hours: N=15, 48 hours: N=6].  The effect of LPS administration on 
(D) total CYP epoxygenase (EETs+DHETs) and "-hydroxylase (20-HETE) metabolic 
activity in liver microsomes was determined [Saline (pooled): N=12; LPS 3 hours: N=4, 6 
hours: N=4, 24 hours: N=12, 48 hours: N=6].  * P<0.05 versus saline control group. 
Figure 2.3: (A) Representative immunoblot of CYP and #-actin protein expression in 
liver microsomes after LPS (1 mg/kg, IP) or saline administration. (B) CYP expression 
was quantified by densitometry, normalized to #-actin, and expressed relative to the 
saline control group (Saline: N=8, LPS 3 hours: N=4, 6 hours: N=3, 24 hours: N=8, 48 
hours: N=5).  * P<0.05 versus saline control group. 
Figure 2.4:  The effect of LPS (1 mg/kg, IP) and saline administration on 14,15-, 
11,12-, 8,9-, and 5,6-EET+DHET formation was determined in (A) liver, (B) kidney, (C) 
lung, and (D) heart microsomes [Saline (pooled): N=4-12; LPS 3 hours: N=4-6, 6 hours: 
N=3-6, 24 hours: N=4-12, 48 hours: N=2-6].  (E) 14,15-DHET, 11,12-DHET, 8,9-DHET, 
and 5,6-DHET concentrations were quantified in plasma after solid-phase extraction 
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[Saline (pooled): N=17; LPS 3 hours: N=6, 6 hours: N=7, 24 hours: N=15, 48 hours: 
N=6].  * P<0.05 compared to saline-treated mice. 
Figure 2.5:  (A) The relative abundance of renal CYP mRNA was quantified in saline-
treated mice (N.D.: not detected; N=20 for detected isoforms; N=3 for undetectable 
isoforms) and normalized to GAPDH.  The time-dependent effect of LPS administration 
(1 mg/kg, IP) on renal (B) Cyp2c44 and Cyp2j5 and (C) Cyp4a12a, Cyp4a12b, Cyp4f13, 
and Cyp4f16 mRNA levels were quantified by qRT-PCR and expressed relative to the 
saline control group [Saline (pooled): N=20; LPS 3 hours: N=6, 6 hours: N=6, 24 hours: 
N=15, 48 hours: N=6].  The effect of LPS administration on (D) total CYP epoxygenase 
(EETs+DHETs) and !-hydroxylase (20-HETE) metabolic activity in kidney microsomes 
was determined [Saline (pooled): N=9; LPS 3 hours: N=6, 6 hours: N=6, 24 hours: N=9, 
48 hours: N=6].  * P<0.05 versus saline control group. 
Figure 2.6:  (A) The relative abundance of pulmonary CYP mRNA was quantified in 
saline-treated mice (N.D.: not detected; N=23 for detected isoforms; N=3 for 
undetectable isoforms) and normalized to GAPDH.  The time-dependent effect of LPS 
administration (1 mg/kg, IP) on pulmonary (B) Cyp2c44, Cyp2j5, and Cyp2j9 and (C) 
Cyp4a12a, Cyp4a12b, Cyp4f13, and Cyp4f16 mRNA levels were quantified by qRT-PCR 
and expressed relative to the saline control group [Saline (pooled): N=23; LPS 3 hours: 
N=9, 6 hours: N=9, 24 hours: N=18, 48 hours: N=6].  The effect of LPS administration on 
(D) total CYP epoxygenase (EETs+DHETs) and !-hydroxylase (20-HETE) metabolic 
activity in lung microsomes (N=2 mice per microsome preparation) was determined 
[Saline (pooled): N=6, LPS 3 hours: N=4, 6 hours: N=3, 24 hours: N=6, 48 hours: N=3].  
* P<0.05 versus saline control group.  
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Figure 2.7:  (A) The relative abundance of myocardial CYP mRNA was quantified in 
saline-treated mice (N.D.: not detected; N=24 for detected isoforms; N=3 for 
undetectable isoforms) and normalized to GAPDH.  The time-dependent effect of LPS 
administration (1 mg/kg, IP) on myocardial (B) Cyp2c44 and (C) Cyp4f13 and Cyp4f16 
mRNA levels were quantified by qRT-PCR and expressed relative to the saline control 
group [Saline (pooled): N=24; LPS 3 hours: N=9, 6 hours: N=9, 24 hours: N=18, 48 
hours: N=6].  The effect of LPS administration on (D) total CYP epoxygenase 
(EETs+DHETs) and !-hydroxylase (20-HETE) metabolic activity in heart microsomes 
(N=3-4 mice per microsome preparation) was determined [Saline (pooled): N=4; LPS 24 
hours: N=4, 48 hours: N=2).  * P<0.05 versus saline control group.  
Figure 2.8:  The time-dependent effect of LPS administration (1 mg/kg, IP) on Ephx2 
mRNA levels in liver, kidney, lung, heart, and aorta were quantified by qRT-PCR and 
expressed relative to the saline control group [Saline (pooled): N=18-24; LPS 3 hours: 
N=6-9, 6 hours: N=6-9, 24 hours: N=15-18, 48 hours: N=6].  * P<0.05 versus saline 
control group. 
Figure 2.9:  The time-dependent effect of LPS administration (1 mg/kg, IP) on the ratio 
of 20-HETE to EET+DHET formation was determined in (A) liver, (B) kidney, (C) lung, 
and (D) heart microsomes.  Saline: N=4-12; LPS 3 hours: N=4-6, 6 hours: N=3-6, 24 
hours: N=4-12, 48 hours: N=2-6.  * P<0.05 compared to saline-treated mice. 
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Figure 2.1:  Effect of LPS administration on TNF-! mRNA levels over 48 hours in liver, 
kidney, lung, heart, and aorta 
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Figure 2.2:  Effect of LPS administration on hepatic CYP epoxygenase and !-
hydroxylase mRNA levels and metabolic activity 
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Figure 2.3:  Effect of LPS administration on hepatic CYP epoxygenase and !-
hydroxylase protein expression 
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Figure 2.4:  Effect of LPS administration on 14,15-, 11,12-, 8,9-, and 5,6-EET+DHET 
formation in liver kidney, lung, heart, and plasma 
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Figure 2.5:  Effect of LPS administration on renal CYP epoxygenase and !-
hydroxylase mRNA levels and metabolic activity  
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Figure 2.6:  Effect of LPS administration on pulmonary CYP epoxygenase and !-
hydroxylase mRNA levels and metabolic activity  
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Figure 2.7:  Effect of LPS administration on myocardial CYP epoxygenase and !-
hydroxylase mRNA levels and metabolic activity 
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Figure 2.8:  Effect of LPS administration on Ephx2 mRNA levels over 48 hours in liver, 
kidney, lung, heart, and aorta 
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Figure 2.9:  Effect of LPS administration on the functional balance between the CYP 
epoxygenase and !-hydroxylase pathways in liver, kidney, lung, and heart 
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Chapter I I I:  Inhibition of the CYP !-hydroxylase pathway does not 
attenuate LPS-induced acute inflammation 
Accumulating evidence has demonstrated that cytochrome P450 (CYP)-derived 
metabolites of arachidonic acid regulate inflammation.  Epoxyeicosatrienoic acids 
(EETs) possess potent anti-inflammatory properties by attenuating cytokine-induced 
leukocyte adhesion to the vascular wall via inhibition of nuclear factor-!B (NF-!B) 
activation [1].  Conversely, 20-hydroxyeicosatetraenoic acid (20-HETE) activates NF-!B 
signaling and induces expression of cellular adhesion molecules and cytokines, thereby 
promoting inflammation [2].  Because vascular inflammation is integral to the 
pathophysiology of atherosclerosis, modulation of CYP-mediated eicosanoid metabolism 
may represent a novel therapeutic strategy for the management of cardiovascular 
disease.   
 Although the anti-inflammatory properties of EETs have been well-established in 
vitro, the functional effects of potentiation of the CYP epoxygenase pathway, via 
enhancement of CYP-mediated EET formation or inhibition of sEH-mediated EET 
hydrolysis, on local, NF-!B-dependent inflammatory responses in vivo had not been 
rigorously investigated.  Therefore, we assessed the acute vascular inflammatory 
response following lipopolysaccharide (LPS) administration in transgenic mice with 
endothelial expression of the human CYP epoxygenases (CYP2J2, CYP2C8) and mice 
with targeted disruption of sEH (Ephx2-/-) [3].  LPS-induced NF-!B activation, cytokine, 
chemokine, and cellular adhesion molecule expression, and neutrophil infiltration in lung 
in vivo were significantly attenuated in CYP2J2 transgenic, CYP2C8 transgenic, and 
Ephx2
-/- mice, compared to wild-type controls.  Similar attenuation of NF-!B activation 
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and inflammatory mediator expression was observed in primary endothelial cells in vitro.  
Treatment with a putative EET receptor antagonist and CYP epoxygenase inhibitor 
abrogated this effect, demonstrating that the observed anti-inflammatory phenotype was 
mediated by CYP epoxygenase-derived EETs.  These data demonstrate that 
potentiation of the CYP epoxygenase pathway attenuates acute vascular inflammation in 
vivo and may be a viable anti-inflammatory therapeutic strategy.   
CYP-derived EETs and 20-HETE exhibit divergent effects on the regulation of 
inflammation in vitro, suggesting that dual modulation of the CYP epoxygenase and !-
hydroxylase pathways to increase EETs and decrease 20-HETE may have a greater 
anti-inflammatory effect than modulating either pathway independently.  However, the 
role of 20-HETE in the regulation of acute inflammation in vivo has not been 
investigated.  Therefore, we sought to determine whether inhibition of the CYP !-
hydroxylase pathway attenuates acute inflammation induced by LPS administration in 
vivo. 
Methods 
Reagents 
All reagents were purchased from Fisher Scientific (Pittsburgh, PA, USA) unless 
otherwise noted. 
Experimental protocol  
All experiments were performed in 5-6 week old male C57BL/6 mice (Taconic, 
Hudson, NY).  N-hydroxy-N'-(4-n-butyl-2-methylphenyl) formamidine (HET0016, Cayman 
Chemical, Ann Arbor, MI), an inhibitor of 20-HETE biosynthesis [4,5], was formulated as 
a hydroxypropyl-"-cyclodextrin complex, as previously described [6].  The putative 20-
HETE receptor antagonist, N-[20-hydroxyeicosa-6(Z),15(Z)-dienoyl]glycine (20-HEDGE, 
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kindly provided by Dr. John Falck, University of Texas Southwestern Medical Center) 
was administered as a solution in sodium phosphate buffer [7].  In experiments 2 and 3, 
acute inflammation was induced by intraperitoneal (IP) injection of E. coli LPS (serotype 
O111:B4, 1,000,000 EU/mg; Sigma, St. Louis, MO). 
Experiment 1:  Mice were treated with HET0016 at a dose of 1 mg/kg or 2.5 mg/kg IP 
and were euthanized by CO2 inhalation 30, 60, or 90 minutes following HET0016 
administration (N=4/time point).  Untreated mice (N=4) were used to assess basal 20-
HETE levels.  Liver was harvested and flash frozen in liquid nitrogen. 
Experiment 2:  Mice were treated with LPS 1 mg/kg (N=36) or endotoxin-free saline 
(N=20) by IP injection.  HET0016 1 mg/kg IP, HET0016 2.5 mg/kg IP, or 20-HEDGE 30 
mg/kg SC [7] was administered concurrently with LPS (N=8/group) or saline 
(N=4/group), and mice were euthanized by CO2 inhalation 3 hours after treatment.  Liver 
and heart were harvested and flash frozen in liquid nitrogen.  Blood was collected in 
heparinized tubes, and plasma was separated by centrifugation.   
Experiment 3:  Mice were randomized to receive HET0016 as a single-dose (1 mg/kg IP) 
or multiple-dose (1 mg/kg IP x 3 days).  Concurrent with the final dose of HET0016, mice 
were treated with LPS 1 mg/kg (N=8/group), LPS 10 mg/kg (N=8/group), or endotoxin-
free saline (N=4/group) by IP injection and were euthanized by CO2 inhalation 90 
minutes later.  Liver and lung were harvested and flash frozen in liquid nitrogen. 
All studies were in accordance with principles outlined in the NIH Guide for the Care and 
Use of Laboratory Animals and were approved by the Institutional Animal Care and Use 
Committee at the University of North Carolina at Chapel Hill. 
RNA isolation, reverse transcription, and qRT-PCR 
 Total RNA was isolated from whole tissue homogenates using the RNeasy 
Miniprep Kit (QIAGEN, Valencia, CA) per the manufacturer’s instructions, as previously 
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described [8].  Total RNA was reverse transcribed to cDNA using the ABI High Capacity 
cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA) with a reaction 
temperature of 25ºC for 10 minutes then 37ºC for 120 minutes.  Expression of murine 
Ccl2 (Mm00441242_m1), Sele (Mm00441278_m1), Tnf (Mm00443258_m1), and 
GAPDH (Mm99999915_m1) were quantified by quantitative RT-PCR using commercially 
available Taqman® Assays on Demand (Applied Biosystems).  mRNA levels were 
normalized to GAPDH and expressed relative to the saline/no inhibitor controls using the 
2-!!Ct method [9]. 
Tissue Extraction 
 Liver tissue was homogenized in 0.12 M potassium phosphate buffer containing 
0.113 mM butylated hydroxytoluene.  Homogenates were centrifuged at 4ºC at 10000 x 
g for 30 minutes to remove cellular debris.  The supernatant was retained, and 20-
HETE-d6 was added as an internal standard.  Samples were loaded onto Oasis HLB (30 
mg) SPE cartridges (Waters, Milford, MA) that were conditioned and equilibrated with 1 
mL of methanol and 1 mL of water, respectively. Columns were washed with three 1 mL 
volumes of 5% methanol and were eluted with 100% methanol. Extracts were dried 
under nitrogen gas at 37°C and reconstituted in 125 µL of 80:20 methanol:deionized 
water.  
UPLC-MS/MS 
 Arachidonic acid metabolites (14,15-EET, 11,12-EET, 8,9-EET, 14,15-DHET, 
11,12-DHET, 8,9-DHET, 5,6-DHET, and 20-HETE) in tissue extracts were quantified by 
UPLC-MS/MS as previously described [8,10].  Briefly, analytes were separated on a 
UPLC BEH C-18, 1.7 µm (2.1 mm x 100 mm) reversed-phase column (Waters, Milford, 
MA).  Mass spectrometric analysis was performed with a TSQ Quantum Ultra (Thermo 
Fisher Scientific, San Jose, CA) triple quadrupole mass spectrometer coupled with 
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heated electrospray ionization (HESI) operated in negative selective reaction monitoring 
(SRM) mode.  Analytical data was acquired and analyzed using Xcaliber software 
version 2.0.6 (ThermoFinnigan, San Jose, CA).  Metabolite concentrations were 
calculated from a standard curve and expressed relative to tissue weight (pmol/g tissue). 
Quantification of plasma leukotriene B4 levels 
Plasma leukotriene B4 (LTB4) concentrations were quantified using the LTB4 
Parameter™ immunoassay kit, according to the manufacturer’s instructions (R&D 
Systems, Minneapolis, MN, USA).   
NF-!B activation 
 Liver tissue was homogenized in ice-cold lysis buffer containing 50 mM Tris-HCl 
(pH 7.4), 150 mM NaCl, 1 mM EDTA, 1% Triton X, 1 mM NaF, 0.25% Na deoxycholate 
and protease inhibitors, and the S9 fraction was separated by centrifugation.  NF-!B 
activity was assessed in liver lysates using the NF-!B p50/p65 EZ-TFA Transcription 
Factor Assay kit (Millipore, Billerica, MA), according to the manufacturer’s instructions. 
Statistical analysis 
All data are expressed as mean ± standard error of the mean (SEM).  The sum 
concentration of all EET and DHET regioisomers was calculated and used as an index 
of total CYP epoxygenase metabolic activity.  Because the data were not normally 
distributed, mRNA levels were transformed to ranks and metabolite concentrations were 
log-transformed prior to statistical analysis.  Data were analyzed by one-way ANOVA 
followed by post-hoc Tukey’s test.  Statistical analysis was performed using SAS 
software version 9.1.3 (SAS Institute, Cary, NC).  P<0.05 was considered statistically 
significant. 
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Results 
Experiment 1:  Effect of HET0016 on hepatic CYP-derived eicosanoid concentrations 
We quantified hepatic 20-HETE and EET+DHET concentrations following 
HET0016 administration to determine the time course of inhibition of 20-HETE formation 
and confirm that HET0016 selectively inhibited the CYP !-hydroxylase pathway.  Both 
doses of HET0016 (1 mg/kg and 2.5 mg/kg) significantly decreased hepatic 20-HETE 
levels by 75-80% 30 minutes after administration (Figure 3.1A).  At 90 minutes, hepatic 
20-HETE concentrations remained 55-60% lower in HET0016-treated mice, compared 
baseline (36.1±4.6 pmol/g tissue).  Compared to untreated mice, hepatic EET+DHET 
concentrations were modestly lower in mice treated with HET0016 1 mg/kg at 30 
minutes.  However, no other significant alterations in hepatic EET+DHET concentrations 
were observed (Figure 3.1B), demonstrating that HET0016 selectively inhibited 20-
HETE biosynthesis.   
Experiment 2:  Effect of HET0016 and 20-HEDGE on LPS-induced inflammatory gene 
expression in liver and heart 
HET0016 or 20-HEDGE was administered to evaluate the effects of inhibition of 
20-HETE biosynthesis or the putative 20-HETE receptor, respectively, on inflammatory 
gene expression 3 hours after LPS administration.  In both liver and heart, LPS 
significantly induced Tnf expression, relative to saline control.  In liver, treatment with 
HET0016 1 mg/kg, HET0016 2.5 mg/kg, or 20-HEDGE did not attenuate LPS-induced 
Tnf expression (Figure 3.2A).  Myocardial Tnf mRNA levels were significantly higher in 
HET0016-treated mice, compared to LPS alone (P<0.05) (Figure 3.2B).  No differences 
in myocardial Tnf expression were observed in 20-HEDGE-treated mice.  Similar results 
were observed for myocardial Ccl2 and Sele mRNA expression (data not shown).  No 
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differences in Tnf mRNA levels in either liver or heart were observed across inhibitor 
groups in saline-treated mice.   
CYP4F isoforms inactivate LTB4, a pro-inflammatory eicosanoid, in addition to 
catalyzing 20-HETE formation [11].  Consequently, inhibition of CYP4F isoforms may 
result in elevated LTB4 levels.  Although no studies have reported elevations in LTB4 
levels following HET0016 administration, we measured plasma LTB4 levels in LPS-
treated mice to determine whether the lack of an anti-inflammatory effect of HET0016 
treatment was due to inhibition of CYP4F-mediated LTB4 clearance.  Mice treated with 
HET0016 2.5 mg/kg tended to have higher plasma LTB4 concentrations following LPS 
administration compared to mice that received no inhibitor, but this difference was not 
statistically significant (P=0.210) (Figure 3.3).   
Liver 20-HETE and EET+DHET concentrations were also measured to confirm 
that HET0016 had selectively inhibited 20-HETE formation.  No significant differences in 
hepatic 20-HETE or EET+DHET concentration were observed between the treatment 
groups (Figure 3.4), indicating that CYP !-hydroxylase activity had returned to basal 
levels 3 hours after HET0016 administration. 
Experiment 3:  Effect of single- and multiple-dose HET0016 on LPS-induced 
inflammatory gene expression and NF-!B activation 
Because 20-HETE formation had returned to basal levels at 3 hours, we 
evaluated the effect of single- or multiple-dose HET0016 on inflammatory gene 
expression and NF-"B activation 90 minutes after LPS administration.  Both LPS 1 
mg/kg (1256.8±161.4) and 10 mg/kg (877.9±108.9) significantly induced hepatic Sele 
expression at 90 minutes, compared to saline (1.1±0.4, P<0.05).  Neither single- nor 
multiple-dose HET0016 treatment attenuated the upregulation of hepatic Sele 
expression (Figure 3.5A).  Similar results were observed for hepatic Tnf and Ccl2 mRNA 
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expression (data not shown).  Consistent with these observations, no differences in 
hepatic NF-!B activation was observed with either single- or multiple-dose HET0016, 
compared to LPS alone (Figure 3.5C).  Similarly, pulmonary Sele mRNA levels were 
significantly higher in LPS-treated mice (1 mg/kg:  218.3±34.5; 10 mg/kg:  246.1±58.8), 
compared to saline (1.1±0.3, P<0.05).  HET0016 administered as a single- or multiple-
dose regimen did not attenuate this response (Figure 3.5B). 
Discussion 
In vitro, 20-HETE activates NF-!B and stimulates cytokine and cellular adhesion 
molecule expression, but the role of the CYP "-hydroxylase pathway in regulating the 
acute inflammatory response in vivo has not been investigated.  Following LPS 
administration, inhibition of 20-HETE biosynthesis or the putative 20-HETE receptor did 
not attenuate inflammatory gene expression, regardless of the dose or treatment 
regimen.    Collectively, our findings demonstrate the CYP "-hydroxylase pathway does 
not contribute to the acute inflammatory response following LPS administration. 
We have recently shown that potentiation of the CYP epoxygenase attenuates 
acute vascular inflammation in vivo [3].  Therefore, a similar study design was used in 
Experiment 2 to investigate the effect of inhibition of the CYP "-hydroxylase pathway on 
the acute inflammatory response.  In contrast to our hypothesis, inhibition of 20-HETE 
biosynthesis with HET0016 or inhibition of the putative 20-HETE receptor with 20-
HEDGE did not attenuate hepatic or myocardial inflammatory gene expression 3 hours 
after LPS administration.  We investigated several potential explanations for the negative 
results that we observed.  Because CYP4F isoforms inactivate LTB4, a pro-inflammatory 
eicosanoid, in addition to catalyzing 20-HETE formation [11], we measured plasma LTB4 
levels to determine whether HET0016 administration impaired LTB4 clearance.  Although 
not statistically significant, there was a trend toward higher plasma LTB4 concentrations 
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in the mice treated with HET0016 2.5 mg/kg, which may have contributed to the trend 
toward modestly higher inflammatory gene expression in this treatment group.  
Consequently, only the HET0016 1 mg/kg dose was used in Experiment 3.  We also 
measured hepatic 20-HETE concentrations to determine whether HET0016 
administration had inhibited the CYP !-hydroxylase pathway for the full duration of the 
experiment.  Previous studies have shown that HET0016 has a short half-life [12], 
suggesting that the inhibitor may have been cleared before the 3-hour time point.  We 
observed no significant differences in hepatic 20-HETE concentrations between mice 
that received no inhibitor and those treated with HET0016, indicating that CYP !-
hydroxylase activity had returned to basal levels.   
Experiment 3 was designed to address these limitations, as well as investigate 
other potential explanations for the lack of an effect in Experiment 2.  First, the time point 
was changed to 90 minutes, rather than 3 hours, because HET0016 inhibited 20-HETE 
formation through 90 minutes in Experiment 1.  Studies evaluating the anti-inflammatory 
effect of potentiating the CYP epoxygenase pathway have typically used doses of LPS 
ranging from 10 to 40 mg/kg [3,13,14].  Consequently, we included a 10 mg/kg dose of 
LPS to determine whether an anti-inflammatory effect of inhibiting the CYP !-
hydroxylase pathway would become apparent at higher LPS doses.  In addition to being 
formed de novo, 20-HETE can be stored in cell membranes and released pre-formed 
upon activation of phospholipase A2 by inflammatory stimuli [15].  Therefore, we included 
a multiple-dose HET0016 regimen in Experiment 3 to deplete membrane stores of 20-
HETE prior to LPS administration.  Finally, the anti-inflammatory effect of potentiating 
the CYP epoxygenase pathway was most apparent in lung [3].  Therefore, we measured 
inflammatory gene expression in lung, as well as in liver.  Regardless of the time point, 
LPS dose, HET0016 treatment regimen, or tissue evaluated, inhibition of the CYP !-
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hydroxylase pathway did not attenuate the acute inflammatory response to LPS 
administration.   
LPS potently stimulates the acute innate immune response and activates multiple 
cell signaling cascades to promote NF-!B activation and inflammatory gene expression 
[16].  Our findings demonstrate that 20-HETE is not a key contributor to LPS-induced 
acute inflammation in vivo.  However, accumulating evidence suggests that 20-HETE 
may be more relevant in the regulation of vascular inflammation in models of 
cardiovascular disease.  In endothelial cell culture, 20-HETE stimulated the production of 
reactive oxygen species by NADPH oxidase [17] and endothelial nitric oxide synthase 
uncoupling via NF-!B activation [18,19], which are key processes in the development of 
endothelial dysfunction and vascular inflammation in vivo [20].  A recent study 
demonstrated that 20-HETE induced expression of angiotensin converting enzyme and 
the angiotensin II receptor in aorta [21], suggesting the CYP "-hydroxylase pathway 
may also promote vascular inflammation by directly activating the renin-angiotensin 
system.  In a model of androgen-induced hypertension, which is mediated by 
overproduction of 20-HETE in the vasculature, inhibition of the CYP "-hydroxylase 
pathway lowered blood pressure, attenuated NF-!B activation, and improved endothelial 
function  [22].  Further studies to elucidate the role of the CYP "-hydroxylase pathway in 
other models of cardiovascular disease and chronic vascular inflammation are 
warranted. 
In conclusion, our findings demonstrate that inhibition of 20-HETE biosynthesis 
or the putative 20-HETE receptor does not attenuate the acute inflammatory response to 
LPS in vivo.  Future studies investigating the anti-inflammatory effect of inhibiting the 
CYP "-hydroxylase pathway on chronic vascular inflammation are necessary. 
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Figure Legends 
Figure 3.1:  Time course of liver (A) 20-HETE and (B) EET+DHET tissue 
concentrations after intraperitoneal administration of HET0016 1 mg/kg (N=4/time point) 
or HET0016 2.5 mg/kg (N=4/time point).  *P<0.05 versus baseline 
Figure 3.2:  The effect of HET0016 1 mg/kg, HET0016 2.5 mg/kg, or 20-HEDGE 
administration on Tnf mRNA levels in (A) liver and (B) heart, 3 hours after LPS treatment 
(1 mg/kg), expressed relative to the saline control group (LPS: N=12; HET0016 1 mg/kg: 
N=8; HET0016 2.5 mg/kg: N=8; 20-HEDGE: N=8).  *P<0.05 versus LPS 
Figure 3.3:  The effect of HET0016 1 mg/kg or HET0016 2.5 mg/kg on plasma LTB4 
concentrations 3 hours after LPS treatment (N=5/group). 
Figure 3.4:  The effect of HET0016 1 mg/kg and HET0016 2.5 mg/kg on liver (A) 20-
HETE and (B) EET+DHET tissue concentrations, 3 hours after the administration of LPS 
(N=6/group) or saline (N=4/group). 
Figure 3.5:  The effect of single- or multiple-dose HET0016 on (A) hepatic and (B) 
pulmonary Sele mRNA levels (N=8/group) and (C) NF-!B activity in liver lysates 
(N=4/group), 90 minutes after LPS treatment (1 mg/kg or 10 mg/kg), expressed relative 
to the saline control group.   
 
 
  
!!
"#!
Figure 3.1:  Effect of HET0016 on hepatic 20-HETE and EET+DHET concentrations 
!  
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Figure 3.2:  Effect of HET0016 and 20-HEDGE on LPS-induced TNF-! expression  
 
  
B Heart:  TNF-!
No Inhibitor HET0016 1 mg/kg HET0016 2.5 mg/kg 20-HEDGE 30 mg/kg
A Liver:  TNF-!
0
20
40
60
80
100
T
N
F
/G
A
P
D
H
 
(r
e
la
ti
v
e
 t
o
 s
a
li
n
e
)
0
5
10
15
20
25
30
T
N
F
/G
A
P
D
H
 
(r
e
la
ti
v
e
 t
o
 s
a
li
n
e
)
*
*
!!
""!
Figure 3.3:  Effect of HET0016 on plasma LTB4 levels 
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Figure 3.4:  Effect of HET0016 on hepatic 20-HETE and EET+DHET concentrations 3 
hours after administration 
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Figure 3.5:  Effect of HET0016 on LPS-induced E-selection mRNA expression and 
NF-!B activation 
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Chapter IV:  Enalapril reverses high fat diet-induced alterations in 
cytochrome P450-mediated eicosanoid metabolism 
Cytochrome P450 enzymes (CYPs) metabolize arachidonic acid to various 
biologically active eicosanoids.  Olefin epoxidation by CYP2C and CYP2J isoforms 
produces four epoxyeicosatrienoic acid regioisomers (5,6-, 8,9-, 11,12-, and 14,15-EET), 
which possess potent vasodilatory and anti-inflammatory properties [1,2].  The EETs are 
rapidly hydrolyzed by soluble epoxide hydrolase (sEH) to the corresponding 
dihydroxyeicosatrienoic acids (DHETs), which are generally less biologically active [1,2].  
In contrast, CYP4A and CYP4F isoforms catalyze the !-hydroxylation of arachidonic 
acid to 20-hydroxyeicosatetraenoic acid (20-HETE), a vasoconstrictive and pro-
inflammatory eicosanoid [3].  Numerous preclinical studies have demonstrated that the 
CYP epoxygenase and !-hydroxylase pathways are important in the maintenance of 
cardiovascular homeostasis following pathologic insult [1,2,3], and modulating these 
pathways may be a therapeutic strategy for the treatment of cardiovascular disease.  
The pathophysiology of cardiovascular disease is complex, and multiple risk 
factors contribute to its development and progression.  One risk factor that is becoming 
increasing prevalent is metabolic syndrome, a pro-thrombotic, pro-inflammatory state 
characterized by the presence of dyslipidemia, insulin resistance, and hypertension [4].  
The liver and kidney are integrally involved in the pathophysiology of metabolic 
syndrome via their roles in the regulation of inflammation, insulin sensitivity, and blood 
pressure, and CYP epoxygenases and !-hydroxylases are most abundantly expressed 
in both tissues [5].  Due to the divergent effects of the CYP epoxygenase-derived EETs 
and CYP !-hydroxylase-derived 20-HETE in the regulation of vascular tone and 
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inflammation, alterations in the functional balance between these parallel pathways in 
liver and kidney may contribute to the pathogenesis and progression of metabolic 
syndrome and cardiovascular disease.   
Preclinical studies suggest that CYP expression and metabolic activity is altered 
in models of metabolic syndrome.  Alterations in hepatic and renal CYP expression and 
metabolic activity have been observed in rodents genetically predisposed to obesity, 
including obese Zucker rats [6,7,8], ob/ob mice [9,10], and db/db mice [11,12].  Although 
these models exhibit many of the characteristics of human metabolic syndrome, other 
metabolic derangements may also be present [13].  For example, these obese rodent 
models appear to have lower renin-angiotensin system activity compared to lean 
controls [14,15,16], while the renin-angiotensin system is activated in obese humans 
[17].  Consequently, the alterations in CYP expression and metabolic activity observed in 
rodents genetically predisposed to obesity may not accurately model the 
pathophysiology underlying human metabolic syndrome. In contrast, the phenotype 
induced by high fat diet feeding in rodents more closely mimics human metabolic 
syndrome [18].   
Importantly, the effects of high fat diet on hepatic and renal CYP epoxygenase 
and !-hydroxylase expression and metabolic activity and the functional balance 
between the pathways have not been rigorously evaluated to date.  Moreover, the 
mechanisms underlying the observed alterations in CYP expression and metabolic 
activity in response to high fat diet feeding have not been elucidated.  Therefore, we 
sought to (1) characterize the effect of high fat diet feeding on the functional balance 
between the CYP epoxygenase and !-hydroxylase pathways in liver and kidney, and (2) 
investigate the role of hypercholesterolemia, insulin resistance, and renin-angiotensin 
system activation in mediating alterations in CYP-mediated eicosanoid metabolism in 
high fat diet-fed mice. 
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Methods 
Reagents 
All reagents were purchased from Fisher Scientific (Pittsburgh, PA) unless 
otherwise noted. 
Experimental Protocol 
All experiments were performed in 8-10 week old male mice (Taconic, Hudson, 
NY).  Mice randomized to high fat diet received RD Western Diet (21% fat, 0.21% 
cholesterol; Research Diets Inc., New Brunswick, NJ).  Standard diet-fed mice received 
ProLab RMH 3000 rodent chow (5% fat; PMI Nutrition International LLC, Brentwood, 
MO).  Mice had access to food and water ad libitum.  The treatment schemes for the 
effect of high fat diet over time (Experiment 1) and the effects of enalapril and metformin 
treatment (Experiments 2 and 3) are depicted in Figure 4.1.  
Experiment 1: Wild-type C57BL/6 (WT) and ApoE-/- mice were randomized to 
receive high fat or standard diet for two, four, or eight weeks (N=4 per group), as shown 
in Figure 4.1A.   
Experiment 2: WT and ApoE-/- mice were randomized to high fat (N=10 per 
genotype) or standard diet (N=4 per genotype). After two weeks of the assigned diet, a 
subset of high fat diet-fed mice were treated with enalapril (30 mg/kg/day, Sigma-Aldrich, 
St. Louis, MO) [19] administered in the drinking water for two weeks (N=6 per genotype), 
as shown in Figure 4.1B. 
Experiment 3: WT mice were randomized to high fat (N=18) or standard diet 
(N=23).  After two weeks of the assigned diet, a subset of mice were treated with 
metformin (300 mg/kg/day, Sigma-Aldrich, N=6 per diet) [20] or enalapril (30 mg/kg/day, 
N=6 per diet) administered in the drinking water for two weeks, as shown in Figure 4.1B.  
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Mice were euthanized by CO2 inhalation, and liver and kidney tissue was 
harvested and flash frozen in liquid nitrogen.  Blood was collected via cardiac puncture, 
and plasma was separated by centrifugation.  Tissue and plasma were stored at -80ºC 
pending analysis.  Plasma insulin concentrations were measured with the Rat/Mouse 
Insulin ELISA kit (Millipore, Billerica, MA), per the manufacturer’s instructions.  Plasma 
glucose and total cholesterol levels were measured by the Animal Clinical Laboratory 
Core Facility at UNC-Chapel Hill using a Vitros 350 automated chemical analyzer 
(Ortho-Clinical Diagnostics, Rochester, NY). 
All studies were in accordance with principles outlined in the NIH Guide for the 
Care and Use of Laboratory Animals and were approved by the Institutional Animal Care 
and Use Committee at the University of North Carolina at Chapel Hill. 
RNA isolation, reverse transcription, and qRT-PCR 
 Total RNA was isolated from whole tissue homogenates using the RNeasy 
Miniprep Kit (QIAGEN, Valencia, CA) per the manufacturer’s instructions, as previously 
described [5].  Total RNA was reverse transcribed to cDNA using the ABI High Capacity 
cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA) with a reaction 
temperature of 25ºC for 10 minutes then 37ºC for 120 minutes.  Expression of murine 
Cyp2c29, Cyp2j5, Cyp4a12a, and GAPDH were quantified by quantitative RT-PCR 
using commercially available Taqman® Assays on Demand (Applied Biosystems).  CYP 
isoforms were selected because they are the most abundant CYP epoxygenase (liver: 
Cyp2c29; kidney: Cyp2j5) or !-hydroxylase (liver and kidney: Cyp4a12a) in each tissue 
[5].  CYP mRNA levels were normalized to GAPDH and expressed relative to the 
WT/standard diet controls using the 2-""Ct method [21].  
Microsome isolation 
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 Hepatic and renal microsomal fractions were isolated as previously described [5].  
Briefly, frozen tissue was homogenized in 0.25 M sucrose/10mM Tris-HCl buffer (pH 7.5) 
containing protease inhibitors.  Homogenates were centrifuged at 4ºC at 2570 x g for 20 
minutes, then at 10300 x g for 20 minutes to remove cellular debris.  The supernatants 
were then centrifuged at 100000 x g at 4ºC for 90 minutes.  The resulting microsomal 
pellets were resuspended in 50 mM Tris/1 mM DTT/1 mM EDTA buffer (pH 7.5) 
containing 20% glycerol.  Protein concentrations were quantified using the Bio-Rad 
protein assay (Bio-Rad, Hercules, CA), per the manufacturer’s instructions. 
Microsomal incubations  
 Incubations contained 300 µg microsomal protein and 50 µM arachidonic acid in 
a 1 mL volume of 0.12 M potassium phosphate incubation buffer containing 5 mM 
magnesium chloride, as previously described [5,22].  Reactions were initiated by the 
addition of 1 mM NADPH and were carried out at 37ºC for 20 minutes.  Incubations were 
carried out at saturating concentrations of substrate, and metabolite formation was linear 
with respect to incubation time and microsomal protein, as determined from preliminary 
incubations.  In the presence of these saturating substrate concentrations, formation 
rates reflect the amount of metabolically active protein [22], and are significantly 
correlated with CYP mRNA and protein levels [5].  The reactions were stopped by 
placing the samples on ice, and 12.5 ng 20-HETE-d6 was added as an internal 
standard.  Due to high metabolite formation, liver incubations were diluted 10-fold in 
incubation buffer prior to addition of internal standard.  Metabolites were extracted with 
diethyl ether, evaporated to dryness under nitrogen gas, and reconstituted in 80% 
methanol in deionized water for analysis.  
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UPLC-MS/MS 
 Arachidonic acid metabolites (14,15-EET, 11,12-EET, 8,9-EET, 14,15-DHET, 
11,12-DHET, 8,9-DHET, 5,6-DHET, and 20-HETE) in microsomal incubations were 
quantified by UPLC-MS/MS as previously described [5,23].  Briefly, analytes were 
separated on a UPLC BEH C-18, 1.7 µm (2.1 mm x 100 mm) reversed-phase column 
(Waters, Milford, MA).  Mass spectrometric analysis was performed with a TSQ 
Quantum Ultra (Thermo Fisher Scientific, San Jose, CA) triple quadrupole mass 
spectrometer coupled with heated electrospray ionization (HESI) operated in negative 
selective reaction monitoring (SRM) mode.  Analytical data was acquired and analyzed 
using Xcaliber software version 2.0.6 (ThermoFinnigan, San Jose, CA).  Metabolite 
concentrations were calculated from a standard curve and expressed as formation rates 
(pmol/mg protein/min).  
Statistical analysis 
 All data are expressed as mean ± standard error of the mean (SEM).  The sum 
formation rate of all EET and DHET regioisomers was calculated and used as an index 
of total CYP epoxygenase metabolic activity.  The functional balance between the CYP 
epoxygenase and !-hydroxylase pathways was assessed by calculating the ratio of 20-
HETE formation to EET+DHET formation (20-HETE:EET+DHET).  Because the data 
were not normally distributed, mRNA levels were transformed to ranks and metabolite 
formation rates and clinical chemistry values were log-transformed prior to statistical 
analysis.  To evaluate the effect of high fat diet on CYP expression and metabolic 
activity over time, data from WT/standard diet-fed mice at each time point were pooled to 
create a single control group, and data were analyzed by one-way ANOVA followed by 
post-hoc Dunnett’s test for comparison to the pooled control group.  To determine the 
effect of enalapril and metformin treatment, data were analyzed by one-way ANOVA 
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followed by post-hoc Tukey’s test.  The relationship between CYP mRNA levels and 
EET+DHET or 20-HETE formation was evaluated by Spearman rank correlation.  
Statistical analysis was performed using SAS software (v.9.1.3, SAS Institute, Cary, 
NC).  P<0.05 was considered statistically significant.  
Results 
Experiment 1:  Effect of high fat diet on CYP epoxygenase and !-hydroxylase metabolic 
activity over time 
To characterize the effect of high fat diet feeding on hepatic and renal CYP 
epoxygenase and !-hydroxylase metabolic activity over time, we randomized WT and 
ApoE-/- mice to high fat or standard diet for 2, 4, or 8 weeks.  Baseline body weight was 
significantly greater in ApoE-/- mice (25.5±0.5! g) compared to WT mice (21.4±0.2! g, 
P<0.001).  High fat diet promoted weight gain and altered clinical chemistry values in 
both WT and ApoE-/- mice (Table 4.1).  ApoE-/- mice had significantly higher plasma total 
cholesterol levels compared to WT mice fed the same diet.  Within each genotype, high 
fat diet-fed mice had significantly higher plasma total cholesterol levels than standard 
diet-fed mice.  In contrast, plasma insulin levels were not significantly different between 
WT and ApoE-/- mice fed a standard diet, but high fat diet feeding resulted in significantly 
higher plasma insulin levels in both genotypes.  No significant differences in plasma 
glucose levels were observed among the diet and genotype groups. 
High fat diet feeding differentially altered CYP epoxygenase and !-hydroxylase 
expression and metabolic activity in liver and kidney in both WT and ApoE-/- mice (Figure 
4.2).  However, no significant differences were observed between WT and ApoE-/- mice 
fed a standard diet.   
In liver, high fat diet significantly suppressed EET+DHET formation at 4 and 8 
weeks in both WT and ApoE-/- mice, relative to the WT/standard diet control group 
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(Figure 4.2A).  At 2 weeks, EET+DHET formation appeared lower in WT mice, but this 
difference was not statistically significant (P=0.204).  Hepatic Cyp2c29 mRNA levels 
were also significantly lower in high fat diet-fed mice (Figure 4.3A) and significantly 
correlated with total CYP epoxygenase activity (rS=0.68, P<0.001).  In contrast, no 
significant differences in hepatic 20-HETE formation (Figure 4.2B) or Cyp4a12a mRNA 
levels (Figure 4.3B) were observed in response to high fat diet.  The 20-
HETE:EET+DHET formation rate ratio was significantly greater in high fat diet-fed mice 
at 4 and 8 weeks, suggesting that the functional balance was shifted in favor of the CYP 
!-hydroxylase pathway secondary to suppression of EET+DHET formation (Figure 
4.2C). 
In contrast to what was observed in liver, no significant differences in renal 
EET+DHET formation (Figure 4.2D) or Cyp2j5 mRNA levels (Figure 4.3C) were 
observed in high fat diet-fed mice.  Renal 20-HETE formation, however, was markedly 
induced after 2, 4, and 8 weeks of high fat diet in both WT and ApoE-/- mice, relative to 
the WT/standard diet group (Figure 4.2E), and was significantly correlated with 
Cyp4a12a mRNA levels (rS=0.60, P<0.001).  This induction of renal CYP !-hydroxylase 
metabolic activity resulted in a significantly higher renal 20-HETE:EET+DHET formation 
rate ratio in high fat diet-fed mice in both genotype groups (Figure 4.2F).   
Experiment 2:  Effect of enalapril administration on high fat diet-induced alterations in 
CYP epoxygenase and !-hydroxylase metabolic activity  
Consistent with the results of Experiment 1, high fat diet significantly suppressed 
CYP epoxygenase metabolic activity in liver (Figure 4.4A).  Hepatic Cyp2c29 mRNA 
levels also tended to be lower in high fat diet-fed mice, but this difference was not 
statistically significant (Figure 4.4C; WT: P=0.129 vs. standard diet; ApoE-/-:  P=0.139 vs. 
standard diet). Enalapril administration reversed these effects in both WT and ApoE-/- 
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mice.  Similarly, the high fat diet-induced elevation in 20-HETE:EET+DHET formation 
rate ratio in liver was reversed by enalapril treatment (Figure 4.4E).  No significant 
differences in hepatic CYP !-hydroxylase metabolic activity (Figure 4.4B) or Cyp4a12a 
mRNA levels (Figure 4.4D) were observed in high fat diet-fed mice.  Enalapril 
significantly decreased hepatic 20-HETE formation (P=0.035 vs. standard diet) and 
Cyp4a12a mRNA levels (P<0.001 vs. standard diet; P=0.014 vs. high fat diet) in ApoE-/- 
mice, but no significant differences were observed in WT mice. 
In kidney, 20-HETE formation (Figure 4.5B), Cyp4a12a mRNA levels (Figure 
4.5D), and the 20-HETE:EET+DHET formation rate ratio (Figure 4.5E) were significantly 
higher in high fat diet fed mice, regardless of genotype, and these effects were reversed 
by enalapril treatment.  No significant differences in renal EET+DHET formation (Figure 
4.5A) or Cyp2j5 mRNA levels (Figure 4.5C) were observed in high fat diet-fed mice.  
Enalapril appeared to modestly increase renal EET+DHET formation in WT (P=0.072 vs. 
high fat diet) and ApoE-/- (P=0.009 vs. high fat diet) mice; however, no significant 
differences in Cyp2j5 mRNA levels were observed.   
Consistent with prior studies demonstrating that angiotensin converting enzyme 
(ACE) inhibitors have insulin-sensitizing effects [24], enalapril significantly lowered 
plasma insulin levels in high fat diet-fed WT mice (High fat diet/no treatment:  2.95±0.82!
ng/mL, High fat diet/enalapril:  0.72±0.08! ng/mL, P=0.022).  A similar trend was 
observed in ApoE-/- mice, but this difference was not statistically significant (High fat 
diet/no treatment:  1.85±0.27!ng/mL, High fat diet/enalapril: 0.90±0.07!ng/mL, P=0.260). 
Experiment 3:  Effect of enalapril and metformin administration on high fat diet-induced 
alterations in CYP epoxygenase and !-hydroxylase metabolic activity  
To discern whether the effect of enalapril on high fat diet-induced alterations in 
CYP epoxygenase and !-hydroxylase metabolic activity was related to its insulin-
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sensitizing effects, high fat diet-fed mice were administered metformin, an insulin 
sensitizing agent with a mechanism of action independent of the renin-angiotensin 
system.  Compared to untreated high fat diet-fed mice (3.14±0.60!ng/mL), both enalapril 
(1.53±0.30! ng/mL, P=0.036) and metformin (1.40±0.16! ng/mL, P=0.028) significantly 
lowered plasma insulin levels.  As observed in the two previous experiments, high fat 
diet significantly suppressed hepatic CYP epoxygenase (Figure 4.6A) and induced renal 
CYP !-hydroxylase metabolic activity (Figure 4.6D), and enalapril administration 
reversed these effects.  In contrast, metformin treatment had no effect on high fat diet-
induced changes in hepatic EET+DHET or renal 20-HETE formation.  Hepatic CYP 
epoxygenase activity was modestly higher in standard diet-fed mice treated with 
metformin compared to untreated mice (Figure 4.6A).  Enalapril modestly increased 
hepatic 20-HETE formation in high fat diet-fed mice (Figure 4.6B), but no significant 
differences in renal EET+DHET formation (Figure 4.6C) were observed across diet or 
treatment groups.   
Discussion 
 CYP expression and metabolic activity is altered in rodent models of metabolic 
syndrome, but the mechanisms underlying the observed alterations remain poorly 
understood.  To our knowledge, this is the first study to demonstrate that high fat diet 
feeding shifts the functional balance between the CYP epoxygenase and !-hydroxylase 
pathways in liver and kidney in favor of pro-inflammatory, vasoconstrictive 20-HETE 
formation.  Moreover, enalapril, but not metformin, reverses high fat diet-induced 
suppression of hepatic CYP epoxygenase metabolic activity and induction of renal CYP 
!-hydroxylase metabolic activity and restores the functional balance between the 
pathways.  Collectively, these findings implicate the renin-angiotensin system as a key 
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regulator of CYP-mediated eicosanoid metabolism in the presence of metabolic 
syndrome. 
High fat diet feeding lowered hepatic CYP epoxygenase activity and Cyp2c29 
expression relative to standard diet controls, consistent with a prior study showing that 
hepatic Cyp2c protein was suppressed by high fat diet [25].  In kidney, we observed a 
marked induction of 20-HETE formation, but no differences in EET+DHET formation, in 
high fat diet-fed mice.  In contrast, suppression of renal tubular CYP2C and CYP4A 
expression and metabolic activity has been observed in rats fed a high fat diet, relative 
to lean controls [26,27].  These conflicting results may be due to species differences in 
the regulation of renal CYP expression.  In both liver and kidney, the 20-
HETE:EET+DHET ratio was significantly greater in high fat diet-fed mice relative to 
controls, suggesting that the functional balance between the pathways had been shifted 
toward the CYP !-hydroxylase pathway.   
High fat diet feeding induces multiple metabolic derangements, including 
dyslipidemia, insulin resistance, and activation of the renin-angiotensin system [17,18], 
which may contribute to the alterations in CYP-mediated eicosanoid metabolism that we 
observed.  In order to investigate the effect of dyslipidemia on CYP-mediated eicosanoid 
metabolism, we evaluated CYP epoxygenase and !-hydroxylase expression and 
metabolic activity in WT and ApoE-/- mice.  ApoE-/- mice have impaired cholesterol 
clearance and develop profound hyperlipidemia, which promotes the development of 
atherosclerotic lesions and vascular inflammation similar to what is observed in humans 
with atherosclerotic disease [28].  Although plasma total cholesterol was substantially 
higher in ApoE-/- mice compared to WT mice, no significant differences in CYP 
epoxygenase or !-hydroxylase activity in liver or kidney were observed between WT 
and ApoE-/- mice fed a standard diet, and suppression of hepatic EET+DHET formation 
and induction of renal 20-HETE formation was observed in both genotypes in response 
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to high fat diet feeding.  Thus, the observed changes in CYP epoxygenase and !-
hydroxylase metabolic activity were driven by the high fat diet, rather than by genotype, 
and were independent of plasma cholesterol levels. 
 Interestingly, enalapril treatment reversed the effects of high fat diet feeding on 
CYP-mediated eicosanoid metabolism in both ApoE-/- and WT mice.  In addition to 
modulating the renin-angiotensin system to lower blood pressure, ACE inhibitors and 
angiotensin receptor blockers also improve insulin sensitivity in animal models [24] and 
prevent the development of diabetes in humans [29].  Consistent with these reports, 
enalapril lowered plasma insulin levels in high fat diet-fed mice.  Insulin modulates CYP 
expression in vitro [30,31], and CYP expression and metabolic activity is altered in 
models of diabetes [11,12,32,33].  Consequently, we administered metformin, an insulin 
sensitizing agent, to determine whether insulin resistance was driving the changes in 
CYP-mediated eicosanoid metabolism observed in high fat diet-fed mice.  Although 
metformin treatment normalized plasma insulin levels, it did not reverse the alterations in 
CYP expression and metabolic activity.  These results support the hypothesis that 
enalapril reverses the high fat diet-induced suppression of hepatic CYP epoxygenase 
and induction of renal CYP !-hydroxylase metabolic activity via inhibition of angiotensin 
II production, rather than by improving insulin sensitivity.   
Accumulating evidence indicates that angiotensin II can regulate CYP-mediated 
eicosanoid metabolism.  Studies evaluating the relationship between the CYP 
epoxygenase pathway and renin-angiotensin system are limited, but most suggest that 
angiotensin II suppresses CYP epoxygenase expression and metabolic activity.  For 
example, renal and vascular CYP2C and EET formation are suppressed in angiotensin 
II-infused rats [34,35] and double transgenic rats that overexpress the human renin and 
angiotensinogen genes [36].  Humans with renovascular disease, a condition 
characterized by activation of the renin-angiotensin system, tended to have lower 
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plasma EET levels, compared to healthy controls [37].  Due to their similar effects on 
vasomotor tone, the interaction between angiotensin II and 20-HETE has been more 
rigorously investigated.  Angiotensin II stimulates 20-HETE release in isolated perfused 
kidneys [38] and renal microvessels [39].   Ren-2 transgenic rats, which have elevated 
renal and plasma angiotensin II levels, exhibit significantly higher renal 20-HETE 
formation and urinary 20-HETE levels, relative to wild-type controls [40].  In humans, 
plasma 20-HETE levels correlated with plasma renin activity, and renovascular disease 
patients have significantly higher plasma 20-HETE compared to healthy controls [37].  A 
recent study has demonstrated that 20-HETE directly activates the renin-angiotensin 
system by stimulating expression of ACE and the angiotensin II receptor [41].  Although 
we did not directly demonstrate that angiotensin II suppresses hepatic CYP 
epoxygenase metabolic activity and induces renal CYP !-hydroxylase metabolic activity 
in this study, our findings, taken together with prior observations, strongly implicate 
angiotensin II in mediating the observed high fat diet-induced alterations in CYP-
mediated eicosanoid metabolism.  Further investigation of the interplay between the 
renin-angiotensin system and CYP-mediated eicosanoid metabolism is warranted. 
 We did not evaluate the pathophysiologic consequences of high fat diet feeding 
in this study, but prolonged high fat diet feeding has been used to induced insulin 
resistance, steatohepatitis, hypertension, and renal injury in rodents [18,27,42,43].  CYP 
epoxygenase-derived EETs are vasodilatory and possess potent anti-inflammatory 
effects.  Potentiation of the CYP epoxygenase pathway, via enhanced EET biosynthesis 
or inhibition of EET hydrolysis, has been shown to lower blood pressure in angiotensin 
II-dependent models of hypertension [44,45,46] and attenuate acute and chronic 
inflammation [47,48,49].  A series of studies have demonstrated that EETs also activate 
the phosphatidylinositol 3-kinase (PI3K)/Akt pathway [2], a key component of insulin 
signaling.  Recent evidence suggests that potentiation of EETs enhances insulin 
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signaling and improves insulin sensitivity [50,51].  Thus, prolonged suppression of 
hepatic CYP epoxygenase metabolic activity in the presence of the metabolic syndrome 
would be hypothesized to promote inflammation and hepatic insulin resistance.  In 
contrast, 20-HETE is a potent vasoconstrictor [3] and promotes inflammation via 
activation of nuclear factor-!B [52]; thus induction of renal CYP "-hydroxylase metabolic 
activity would be hypothesized to promote hypertension and renal injury.  Indeed, 
inhibition of 20-HETE formation has anti-hypertensive effects and attenuates renal injury 
[40,53].  A recent study demonstrated that elevations in plasma 20-HETE levels were 
associated with shortened bleeding time in mice [54], suggesting that induction of 20-
HETE formation may also contribute to the pro-thrombotic state observed in metabolic 
syndrome patients.  Collectively, our findings suggest that an angiotensin II-dependent 
shift in the functional balance between the CYP epoxygenase and "-hydroxylase 
pathways in favor of 20-HETE formation may be a key contributor to the pathologic 
consequences of a high fat diet and the metabolic syndrome, and that modulating the 
pathways to increase EETs and/or decrease 20-HETE may have therapeutic utility to 
abrogate these effects.  Moreover, the beneficial effects of ACE inhibitors in the 
metabolic syndrome may be mediated in part by restoration of the functional balance 
between the CYP epoxygenase and "-hydroxylase pathways.  However, further studies 
are necessary to test these hypotheses. 
 In conclusion, induction of the metabolic syndrome by high fat diet feeding 
suppressed hepatic CYP epoxygenase and induced renal CYP "-hydroxylase 
expression and metabolic activity, thereby shifting the functional balance between the 
pathways in favor of 20-HETE formation.  Treatment with enalapril, but not metformin, 
reversed this effect, implicating the renin-angiotensin system in mediating high fat diet-
induced alterations in CYP-mediated eicosanoid metabolism.  Further studies are 
necessary to elucidate the pathophysiologic significance of these alterations and 
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determine the therapeutic potential of modulating the CYP epoxygenase and !-
hydroxylase pathways in metabolic diseases. 
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Table 4.1:  Weight and plasma clinical chemistry in WT and ApoE-/- mice fed a 
standard or high-fat diet 
  2 weeks 4 weeks 8 weeks 
Weight, change from baseline (g) 
 WT/Standard diet 2.1 ± 0.6 3.6 ± 0.2 5.0 ± 0.5 
 WT/High fat diet 3.5 ± 0.9  10.3 ± 0.2 * 11.0 ± 1.5 * 
 ApoE-/-/ Standard diet 3.7 ± 0.1 4.3 ± 0.2 4.2 ± 0.2  
 ApoE-/-/ High fat diet 3.5 ± 0.3 4.7 ± 0.2 10.0 ± 0.9 *  
Total cholesterol (mg/dL)   
 WT/Standard diet <45 # 86 ± 2 81 ± 8 
 WT/High fat diet 104 ± 16 248 ± 14 * 194 ± 23 * 
 ApoE-/-/ Standard diet 614 ± 84 * 512 ± 49 * 918 ± 70 * 
 ApoE-/-/ High fat diet 902 ± 207 * 1099 ± 130 * 1398 ± 125 *  
Insulin (ng/mL)  
 WT/Standard diet 0.72 ± 0.08 0.95 ± 0.14 0.68 ± 0.14 
 WT/High fat diet 2.23 ± 0.61 * 2.67 ± 0.54 * 4.55 ± 0.82 * 
 ApoE-/-/ Standard diet 0.83 ± 0.08 0.56 ± 0.04 1.06 ± 0.17 
 ApoE-/-/ High fat diet 1.90 ± 0.54 * 1.72 ± 0.31 * 4.09 ± 0.87 * 
Glucose (mg/dL)  
 WT/Standard diet 331 ± 19 399 ± 52 335 ± 15 
 WT/High fat diet 446 ± 57 386 ± 26 382 ± 32 
 ApoE-/-/ Standard diet 359 ± 16 325 ± 19 306 ± 20 
 ApoE-/-/ High fat diet 361 ± 34 382 ± 19 418 ± 34 
* P<0.05 compared to WT/Standard diet  
# All values were below the limit of quantitation 
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Figure Legends 
Figure 4.1:  Treatment schemes to assess (A) the effect of high fat diet on CYP 
epoxygenase and !-hydroxylase metabolic activity and mRNA levels over time and (B) 
the effect of enalapril and metformin treatment on high fat diet-induced alterations in 
CYP epoxygenase and !-hydroxylase metabolic activity 
Figure 4.2:  Effect of high fat diet on (A) hepatic total CYP epoxygenase (EET+DHET) 
metabolic activity, (B) hepatic CYP !-hydroxylase (20-HETE) metabolic activity, (C) 
hepatic 20-HETE:EET+DHET formation rate ratio, (D) renal total CYP epoxygenase 
(EET+DHET) metabolic activity, (E) renal CYP !-hydroxylase (20-HETE) metabolic 
activity, and (E) renal 20-HETE:EET+DHET formation rate ratio in WT and ApoE-/- mice 
(N=4 per group).  * P<0.05 versus WT/standard diet control group. 
Figure 4.3: Effect of high fat diet on (A) hepatic Cyp2c29, (B) hepatic Cyp4a12a, (C) 
renal Cyp2j5 and (D) renal Cyp4a12a mRNA levels in WT and ApoE-/- mice (N=4 per 
group).  * P<0.05 versus WT/standard diet control group. 
Figure 4.4: Effect of high fat diet and enalapril treatment on hepatic (A) total CYP 
epoxygenase (EET+DHET) metabolic activity, (B) CYP !-hydroxylase (20-HETE) 
metabolic activity, (C) Cyp2c29 mRNA levels, (D) Cyp4a12a mRNA levels, and (E) 20-
HETE:EET+DHET formation rate ratio in WT and ApoE-/- mice (Standard diet: N=4, High 
fat diet: N=4, High fat diet + Enalapril: N=6).  * P<0.05. 
Figure 4.5: Effect of high fat diet and enalapril treatment on renal (A) total CYP 
epoxygenase (EET+DHET) metabolic activity, (B) CYP !-hydroxylase (20-HETE) 
metabolic activity, (C) Cyp2j5 mRNA levels, (D) Cyp4a12a mRNA levels, and (E) 20-
HETE:EET+DHET formation rate ratio in WT and ApoE-/- mice (Standard diet: N=4, High 
fat diet: N=4, High fat diet + Enalapril: N=6).  * P<0.05. 
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Figure 4.6: Effect of enalapril and metformin treatment on (A) hepatic total CYP 
epoxygenase (EET+DHET) metabolic activity, (B) hepatic CYP !-hydroxylase (20-
HETE) metabolic activity, (C) renal total CYP epoxygenase (EET+DHET) metabolic 
activity, and (D) renal CYP !-hydroxylase (20-HETE) metabolic activity (Standard diet: 
No treatment: N=11, Metformin: N=6, Enalapril: N=6; High fat diet: N=6 per group).   
* P<0.05 versus no treatment/standard diet.  # P<0.05 versus no treatment/high fat diet. 
  
!!
"#!
Figure 4.1:  Treatment scheme for high-fat diet and enalapril and metformin 
administration 
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Figure 4.2:  Effect of high fat diet on CYP epoxygenase and !-hydroxylase metabolic activity in liver and kidney 
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Figure 4.3:  Effect of high fat diet on hepatic and renal CYP mRNA levels 
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Figure 4.4:  Effect of enalapril on high fat diet-induced alterations in hepatic CYP 
epoxygenase and !-hydroxylase mRNA expression and metabolic activity 
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Figure 4.5:  Effect of enalapril on high fat diet-induced alterations in renal CYP 
epoxygenase and !-hydroxylase mRNA expression and metabolic activity 
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Figure 4.6:  Effect of enalapril and metformin on high fat diet-induced alterations in 
CYP epoxygenase and !-hydroxylase metabolic activity in liver and kidney 
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Chapter V:  CYP-mediated eicosanoid metabolism differs between CAD 
patients and healthy volunteers 
 Coronary artery disease (CAD) is a leading cause of morbidity and mortality in 
the United States [1].  Despite advances in the diagnosis and treatment of CAD, it 
remains a significant public health concern, and novel therapies are needed to improve 
outcomes.  Accumulating preclinical and epidemiologic evidence suggests that 
modulation of cytochrome P450 (CYP)-mediated eicosanoid metabolism may be a viable 
therapeutic strategy for the management of CAD.  
CYPs metabolize arachidonic acid to various biologically active eicosanoids.  The 
CYP epoxygenases (CYP2J2, CYP2C8) catalyze the formation of four 
epoxyeicosatrienoic acid regioisomers (5,6-, 8,9-, 11,12-, 14,15-EET), which possess 
potent vasodilatory and anti-inflammatory effects [2,3].  EETs are rapidly hydrolyzed by 
soluble epoxide hydrolase (sEH) to the corresponding dihydroxyeicosatrienoic acids 
(DHETs), which are generally less biologically active [3,4].  Numerous preclinical studies 
have demonstrated that potentiation of the CYP epoxygenase pathway, via enhanced 
EET biosynthesis or inhibition of sEH-mediated EET hydrolysis, is protective in models 
of cardiovascular disease.  For example, endothelial overexpression of CYP2J2 or 
CYP2C8 or global genetic deletion of sEH (Ephx2-/-) attenuates angiotensin II/high-salt-
induced hypertension [5,6] and lipopolysaccharide-induced acute inflammation [7,8] in 
mice.  Enhanced EET biosynthesis and inhibition of EET hydrolysis are also 
cardioprotective [9,10,11] and neuroprotective [12] in models of ischemia/reperfusion 
injury, and pharmacological inhibition of sEH attenuates atherosclerotic lesion 
development in apolipoprotein E-deficient mice [13,14].  In contrast, !-hydroxylation of 
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arachidonic acid by CYP4A11 and CYP4F2 produces 20-hydroxyeicosatetraenoic acid 
(20-HETE), a vasoconstrictive and pro-inflammatory eicosanoid [4].  20-HETE promotes 
hypertension [15,16] and endothelial dysfunction [17,18] in rodents, and administration 
of a CYP !-hydroxylase inhibitor is cardioprotective [19] and neuroprotective [20] in 
models of ischemia/reperfusion injury.   
Although preclinical studies suggest that the CYP epoxygenase and !-
hydroxylase pathways are important in the maintenance of cardiovascular homeostasis 
following pathologic insult, the role of CYP-mediated eicosanoid metabolism in humans 
is poorly understood. Functional genetic polymorphisms in the CYP epoxygenases 
(CYP2J2, CYP2C8) [21], sEH (EPHX2) [22], and CYP !-hydroxylases (CYP4A11, 
CYP4F2) [23,24,25,26] have been associated with cardiovascular disease susceptibility 
in several genetic epidemiologic studies, but few studies have directly measured CYP-
derived eicosanoids in humans.  Importantly, CYP-mediated eicosanoid metabolism has 
not been assessed in patients with established atherosclerotic cardiovascular disease, 
and the clinical factors that are associated with CYP epoxygenase, sEH, and CYP !-
hydroxylase function in this patient population have not been described.  Therefore, the 
objectives of this study were (1) to identify clinical factors that are associated with 
circulating biomarkers of CYP epoxygenase, sEH, and CYP !-hydroxylase function in a 
well-treated cohort of patients with established CAD and (2) to compare the plasma 
concentrations of EETs, DHETs, and 20-HETE between these CAD patients and healthy 
individuals without risk factors for cardiovascular disease. 
Methods 
Study population and protocol 
 A cohort of individuals "65 years of age with established CAD, defined as #50% 
stenosis in at least one major epicardial coronary artery by coronary angiography, were 
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identified in the UNC Cardiac Catheterization Laboratory. Exclusion criteria included 
pregnancy, atrial fibrillation, left-ventricular systolic dysfunction (ejection fraction !35%), 
current use of long-acting nitrates or insulin, active autoimmune disease, history of 
severe aortic stenosis, history of solid organ transplant or dialysis, or history of cancer 
within the previous 5 years.  
 A cohort of healthy volunteers (HV) !65 years of age were identified from the 
local Chapel Hill, NC community by advertisement. Following a detailed medical and 
medication history and a fasting serum chemistry and cholesterol panel, individuals with 
a history of cardiovascular disease, risk factors for CAD (including physician-diagnosed 
hypertension or diabetes, cigarette smoking within the previous 6 months, high 
cholesterol [defined as total cholesterol >240 mg/dL, triglycerides >200 mg/dL or LDL 
cholesterol >160 mg/dL], or body mass index >30 kg/m2), or currently taking any 
medication for a chronic medical condition were excluded.  
 The study protocol was approved by the University of North Carolina at Chapel 
Hill Biomedical Institutional Review Board. Eligible participants provided written informed 
consent and returned to the UNC Clinical and Translational Research Center (CTRC) for 
a single morning study visit after fasting overnight and withholding their morning 
medications.  CAD patients returned to the CTRC 62±34 days after their index 
catheterization and were clinically stable at the time of their study visit.  Participants 
were also instructed to refrain from tobacco products, caffeine, and vigorous exercise 
the morning of the study visit, and from use of vitamin C, vitamin E, fish oil, niacin or 
arginine supplements, oral decongestants, non-steroidal anti-inflammatory drugs (other 
than low-dose aspirin), or erectile dysfunction medications for at least 7 days prior to the 
study visit. Individuals experiencing a respiratory tract infection within 4 weeks of the 
study visit were not eligible to participate.  At the study visit, blood was collected by 
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venipuncture.  Plasma was separated by centrifugation and stored at -80oC pending 
analysis.   
Quantification of plasma CYP-derived eicosanoids  
Plasma eicosanoid levels were quantified as previously described [5,27].  Briefly, 
plasma (0.25 mL) was diluted in 0.1% acetic acid/5% methanol solution containing 0.009 
mM butylated hydroxytoluene.  Samples were loaded onto HyperSep Retain PEP SPE 
cartridges (Thermo Fisher Scientific, Waltham, MA) that had been conditioned with 0.1% 
acetic acid/5% methanol and spiked with 30 ng each of 10,11-epoxyheptadecanoic acid 
and 10,11-dihydroxynonadecanoic acid as internal standards. Columns were washed 
with two column volumes of 0.1% acetic acid/5% methanol, and analytes were eluted 
with 1 mL acetonitrile. Extracts were dried under nitrogen gas at 37°C and reconstituted 
in 40% ethanol. 
CYP-derived metabolites of arachidonic acid (14,15-EET, 11,12-EET, 8,9-EET, 
14,15-DHET, 11,12-DHET, 8,9-DHET, 5,6-DHET, and 20-HETE) and linoleic acid (9,10- 
and 12,13-epoxyoctadecenoic acid (9,10-EpOME and 12,13-EpOME) and 9,10- and 
12,13-dihydroxyoctadecenoic acid (9,10-DHOME and 12,13-DHOME)) were separated 
by reverse phase HPLC on a 1x150 mm, 5µm Luna C18(2) column (Phenomenex, 
Torrance, CA) and quantified using a MDS Sciex API 3000 triple quadrupole mass 
spectrometer (Applied Biosystems, Foster City, CA) with negative mode electrospray 
ionization and multiple reaction monitoring, as previously described [28].  
Data were acquired and analyzed with Analyst software, version 1.5 (Applied 
Biosystems), and the relative response ratios of each analyte to the appropriate internal 
standard were used to calculate concentrations.  Extraction efficiency for each sample 
was calculated based on the recovery of the internal standards.  Samples for which the 
extraction efficiency was greater than two standard deviations below the mean were 
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considered to be analytical failures and excluded from the statistical analysis.  A 
concentration equal to half that of the lowest standard was imputed for samples in which 
the calculated concentration fell below that value.  Analytes for which more than 20% of 
the values were imputed were dropped from the statistical analysis [29].  Consequently, 
11,12-EET was excluded from the analysis. 
Statistical analysis 
Data are presented as mean ± standard deviation or median (interquartile range) 
unless otherwise indicated.  In addition to analyzing each separately, EET regioisomers 
(14,15-EET and 8,9-EET) and DHET regioisomers (14,15-DHET, 11,12-DHET, 8,9-
DHET, and 5,6-DHET) were summed to evaluate total plasma concentrations of EETs 
and DHETs, respectively.  The sum of all EET and DHET regioisomers (EETs+DHETs) 
was calculated as an index of total epoxygenase activity.  Epoxide:diol ratios (14,15-
EET:14,15-DHET, 9,10-EpOME:9,10-DHOME, and 12,13-EpOME:12,13-DHOME) were 
calculated as indices of sEH activity.  Previous studies in Ephx2-/- mice and in humans 
demonstrate that these ratios in plasma are sensitive and specific biomarkers of sEH 
activity in vivo, with lower ratios indicative of higher sEH activity [10,22].  Parameters 
that were not normally distributed, including serum chemistry, plasma CYP-derived 
eicosanoid levels, and epoxide:diol ratios, were log-transformed prior to statistical 
analysis. 
Study population characteristics were compared across the CAD and HV cohorts 
using a one-way ANOVA or chi-squared test, as appropriate.  Inter-metabolite 
correlations were assessed by Spearman rank correlation.  To identify clinical factors 
that influence sum EETs, sum DHETs, 20-HETE, and 14,15-EET:14,15-DHET ratios in 
CAD patients, stepwise multiple regression analysis was performed. Potential covariates 
included demographic factors (age, gender, race), indices of CAD severity (presence of 
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multivessel disease, presence of acute coronary syndrome at index catheterization), 
comorbidities (hypertension, diabetes, cigarette smoking), body mass index, and ACE 
inhibitor/angiotensin receptor blocker use.  These comorbidities were considered 
because alterations in CYP epoxygenase and !-hydroxylase pathway expression and 
metabolic activity have been observed in rodent models of hypertension [30], obesity 
[31,32,33], and chronic tobacco smoke exposure [34].  ACE inhibitor/angiotensin II 
receptor blocker use was included because angiotensin II regulates CYP-mediated 
eicosanoid metabolism in preclinical models [35,36] and in humans [37].  Due to the high 
prevalence of beta-blocker, aspirin, and statin use in CAD patients, use of these 
medications was not considered as a covariate.  Covariates with p<0.15 were included 
in the final model.   
Sum EETs, sum DHETs, 20-HETE, and epoxide:diol ratios in the CAD and HV 
cohorts were compared by regression in an unadjusted model; a model adjusted for age, 
gender, and race; and a model adjusted for continuous covariates identified in the 
multiple regression analysis in CAD patients.  Analyses stratified by the categorical 
covariates identified in the multiple regression analysis were also performed.  Stratified 
analyses were also completed to assess the potential contribution of confounding factors 
to the observed differences in each biomarker between the CAD and HV cohorts.  The 
primary analysis was the case-control comparison of the sum EETs, sum DHETs, 20-
HETE, and epoxide:diol ratios. Therefore, the significance level was set at P=0.0125 
(0.05/4) to account for the impact of multiple statistical tests.  At an !=0.0125 level, we 
had >80% power to detect a 35% difference in each biomarker between the CAD and 
HV cohorts, assuming a coefficient of variation of 50% [22].  In a secondary analysis, 
plasma levels of individual EET and DHET regioisomers were compared between the 
CAD and HV cohorts by one-way ANOVA.  All analyses were performed using SAS 
9.1.3 (SAS Institute, Cary, NC).  
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Results 
Study population 
The characteristics of the study population are shown in Table 5.1.  Compared to 
the healthy volunteers, CAD patients were significantly older, and had higher body mass 
index, blood pressure, serum triglycerides and C-reactive protein.  CAD patients had 
lower HDL, LDL, and total cholesterol levels than individuals in the HV cohort.  This 
observation is likely due to treatment with lipid-lowering therapies, as no differences in 
the total:HDL cholesterol ratio were observed.  Among the CAD patients, the majority 
had advanced disease, with 25 (30.5%) presenting with an acute coronary syndrome at 
their index catheterization and 52 (63.4%) diagnosed with multivessel disease. 
The plasma levels of EETs, DHETs, 20-HETE, EpOMEs, and DHOMEs in CAD 
patients are shown in Figure 5.1A.  EETs circulated at the lowest concentrations, 
followed by the DHETs and 20-HETE.  The linoleic acid metabolites (9,10-EpOME, 9,10-
DHOME, 12,13-EpOME, 12,13-DHOME) were present at much higher concentrations 
than the arachidonic acid metabolites.  All epoxide metabolites were highly positively 
correlated, as were the diols (Figure 5.1B).  In addition, 20-HETE was positively 
correlated with the diols, but not the epoxides.  Both 14,15-EET and 12,13-EpOME were 
negatively correlated with 14,15-DHET and 11,12-DHET, while 9,10-EpOME was 
negatively correlated with all DHET regioisomers.  The 14,15-EET:14,15-DHET ratio 
was significantly positively correlated with the 9,10-EpOME:9,10-DHOME (rS=0.81; 
P<0.001) and 12,13-EpOME:12,13-DHOME (rS=0.86, P<0.001) ratios, which were also 
significantly correlated (rS=0.88; P<0.001).  Similar inter-metabolite correlations were 
observed in healthy volunteers (Figure 5.2). 
Identification of clinical factors associated with plasma CYP-derived eicosanoid levels in 
CAD patients 
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 Several clinical covariates were associated with CYP epoxygenase pathway 
function in subjects with CAD (Table 5.2).  Plasma sum EETs were negatively 
associated with body mass index and age.  Similarly, plasma sum EETs were 
significantly lower in patients with a body mass index !30 kg/m2 (Median (IQR): 0.25 
(0.17)), compared to patients with a body mass index <30 kg/m2 (0.34 (0.32); P<0.001).  
Plasma sum DHETs were significantly higher in smokers, and significantly lower in 
patients with diabetes.  Consistent with these relationships, the 14,15-EET:14,15-DHET 
ratio tended to be lower in smokers and negatively correlated with body mass index.  
Moreover, the 14,15-EET:14,15-DHET ratio was significantly lower in patients with a 
body mass index !30 kg/m2 (0.23 (0.49)), compared to patients with a body mass index 
<30 kg/m2 (0.52 (0.59); P=0.011).  Plasma 20-HETE levels were significantly lower in 
patients treated with an ACE inhibitor/ARB (Table 5.2); however, no significant 
association with age, body mass index, diabetes or smoking was observed.  Moreover, 
no significant differences in plasma 20-HETE levels were observed in patients with a 
body mass index !30 kg/m2 (1.41 (0.66)), compared to patients with a body mass index 
<30 kg/m2 (1.60 (0.97); P=0.249).  No significant relationships were observed between 
sum EETs, sum DHETs, the 14,15-EET:14,15-DHET ratio, or 20-HETE and gender, 
race, presence of multivessel disease, or presence of acute coronary syndrome at the 
index catheterization.  
Comparison of plasma eicosanoid levels between healthy volunteers and CAD patients 
CAD patients had significantly higher plasma sum EETs compared to healthy 
volunteers (P<0.001; Figure 5.3A).  This relationship remained significant after adjusting 
for age, gender, and race (P<0.001), and age and body mass index (P<0.001), and 
stratifying the study population by body mass index (P<0.001; Figure 5.4A).  CAD 
patients tended to have lower plasma sum DHETs compared to healthy volunteers 
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(P=0.030), but this difference was not statistically significant at the !=0.0125 level 
(Figure 5.3B).  A similar relationship was observed after adjusting for demographic 
factors (P=0.033).  Non-smoking CAD patients exhibited significantly lower plasma sum 
DHETs compared to healthy volunteers (P=0.003; Figure 5.4B), but no significant 
differences in plasma sum DHETs were observed when the CAD cohort was limited to 
patients without diabetes (P=0.152; Figure 5.4C).  No differences in total CYP 
epoxygenase activity (EETs+DHETs) were observed between CAD patients and healthy 
volunteers (Figure 5.3C).  
 The epoxide:diol ratios were markedly different between the cohorts.  The 14,15-
EET:14,15-DHET, 9,10-EpOME:9,10-DHOME, and 12,13-EpOME:12,13-DHOME ratios 
were each significantly higher in CAD patients, compared to healthy volunteers (Figure 
5.5).  These relationships remained statistically significant when adjusted for age, 
gender, and race (P<0.001 versus HV for all), and age and body mass index (P<0.001 
versus HV for all).  Similar results were also observed when the study population was 
stratified by gender (Figure 5.6), body mass index (Figure 5.7A), smoking status (Figure 
5.7B), and diabetes status (Figure 5.7C) (P<0.001 versus HV for all). 
Consistent with the results observed for the sum EETs, CAD patients had 
significantly higher 14,15-EET, 8,9-EET, 9,10-EpOME, and 12,13-EpOME plasma 
concentration compared to healthy volunteers.  CAD patients also tended to have lower 
plasma levels of the individual diol regioisomers, although only 5,6-DHET reached 
statistical significance (Table 5.3). 
 No differences in plasma 20-HETE levels were observed between CAD patients 
and healthy volunteers in either the unadjusted regression model (P=0.988) or after 
adjustment for age, gender, and race (P=0.852).  However when CAD patients were 
stratified by ACE inhibitor/ARB use, plasma 20-HETE levels in CAD patients not treated 
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with an ACE inhibitor or ARB tended to be higher than in healthy volunteers, though this 
difference was not statistically significant (P=0.086; Figure 5.4D). 
Discussion 
Genetic variation in the CYP epoxygenases, sEH, and the CYP !-hydroxylases 
has been associated with cardiovascular disease risk, supporting the hypothesis that 
modulating CYP-mediated eicosanoid metabolism may have therapeutic utility in the 
management of CAD.  However, few studies have measured CYP-derived eicosanoids 
in humans.  To our knowledge, this is the first study to evaluate CYP epoxygenase, sEH, 
and CYP !-hydroxylase function in patients with established atherosclerosis.  
Collectively, our findings identify clinical factors that influence CYP epoxygenase, sEH, 
and CYP !-hydroxylase metabolic function in CAD patients and demonstrate that CYP-
mediated eicosanoid metabolism is altered in the presence of atherosclerotic 
cardiovascular disease.   
Most notably, we observed that the epoxide:diol ratios were markedly higher in 
CAD patients compared to healthy volunteers in all subsets of the population, indicating 
significantly lower apparent sEH metabolic activity in the presence of advanced 
cardiovascular disease.  Consistent with these findings, CAD patients also had higher 
plasma EETs and lower plasma DHETs compared to healthy volunteers, but no 
differences in total CYP epoxygenase activity were observed between the groups.  
Preclinical models have demonstrated that genetic disruption or pharmacological 
inhibition of sEH lowers blood pressure [6,38], attenuates acute inflammation [7,8], is 
cardioprotective following ischemia/reperfusion injury [10,11], and attenuates 
atherosclerotic lesion development [13,14].  In humans, carriers of a genetic 
polymorphism associated with higher sEH activity in vivo (EPHX2 K55R) had a greater 
risk of incident CAD [22].  Thus, the apparent suppression of sEH metabolic activity that 
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we observed in CAD patients may be a compensatory response to the presence of 
cardiovascular disease.  However, few studies have investigated the factors that 
regulate sEH metabolic activity in vivo.  Reactive oxygen species inhibit sEH metabolic 
activity in vitro [39,40], suggesting that oxidative stress contributes to the suppression of 
sEH metabolic activity in CAD patients.  A recent study demonstrated that 15-deoxy 
prostaglandin J2, an electrophilic cyclopentenone prostaglandin, inhibits sEH in vitro via 
covalent adduct formation [41], but levels of 15-deoxy prostaglandin J2 have not been 
measured in CAD patients.  Future studies are necessary to elucidate the mechanisms 
by which sEH metabolic activity is regulated in the presence of cardiovascular disease.  
Importantly, sEH inhibitors are currently in clinical development for the treatment of 
cardiovascular and metabolic disease [42].  Understanding the clinical factors that 
influence CYP epoxygenase pathway function in humans may help identify patients who 
would most benefit from treatment with sEH inhibitors.   
Within the CAD cohort, we identified several clinical factors that were associated 
with CYP epoxygenase and sEH metabolic function.  Body mass index was the 
strongest predictor of plasma EET levels in CAD patients.  The observed inverse 
relationship suggests that CYP epoxygenase activity is suppressed in obese individuals, 
consistent with lower CYP epoxygenase expression and metabolic activity reported in rat 
models of obesity [31,32,33].  We also observed an inverse correlation between body 
mass index and the 14,15-EET:14,15-DHET ratio. This relationship may indicate higher 
sEH activity in obese individuals, but may reflect the observed correlation between 
plasma EET levels and body mass index.  Preclinical studies assessing the effects of 
obesity on sEH expression and activity have yielded conflicting results.  For example, 
elevated sEH expression has been observed in mesenteric arteries of obese Zucker rats 
[33], while sEH activity appeared to be suppressed in a model of diet-induced obesity in 
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mice [43].  Thus, further study is necessary to directly assess the impact of obesity on 
sEH activity.   
Several of the comorbidities present in the CAD cohort were associated with 
CYP epoxygenase pathway function.  CAD patients with diabetes tended to have lower 
plasma DHETs compared to non-diabetic patients, suggesting suppression of CYP 
epoxygenase and/or sEH activity.  Preclinical studies suggest that hyperglycemia and/or 
hyperinsulinemia may influence CYP epoxygenase pathway function.  CYP2C 
expression and metabolic activity is suppressed in rodents treated with streptozotocin, a 
model of Type 1 diabetes [44,45].  In contrast, higher Cyp2c29 expression relative to 
controls was observed in db/db mice, which display a phenotype similar to Type 2 
diabetes [46,47].  High glucose suppressed sEH expression in vitro, and hepatic and 
renal sEH protein levels were significantly lower in streptozotocin-treated mice relative to 
control [40].  Of note, our study population included only non-insulin-dependent diabetes 
patients.  Accumulating preclinical evidence has suggested that potentiation of EETs or 
inhibition of sEH enhances insulin signaling and improves insulin sensitivity [48,49]; thus 
future studies investigating the effect of modulating the CYP epoxygenase pathway in 
patients with diabetes are warranted.  We also observed that cigarette smoking was 
associated with higher sum DHETs and lower epoxide:diol ratios in CAD patients.  This 
suggests that cigarette smoking increases sEH expression or metabolic activity, which is 
consistent with higher vascular sEH expression observed in mice chronically exposed to 
tobacco smoke [34].  Interestingly, cigarette smoking modifies the risk of CAD in 
individuals who carry function genetic variants in EPHX2 [22], CYP2C8 [21], and 
CYP2J2 [50], such that variant allele carriers who smoke have the highest risk.  Our 
findings suggest that these interactions may be mediated in part by upregulation of sEH 
activity by cigarette smoking.  However, studies evaluating the direct effect of cigarette 
smoke exposure on sEH function in humans are needed to confirm this hypothesis. 
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Of the clinical factors that we evaluated, only ACE inhibitor/ARB use was 
associated with plasma 20-HETE concentrations in CAD patients.  Our observation that 
plasma 20-HETE levels were lower in patients treated with an ACE inhibitor/ARB are 
consistent with previous findings that plasma 20-HETE levels are significantly higher in 
patients with renovascular disease, a condition characterized by activation of the renin-
angiotensin system.  Minuz and colleagues also observed a positive correlation between 
plasma 20-HETE levels and plasma renin activity in all study subjects [37].  In preclinical 
models, angiotensin II stimulates 20-HETE release in isolated perfused kidneys [51] and 
renal microvessels [52].  Further study is warranted to investigate the interplay between 
the renin-angiotensin system and the CYP !-hydroxylase pathway in humans. 
 In contrast to prior studies showing a correlation between urinary 20-HETE levels 
and body mass index [53,54], we observed no relationship between plasma 20-HETE 
and obesity in CAD patients.  Several factors may account for these differences.  First, 
our study population was composed of CAD patients with multiple comorbidities, while 
previous studies have enrolled individuals with hypertension or metabolic syndrome.  
Also, the patients in prior studies were untreated. In contrast, we withheld medications 
only the morning of the study visit.  Consequently, effects of drug therapy, such as the 
relationship that we observed with ACE inhibitor/ARB use, may have masked other 
factors that influence plasma 20-HETE levels in CAD patients.   Finally, urinary 20-HETE 
levels may reflect local production in the kidney rather than systemic levels.  As a result, 
the clinical factors that influence urinary 20-HETE excretion may differ from those 
associated with plasma 20-HETE concentrations.  
There are several limitations to our analysis.  Due to the cross-sectional and 
observational design of the study, we are unable to establish a cause-effect relationship 
between presence of CAD and the apparent suppression of sEH activity.  In addition, our 
analysis compared well-treated CAD patients with established atherosclerosis and 
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multiple comorbidities to healthy individuals with no risk factors for cardiovascular 
disease.  Thus there are many potential confounding factors which may have influenced 
the relationships we observed.  For example, we cannot determine whether our 
observations are due to the presence of atherosclerotic disease, the presence of 
comorbidities/cardiovascular risk factors, or a consequence of drug therapy.  Also, 
nearly all the CAD patients were treated with aspirin, statins, and beta-blockers, so we 
were unable to evaluate the effects of these treatments on CYP-mediated eicosanoid 
metabolism.  Moreover, many of the clinical characteristics in the CAD patients, such as 
serum lipid levels and blood pressure values, were influenced by drug therapy, and our 
analysis was underpowered to evaluate such drug-disease interactions.  Consequently, 
our analysis was not comprehensive, and other clinical factors may influence CYP-
derived eicosanoid levels in humans.  Finally, although we adjusted the significance 
level to account for the impact of multiple statistical tests, replication in an independent 
cohort is necessary to validate our results.  Despite these limitations, our analysis is the 
first to measure plasma levels of CYP-derived eicosanoids in CAD patients and lays a 
foundation for future interventional studies seeking to evaluate the therapeutic effect of 
modulating the CYP epoxygenase and !-hydroxylase pathways in humans.   
In conclusion, we observed that CAD patients had significantly higher plasma 
epoxide:diol ratios compared to healthy volunteers, suggesting that sEH activity is 
suppressed in the presence of cardiovascular disease.  Future studies are necessary to 
elucidate the mechanism by which sEH activity is suppressed in CAD patients, as well 
as to investigate the therapeutic potential of modulation of CYP-mediated eicosanoid 
metabolism as a strategy for the treatment of CAD. 
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Table 5.1: Study population characteristics 
Characteristic CAD  HV 
N  82  36   
Age (years) 54.8 ± 7.2  50.0 ± 7.3 *  
Female gender (%) 31 (37.8%)   20 (55.6%)   
African-American race (%) 14 (17.1%)  6 (16.7%) 
Body mass index (kg/m2) 30.6 ± 5.9   25.7 ± 2.4 *  
                       <25 kg/m2 16 (19.5%)   12 (33.3%)   
                        25-29.9 kg/m2 20 (24.4%)   24 (66.7%)   
                       !30 kg/m2 46 (56.1%)  0 (0%) †   
Current smoker (%) 22 (26.8%)  0 (0%) † 
Diabetes (%) 22 (26.8%)  0 (0%) † 
Hypertension (%) 63 (76.8%)  0 (0%) † 
Systolic blood pressure (mmHg) 135 ± 17   122 ± 13 * 
Diastolic blood pressure (mmHg) 80 ± 10   75 ± 8 *  
Total cholesterol (mg/dL) 156 (47)   191 (29) * 
LDL cholesterol (mg/dL) 85 (41)   117 (29) * 
HDL cholesterol (mg/dL) 45 (15)    65 (21) * 
Triglycerides (mg/dL) 104 (81)   69 (36) * 
Total:HDL cholesterol (ratio) 3.4 (1.7)   3.1 (1.1) 
High sensitivity C-reactive protein (mg/L) 1.9 (3.5)   0.7 (1.6) * 
ACE inhibitor or ARB use (%) 50 (61.0%)  0 (0%) † 
Beta-blocker use (%) 69 (84.2%)  0 (0%) †  
Statin use (%) 76 (92.7%)  0 (0%) † 
Aspirin use (%) 79 (96.3%)  0 (0%) †  
Clopidogrel use (%) 65 (79.3%)  0 (0%) †  
ACE = angiotensin converting enzyme, ARB=angiotensin receptor blocker, 
CAD=coronary artery disease, HDL=high density lipoprotein, HV=healthy volunteer, 
LDL=low density lipoprotein 
Data presented as mean ± standard deviation, median (interquartile range) or count 
(proportion). 
*P<0.05 versus CAD. † Exclusion criterion in HV cohort. 
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Table 5.2:  Clinical factors that are significantly associated with plasma CYP-derived 
eicosanoid levels in CAD patients 
  Parameter Estimate SE Partial R
2
 p 
Sum EETs 
 Body mass index -0.036 0.009 0.122 0.001 
 Age -0.014 0.007 0.048 0.037 
  
Sum DHETs 
 Smoking  0.273 0.121 0.051 0.041  
 Diabetes -0.255 0.121 0.051 0.038 
  
20-HETE 
 ACEI/ARB use -0.320 0.109 0.098 0.004  
 
14,15-EET:14,15-DHET 
 Smoking -0.531 0.213 0.043 0.061 
 Body mass index -0.038 0.016 0.041 0.064  
ACEI = angiotensin converting enzyme inhibitor; ARB = angiotensin receptor blocker 
Sum EETs, sum DHETs, 20-HETE, and 14,15-EET:14,15-DHET ratio were log-
transformed prior to analysis. 
 
  
  
116 
Table 5.3:  Comparison of plasma CYP-derived eicosanoid levels between CAD 
patients and healthy volunteers 
Analyte (ng/mL) CAD HV P 
14,15-EET 0.18 (0.19) 0.10 (0.06) <0.001  
8,9-EET 0.11 (0.08) 0.09 (0.02) 0.003 
14,15-DHET 0.53 (0.35) 0.64 (0.34) 0.137 
11,12-DHET 0.48 (0.32) 0.59 (0.30) 0.064 
8,9-DHET 0.14 (0.10) 0.19 (0.09) 0.064 
5,6-DHET 0.15 (0.13) 0.25 (0.12) <0.001 
20-HETE 1.46 (0.90) 1.48 (0.70) 0.988 
9,10-EpOME 3.62 (2.87) 2.33 (1.52) <0.001 
9,10-DHOME 4.63 (3.40) 6.14 (3.32) 0.014 
12,13-EpOME 6.23 (4.87) 4.68 (3.15) 0.018 
12,13-DHOME 3.36 (2.40) 5.61 (4.26) <0.001 
Data presented as median (interquartile range).  Following log-transformation, plasma 
levels of each analyte were compared by one-way ANOVA. 
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Figure Legends 
Figure 5.1: (A) Distribution of plasma concentrations of CYP-derived eicosanoid 
metabolites in CAD patients (n=82) plotted on a log10-scale.  The line within the box 
defines the median, the ends of the boxes define the 25th and 75th percentiles, the error 
bars define the 10th and 90th percentiles, and the individual points identify values outside 
the 10th and 90th percentiles. (B) Heat map depicting strength of Spearman rank 
correlations between analytes.  Gray boxes indicate no significant correlation.  Colored 
boxes indicate a significant correlation, with the strength of the correlation indicated by 
the intensity of the color. 
Figure 5.2: (A) Distribution of plasma concentrations of CYP-derived eicosanoid 
metabolites in healthy volunteers (n=36) plotted on a log10-scale. (B) Heat map depicting 
strength of Spearman rank correlations between analytes.  Gray boxes indicate no 
significant correlation.  Colored boxes indicate a significant correlation, with the strength 
of the correlation indicated by the intensity of the color. 
Figure 5.3: Distribution of plasma (A) sum EETs, (B) sum DHETs, (C) and total 
epoxygenase activity (EETs+DHETs) in healthy volunteers (HV, n=36) and CAD patients 
(n=82) plotted on a log10-scale. *Unadjusted P<0.0125 versus HV. 
†P<0.0125 versus HV 
after adjusting for age, gender, and race. ‡ P<0.0125 versus HV after adjusting for age 
and body mass index. 
Figure 5.4: Distribution of (A) plasma sum EETs in healthy volunteers (HV, n=36) and 
CAD patients with body mass index <30 kg/m2 (CAD: n=36), plasma sum DHETs in 
healthy volunteers (HV, n=36) and (B) non-smoker CAD patients (CAD: n=60) and (C) 
non-diabetic CAD patients (CAD: n=60) and (D) plasma 20-HETE in healthy volunteers 
(HV, n=36) and CAD patients not treated with an ACE inhibitor or ARB (n=32) plotted on 
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a log10-scale. *Unadjusted P<0.0125 versus HV.  
†P<0.0125 versus HV after adjusting 
for age, gender, and race. 
Figure 5.5: Distribution of plasma (A) 14,15-EET:14,15-DHET, (B) 9,10-EpOME:9,10-
DHOME, (C) 12,13-EpOME:12,13-DHOME in healthy volunteers (HV, n=36) and CAD 
patients (n=82) plotted on a log10-scale.  *Unadjusted P<0.0125 versus HV. 
†P<0.0125 
versus HV after adjusting for age, gender, and race. ‡P<0.0125 versus HV after 
adjusting for body mass index.  
Figure 5.6: Distribution of plasma 14,15-EET:14,15-DHET, 9,10-EpOME:9,10-
DHOME, 12,13-EpOME:12,13-DHOME in (A) men (HV: n=16; CAD: n=51) and (B) 
women (HV: n=20; CAD: n=31) plotted on a log10-scale. *Unadjusted P<0.0125 versus 
HV. †P<0.0125 versus HV after adjusting for age and race.  ‡P<0.0125 versus HV after 
adjusting for body mass index. 
Figure 5.7: Distribution of plasma 14,15-EET:14,15-DHET, 9,10-EpOME:9,10-
DHOME, 12,13-EpOME:12,13-DHOME in healthy volunteers (HV, n=36) and (A) CAD 
patients with BMI!30 kg/m2 (n=36), (B) non-smoking CAD patients (n=60), and (C) non-
diabetic CAD patients (n=60) plotted on a log10-scale. *Unadjusted P<0.0125 versus HV. 
†P<0.0125 versus HV after adjusting for age, gender, and race.  ‡P<0.0125 versus HV 
after adjusting for body mass index. 
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Figure 5.1: Plasma CYP-derived eicosanoid levels and inter-metabolite correlations in 
CAD patients 
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Figure 5.2: Plasma CYP-derived eicosanoid levels and inter-metabolite correlations in 
healthy volunteers  
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Figure 5.3: Comparison of plasma EETs, DHETs, and total epoxygenase activity in 
CAD patients and healthy volunteers 
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Figure 5.4: Case-control comparison of plasma EETs, plasma DHETs, and 20-HETE 
stratified by body mass index, smoking status, diabetes status, and ACE inhibitor/ARB 
use 
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Figure 5.5: Comparison of epoxide:diol ratios in CAD patients and healthy volunteers  
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Figure 5.6: Case-control comparison of plasma epoxide:diol ratios stratified by gender 
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Figure 5.7: Case-control comparison of plasma epoxide:diol ratios stratified by body 
mass index, smoking status, and diabetes status 
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Chapter VI: Genetic variation in the CYP epoxygenase and !-hydroxylase 
pathways is associated with survival in ACS patients 
Acute coronary syndromes (ACS), the clinical consequence of unstable coronary 
artery disease (CAD), are a major cause of morbidity and mortality worldwide [1].  
Vascular inflammation is integral to the development and progression of atherosclerotic 
lesions, and ultimately promotes plaque instability and rupture, leading to ACS [2].  
Moreover, elevations in plasma inflammatory biomarkers have been associated with 
poor outcomes following an ACS event [3,4,5,6,7], suggesting that pharmacologic 
agents that attenuate vascular inflammation may have therapeutic potential. 
 Modulation of cytochrome P450 (CYP)-mediated arachidonic acid metabolism 
may represent a novel anti-inflammatory treatment strategy for ACS.  
Epoxyeicosatrienoic acids (EETs), the products of olefin epoxidation of arachidonic acid 
by CYP2J and CYP2C isoforms, possess potent vasodilatory and anti-inflammatory 
properties, but are rapidly hydrolyzed by soluble epoxide hydrolase (sEH) to the less 
biologically active dihydroxyeicosatrienoic acids (DHETs) [8].  In contrast, !-
hydroxylation of arachidonic acid by CYP4A and CYP4F isoforms produces 20-
hydroxyeicosatetraenoic acid (20-HETE), a vasoconstrictive and pro-inflammatory 
eicosanoid [9].  In addition to regulating inflammation, CYP-derived eicosanoids also 
influence the recovery from ischemia/reperfusion injury in preclinical models.  
Potentiation of the CYP epoxygenase pathway, via enhancement of CYP-mediated EET 
biosynthesis or inhibition of sEH-mediated EET hydrolysis, improves functional recovery 
following myocardial ischemia/reperfusion injury [10,11,12].  Conversely, inhibition of the 
! "#$!
CYP !-hydroxylase pathway is cardioprotective following ischemia/reperfusion injury 
[13,14,15,16]. 
 Although these studies suggest that potentiation of CYP epoxygenase-derived 
EETs and inhibition of CYP !-hydroxylase-derived 20-HETE may improve outcomes 
following an ACS event, pharmacologic agents that specifically modulate CYP-mediated 
eicosanoid metabolism are not approved for use in humans.  Thus, the therapeutic utility 
of directly manipulating the CYP epoxygenase and !-hydroxylase pathways in ACS 
patients has not been investigated.  Importantly, functional genetic polymorphisms in the 
CYP epoxygenases (CYP2J2, CYP2C8), sEH (EPHX2), and the CYP !-hydroxylases 
(CYP4A11, CYP4F2) (Table 6.1) have been associated with cardiovascular disease risk 
[17,18,19,20,21,22,23,24], suggesting that CYP-derived eicosanoids play an important 
role in the cardiovascular system in humans.  However, the relationship between these 
variants and prognosis in patients with ACS has not been characterized to date.  
Therefore, we sought to investigate the association between functional genetic variants 
in CYP2J2, CYP2C8, EPHX2, CYP4A11, and CYP4F2 and 5-year survival in a well-
phenotyped cohort of ACS patients.  
Methods 
Study population 
The analysis was performed in a cohort of patients with confirmed ACS 
(INvestigation oF Outcomes from acute coronary syndRoMes study (INFORM); N=721), 
prospectively recruited from the Mid America Heart Institute and Truman Medical Center 
in Kansas City, MO.  The methods of recruitment and characteristics of the population 
have been reported previously [25,26,27].  Briefly, all patients admitted between March 
1, 2001 and October 31, 2002, who had a troponin blood test were screened for possible 
ACS.  Myocardial infarction (MI) was defined by elevated troponin level in combination 
! "##!
with chest pain symptoms or electrocardiographic findings (ST-segment elevation or 
non-ST-segment elevation) consistent with MI.  Unstable angina was defined by a 
negative troponin level and any one of the following: new-onset angina (<2 months), 
prolonged angina (>20 minutes) at rest, recent worsening angina, or angina that 
occurred within 2 weeks of MI [28].!
Demographic, economic, and health status information was obtained by patient 
interview; medical history, laboratory results, and disease severity were ascertained from 
medical records. Patient vital status was assessed by searching the Social Security 
Administration Death Master File (http://www.ntis.gov/products/ssa-dmf.aspx). 
Genotyping 
Genotyping was completed in the laboratory of Dr. Sharon Cresci (Washington 
University, St. Louis, MO), as previously described [29]. Patients were genotyped for the 
variants listed in Table 6.1, which were chosen due to their known functional effect on 
enzyme expression or activity and previous association with cardiovascular disease 
susceptibility. Genotyping was performed by pyrosequencing (rs10509681, rs41507953, 
rs751141, rs1126742, rs3093098, rs2108622) or using a Taqman allelic discrimination 
assay (rs890293) (Applied Biosystems, Foster City, CA).  
Statistical Analysis 
Data are presented as mean ± standard deviation or count (proportion) unless 
otherwise indicated.  Baseline characteristics by genotype were compared by Student’s 
t-test, one-way ANOVA, or chi-squared test, as appropriate.  Deviations from Hardy-
Weinberg equilibrium were evaluated by chi-squared test.   
For each variant, 5-year survival was compared between genotype groups by a 
log-rank test, assuming a dominant mode of inheritance.  If a relationship between 
genotype and survival was observed, Cox proportional hazards modeling adjusted for 
! "#$!
pre-specified covariates (Model 1:  age, sex, and race; Model 2:  age, sex, race, ACS 
type (ST elevation MI/left bundle branch block, non ST elevation MI, unstable angina), 
treatment strategy (medical management, percutaneous coronary intervention/coronary 
artery bypass graft surgery), and diabetes) was performed.  The CYP4F2 -91T>C and 
Val433Met variants have opposite effects on 20-HETE formation in vivo [17,19].  
Therefore, we also constructed a “co-dominant” model for CYP4F2 genotype in which 
patients who were wild-type at both loci were compared to patients who carried only the 
Met433 variant and patients who carried the -91C variant regardless of Val433Met 
genotype.   
Survival analysis was performed in the entire cohort and in Caucasians only to 
account for potential confounding due to population stratification.  The small number of 
events in African-Americans precluded separate statistical analysis in this subgroup.  
Analyses were performed using SAS 9.2 (SAS Institute, Cary, NC), and P<0.05 was 
considered statistically significant.   
To minimize the impact of multiple statistical tests conducted in our analysis, we 
estimated the false discovery rate (FDR) q-value of our findings, which is defined as the 
expected proportion of statistical tests deemed significant that are actually false positives 
(QVALUE) [30].  Due to the significant overlap between the full cohort and the 
Caucasians only cohort, q-values were estimated for just the Caucasians only analyses.  
We considered statistical tests from the unadjusted and adjusted association analyses 
as independent, even though each model assessed the same independent variable.  
Only q-values for significant findings are presented. 
Results 
The study population was 79% Caucasian and 36% women, and the overall 5-
year all-cause mortality rate was 17%.  The genotype distributions within each racial 
! "#$!
group were consistent with Hardy-Weinberg equilibrium (P>0.05), except for the 
CYP4A11 Phe434Ser variant (Table 6.2).  Consequently, the CYP4A11 polymorphism 
was excluded from further statistical analysis.  The CYP2J2 -50G>T, EPHX2 Lys55Arg, 
EPHX2 Arg287Gln, and CYP4F2 Val433Met polymorphisms were more frequent in 
African-Americans; the CYP2C8 Lys399Arg and CYP4F2 -91T>C polymorphisms were 
more frequent in Caucasians. 
 EPHX2 Lys55Arg, CYP2J2 -50G>T, and CYP4F2 genotype were significantly 
associated with survival following an ACS event (Table 6.3).  Patient characteristics by 
EPHX2 Lys55Arg, CYP2J2 -50G>T, and CYP4F2 genotype in all subjects and in 
Caucasians only are shown in Tables 6.4-6.9.  No significant differences in baseline 
characteristics were observed between the EPHX2 Lys55Arg (Tables 6.4 and 6.5) and 
CYP4F2 (Tables 6.8 and 6.9) genotype groups.  In CYP2J2 -50T carriers, discharge 
HDL cholesterol was significantly higher compared to wild-type individuals (Tables 6.6 
and 6.7).    
Compared to wild-type individuals, EPHX2 Arg55 variant allele carriers had a 
significantly higher risk of death following an ACS event (Figure 6.1). This relationship 
was most pronounced in Caucasians and persisted after adjustment for demographic 
and clinical covariates (Model 2:  hazard ratio (HR) 1.61 95% confidence interval (CI) 
1.01-2.55, P=0.045, q=0.064).   
In contrast, the 5-year mortality rate in CYP2J2 -50T carriers was lower than in 
wild-type individuals in the full cohort (9.6% vs. 18.1%) and in Caucasians only (5.6% vs. 
17.3%) (Figure 6.2).  In Caucasians, this association remained significant after 
adjustment for demographic and clinical covariates (Model 2:  HR 0.31 95% CI 0.11-
0.84, P=0.021, q=0.064).  
CYP4F2 genotype also influenced survival in ACS patients.  In the single variant 
analysis, CYP4F2 Met433 carriers tended to have a higher risk of death compared to 
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wild-type individuals in the full cohort (19.5% vs. 14.6%; HR 1.35 95% CI 0.93-1.96, 
P=0.118) and in Caucasians only (17.8% vs. 13.3%; HR 1.32 95% CI 0.86-2.05, 
P=0.207).  No association was observed between survival and CYP4F2 -91T>C in the 
full cohort (HR 0.92 95% CI 0.63-1.35, P=0.677), but 5-year mortality tended to be lower 
in CYP4F2 -91C carriers compared to wild-type individuals in the Caucasians only 
analysis (17.8% vs. 14.4%; HR 0.78 95% CI 0.49-1.23, P=0.275).  In the co-dominant 
analysis, carriers of the CYP4F2 Met433 variant allele alone had a significantly higher 
risk of death compared to individuals who were wild-type at both loci, but this 
relationship was abolished in those also carrying the -91C variant allele (Figure 6.3).  In 
Caucasians, the association between the Met433 variant and mortality remained 
significant after adjusting for age and gender (Model 1: HR 1.69 95% CI 1.01-2.85, 
P=0.048, q=0.064), but the relationship was attenuated and not statistically significant 
after adjusting for clinical covariates (Model 2: HR 1.62 95% CI 0.96-2.75, P=0.072). 
No association was observed between survival and EPHX2 Arg287Gln (All 
Subjects:  HR 0.88 95% CI 0.55-1.41, P=0.598; Caucasians:  HR 0.91 95% CI 0.52-
1.59, P=0.745; Figure 6.4) or CYP2C8 Lys399Arg genotype (All Subjects:  HR 0.87 95% 
CI 0.54-1.40, P=0.574; Caucasians:  HR 0.87 95% CI 0.53-1.45, P=0.600; Figure 6.5). 
Discussion 
Although preclinical studies suggest that potentiation of CYP epoxygenase-
derived EETs and inhibition of CYP !-hydroxylase-derived 20-HETE may improve 
outcomes following an ACS event, investigation of this therapeutic strategy in humans 
has been limited by the lack of approved pharmacologic agents that specifically 
modulate CYP-mediated eicosanoid metabolism.  Consequently, genetic epidemiologic 
studies investigating the association between functional genetic variation in the CYP 
epoxygenase and !-hydroxylase pathways and cardiovascular disease susceptibility 
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have been performed to initially characterize the biologic relevance of the pathways in 
humans at the population level.  To our knowledge, this is the first study to demonstrate 
that genetic variation in the CYP epoxygenases, sEH, and the CYP !-hydroxylases is 
associated with survival in ACS patients.  Our findings suggest that alterations in CYP-
mediated eicosanoid metabolism influence prognosis in patients with established CAD 
Moreover, our observations support the development of drugs that target these 
pathways as treatments for CAD and may help to identify subsets of the population that 
would most benefit from such therapies.  
EETs possess potent vasodilatory and anti-inflammatory effects [8,31], and are 
cardioprotective following ischemia/reperfusion injury [10,11,12].  Therefore, we 
hypothesized that genetic variants which result in lower EET biosynthesis or greater EET 
hydrolysis in vivo would have deleterious effects on survival.  Consistent with this 
hypothesis, presence of the EPHX2 Arg55 variant, which has higher apparent sEH 
activity in vivo [22], was associated with a greater risk of death following an ACS event.  
This association was most apparent in Caucasians and persisted after adjustment for 
demographic and clinical covariates.  Our observations are consistent with a prior study 
in the ARIC cohort demonstrating that presence of the EPHX2 Arg55 variant allele was 
associated with significantly higher risk of incident CAD in Caucasians [22].  Of note, 
sEH inhibitors are currently in clinical development for the treatment of cardiovascular 
and metabolic diseases [32].  Our results suggest that sEH inhibitors may have the 
greatest therapeutic utility in the subset of patients who are EPHX2 Arg55 variant allele 
carriers.  Future studies to evaluate the therapeutic efficacy of sEH inhibition specifically 
in Arg55 carriers are warranted.  
The CYP2J2 -50T polymorphism disrupts a Sp1 transcription factor binding site, 
leading to decreased CYP2J2 transcription in vivo [33].  The -50T polymorphism has 
been associated with higher risk of prevalent CAD in a German population [24], and 
! "#$!
higher risk of prevalent MI in a Han Chinese population [23].  In contrast to our 
hypothesis, we observed that presence of the CYP2J2 -50T variant allele was 
associated with the lower risk of death in ACS patients.  Interestingly, the -50T allele has 
also been associated with a lower risk of incident CAD in African-Americans in the ARIC 
cohort [21] and a lower risk of prevalent hypertension in Caucasians [34].  Although 
lower CYP2J2 transcription would be hypothesized to result in lower EET levels in vivo, 
we did not measure EET levels in this study, and so cannot establish a mechanistic link 
between the CYP2J2 -50T polymorphism, CYP epoxygenase activity, and survival in 
ACS patients.  Thus, additional studies are necessary to elucidate the mechanism 
underlying the observed association between CYP2J2 -50G>T and mortality. 
In contrast to the EETs, 20-HETE is vasoconstrictive and pro-inflammatory [9], 
and inhibition of 20-HETE formation is protective in preclinical models of myocardial 
ischemia/reperfusion injury [13,14,15,16].  CYP4F2 Val433Met has been associated with 
higher urinary 20-HETE excretion [19], and higher risk of hypertension [19] and stroke 
[18].  In contrast, the CYP4F2 -91T>C variant disrupts a nuclear factor-!B (NF-!B) 
binding site, resulting in less CYP4F2 transcription, lower urinary 20-HETE excretion, 
and lower risk of hypertension [17].  Consistent with the opposite effects of the CYP4F2 -
91C>T and Val433Met variants on 20-HETE formation in vivo, we observed that patients 
who carried only the Met433 polymorphism had a significantly greater risk of death, but 
that this relationship was abolished in individuals who also carried the -91C allele.  Of 
note, very few patients in INFORM carried the -91C allele without the Met433 variant.  
Thus future studies in larger cohorts are necessary to determine the relationship 
between the CYP4F2 -91T>C polymorphism and survival.     
There are several limitations to this study.  First, systemic levels of CYP-derived 
eicosanoids or inflammatory biomarkers were not measured in the INFORM cohort.  
Thus, we were unable to evaluate whether the association between EPHX2 Lys55Arg, 
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CYP2J2 -50G>T, and CYP4F2 genotype and mortality was specifically related to 
differences in eicosanoid levels or vascular inflammation, and future studies are 
necessary to elucidate the mechanism underlying the observed associations.  Also, the 
INFORM cohort was recruited exclusively from one city and was composed 
predominantly of Caucasian patients.  Consequently, our results may not be 
generalizable to other patient populations or racial groups.  In addition, although all-
cause mortality is a clinically relevant and robust endpoint, other outcomes, including 
hospitalizations, cardiovascular mortality, or development of heart failure, are also 
important endpoints to consider when evaluating prognosis following an ACS event.  
Finally, although we assessed the false discovery rate to minimize the impact of the 
multiple statistical tests, there is the potential for false positive associations.  The q-
values in the Caucasians only cohort were estimated to be !0.064.  Thus we have a high 
level of confidence in our results, but replication in an independent cohort is needed to 
validate our findings.  Despite these limitations, this is the first study to demonstrate that 
genetic variation in the CYP epoxygenases, sEH, and the CYP "-hydroxylases is 
associated with prognosis in ACS patients and lays an important foundation for future 
studies seeking to elucidate the role of these pathways in patients with established CAD.  
In conclusion, we observed that EPHX2 Lys55Arg, CYP2J2 -50G>T, and 
CYP4F2 genotype were associated with survival in ACS patients.  Future studies are 
necessary to validate these findings and explore the therapeutic potential of modulating 
the CYP epoxygenase and "-hydroxylase pathways in humans with established CAD. 
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Table 6.1:  Functional genetic variants in the CYP epoxygenases (CYP2J2, CYP2C8), sEH (EPHX2), and CYP !-hydroxylases 
(CYP4A11, CYP4F2) genotyped in the INFORM cohort 
Variant Nucleotide * Amino Acid Functional Effect  References 
    In vitro In vivo 
CYP2J2 
rs890293 -50G>T N/A " CYP2J2 transcription " CYP2J2 expression [24,33] 
 
CYP2C8 
rs10509681 30411A>G Lys399Arg " EET formation Unknown [35,36] 
 
EPHX2 
rs41507953  9846A>G Lys55Arg # EET hydrolysis " plasma epoxide:diol [22,37,38,39] 
rs751141 25206G>A Arg387Gln " EET hydrolysis Unknown [37,38,39] 
 
CYP4A11 
rs1126742 8610T>C Phe434Ser " 20-HETE formation " urinary 20-HETE [19,20] 
 
CYP4F2   
rs3093098 -91T>C N/A " CYP4F2 transcription " urinary 20-HETE [17] 
rs2108622 18000G>A Val433Met " 20-HETE formation # urinary 20-HETE  [19,40] 
* Relative to transcriptional start site, GenBank accession numbers:  AF272142 (CYP2J2), AL359672 (CYP2C8), NT_022666 
(EPHX2), AY369778.1 (CYP4A11), and AF467894 (CYP4F2). 
 
 
 
 
 
 
 
 
 
!
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Table 6.2:  Genotype frequencies in INFORM by race 
 Caucasians African-Americans 
Variant Count (Proportion) HW P-value Count (Proportion) HW P-value 
CYP2J2 
 -50G>T      
 G/G 486 (87.3%) 0.109 101 (81.5%) 0.868  
 G/T   66 (11.8%)     22 (17.7%) 
 T/T     5 (0.9%)       1 (0.8%) 
CYP2C8 
 Lys399Arg      
 A/A 416 (76.1%) 0.509 116 (95.1%) 0.781 
 A/G 124 (22.7%)          6 (4.9%) 
 G/G      7 (1.3%)         0 (0%) 
EPHX2     
 Lys55Arg      
 A/A 426 (78.2%) 0.540 76 (62.3%) 0.508 
 A/G 110 (20.2%)  39 (32.0%) 
 G/G      9 (1.7%)    7 (5.7%) 
 Arg287Gln      
 G/G 439 (80.9%) 0.535 89 (72.4%) 0.647 
 G/A   97 (17.9%)  32 (26.0%) 
 A/A      7 (1.3%)    2 (1.6%) 
CYP4A11 
 Phe434Ser      
 T/T     0 (0%) <0.001     0 (0%) <0.001 
 T/C 522 (97.4%)   115 (93.5%) 
 C/C   14 (2.6%)      8 (6.5%) 
CYP4F2   
 -91T>C      
 T/T 354 (66.3%) 0.566   59 (50.4%) 0.789 
 T/C 164 (30.7%)     49 (41.9%) 
 C/C    16 (3.0%)       9 (7.7%) 
 Val433Met 
 G/G 256 (48.1%) 0.678   95 (81.9%) 0.371 
 G/A 229 (43.1%)     19 (16.4%) 
 A/A    47 (8.8%)       2 (1.7%) 
 Co-dominant 
 WT 232 (46.0%) N/A   45 (41.3%) N/A 
 -91C only *     1 (0.2%)     44 (40.4%) 
 Met433 only  103 (20.4%)     10 (9.2%) 
 Both variants 168 (33.3%)     10 (9.2%) 
Genotypes are presented as count (proportion). 
* Because very few individuals carried only the -91C variant, the “-91C only” and “Both 
variants” groups were combined for the survival analysis (-91C±Val433Met).  
HW=Hardy-Weinberg, WT=wild-type 
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Table 6.3:  Hazard ratios between CYP2J2 -50G>T, EPHX2 Lys55Arg, and CYP4F2 genotype and 5-year mortality 
  All Subjects Caucasians only 
Variant HR 95% CI P-value HR 95% CI P-value  
EPHX2 Lys55Arg  
 G/A+G/G vs. AA  
 Unadjusted 1.50 1.02-2.22 0.042 1.64 1.04-2.58 0.032 
 Model 1 1.40 0.94-2.08 0.099 1.58 1.01-2.49 0.047 
 Model 2 1.40 0.93-2.09 0.103 1.61 1.01-2.55 0.045 
 
CYP2J2 -50G>T  
 G/T+T/T vs. G/G  
 Unadjusted 0.51 0.26-0.99 0.049 0.30 0.11-0.83 0.020 
 Model 1 0.52 0.26-1.02 0.060 0.33 0.12-0.91 0.031 
 Model 2 0.51 0.26-1.01 0.052 0.31 0.11-0.84 0.021 
 
CYP4F2 -91T>C ± Val433Met  
 Met433 only vs. WT 
 Unadjusted 1.72 1.07-2.79 0.026 1.75 1.04-2.94 0.035 
 Model 1 1.81 1.11-2.94 0.017 1.69 1.01-2.85 0.048 
 Model 2 1.75 1.08-2.85 0.024 1.62 0.96-2.75 0.072 
 
 -91C ± Met433 vs. WT 
 Unadjusted 1.16 0.75-1.80 0.501 0.96 0.57-1.63 0.883 
 Model 1 1.05 0.68-1.63 0.828 0.88 0.52-1.50 0.637 
 Model 2 1.08 0.69-1.69 0.736 0.99 0.58-1.70 0.977 
Model 1:  adjusted for age, gender, and race 
Model 2:  adjusted for age, gender, race, ACS type (STEMI/LBBB, NSTEMI, unstable angina), diabetes, treatment strategy (medical 
management, PCI/CABG) 
CI=confidence interval, HR=hazard ratio, WT=wild-type 
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Table 6.4:  Study population characteristics by EPHX2 Lys55Arg genotype in all 
subjects 
Characteristic Lys/Lys Lys/Arg+Arg/Arg P-Value 
  N=502 N=165 
Age (years) 60.4 ± 12.4 60.8 ± 12.8 0.693   
Female gender (%) 177 (35.3%) 64 (38.8%) 0.413  
African-American race (%) 76 (15.1%) 46 (27.9%) <0.001 
ACS Classification Type   0.064 
 ST elevation MI/LBBB 154 (30.7%) 36 (21.8%) 
 Non ST elevation MI 152 (30.3%) 52 (31.5%)  
 Unstable angina 196 (39.0%) 77 (46.7%)   
History/Risk Factors  
 MI (%) 159 (31.7%) 58 (35.2%) 0.408 
 Hypertension (%) 324 (64.5%) 113 (68.5%) 0.355 
 Diabetes (%) 136 (27.1%) 51 (30.9%) 0.344 
 Hyperlipidemia (%) 295 (58.8%) 109 (66.1%) 0.096 
 Heart Failure (%) 38 (7.6%) 14 (8.5%) 0.704 
Smoking Status   0.869 
 Current 183 (36.5%) 57 (34.5%) 
 Former 178 (35.5%) 62 (37.6%) 
 Never 140 (27.9%) 46 (27.9%) 
BMI (kg/m2) * 29.6 ± 6.3 30.2 ± 6.7 0.282 
SBP (mmHg) * 136.6 ± 26.6 138.8 ± 25.5 0.339  
DBP (mmHg) * 73.9 ± 15.6 76.2 ± 18.7 0.118  
Total cholesterol (mg/dL) # 178.4 ± 39.6 181.6 ± 49.1 0.436  
LDL (mg/dL) # 103.5 ± 34.5 102.3 ± 44.2 0.757  
HDL (mg/dL) # 41.6 ± 14.7 43.6 ± 17.9 0.183  
Triglycerides (mg/dL) # 176.4 ± 117.8 181.2 ± 144.9 0.698  
Treatment Strategy   0.252 
 Medical Management 182 (36.3%) 68 (41.2%) 
 PCI 299 (59.6%) 87 (52.7%) 
 CABG 21 (4.2%) 10 (6.1%)  
Discharge Medications 
 Beta-blocker (%) 412 (82.2%) 124 (75.6%) 0.063 
 Statin (%) 382 (76.1%) 121 (73.3%) 0.475 
 Aspirin (%) 463 (92.4%) 157 (95.7%) 0.142 
ACS=acute coronary syndrome, BMI=body mass index, CABG=coronary artery bypass 
graft, DBP=diastolic blood pressure, HDL=high density lipoprotein, LBBB=left bundle 
branch block, LDL=low density lipoprotein, MI=myocardial infarction, PCI=percutaneous 
coronary intervention, SBP=systolic blood pressure 
Data presented as mean ± standard deviation or count (proportion).  Continuous 
variables were compared between groups by Student’s t-test.  Categorical variables 
were compared between groups by chi-squared test or Fisher’s exact test. 
* Measured at admission # Measured at discharge 
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Table 6.5:  Study population characteristics by EPHX2 Lys55Arg genotype in 
Caucasians 
Characteristic Lys/Lys Lys/Arg+Arg/Arg P-Value 
  N=426 N=119 
Age (years) 61.6 ± 12.5 63.3 ± 12.3 0.186  
Female gender (%) 143 (33.6%) 46 (38.7%) 0.303  
ACS Classification Type   0.600 
 ST elevation MI/LBBB 134 (31.5%) 35 (29.4%)  
 Non ST elevation MI 135 (31.7%) 41 (34.5%)  
 Unstable angina 157 (36.9%) 43 (36.1%)   
History/Risk Factors  
 MI (%) 135 (31.7%) 38 (31.9%) 0.960 
 Hypertension (%) 265 (62.2%) 76 (63.9%) 0.741 
 Diabetes (%) 101 (23.7%) 33 (27.7%) 0.368 
 Hyperlipidemia (%) 263 (61.7%) 84 (70.6%) 0.076 
 Heart Failure (%) 22 (5.2%) 8 (6.7%) 0.510 
Smoking Status   0.543 
 Current 144 (33.9%) 34 (28.6%) 
 Former 159 (37.4%) 49 (41.2%) 
 Never 122 (28.7%) 36 (30.3%) 
BMI (kg/m2) * 29.4 ± 5.9 29.8 ± 5.8 0.521 
SBP (mmHg) * 134.6 ± 24.6 135.6 ± 24.5 0.713  
DBP (mmHg) * 72.5 ± 14.3 72.4 ± 16.4 0.949  
Total cholesterol (mg/dL) # 177.1 ± 38.8 180.4 ± 48.1 0.469  
LDL (mg/dL) # 102.4 ± 33.2 100.0 ± 41.1 0.550 
HDL (mg/dL) # 40.3 ± 14.0 41.7 ± 17.5 0.419  
Triglycerides (mg/dL) # 182.5 ± 123.2 196.6 ± 157.7 0.340  
Treatment Strategy   0.154 
 Medical Management 131 (30.8%) 27 (22.7%)  
 PCI 277 (65.0%) 84 (70.6%)  
 CABG 18 (4.2%) 8 (6.7%)  
Discharge Medications 
 Beta-blocker (%) 352 (82.8%) 93 (78.2%) 0.243 
 Statin (%) 334 (78.4%) 98 (82.4%) 0.347 
 Aspirin (%) 396 (93.2%) 116 (97.5%) 0.078 
ACS=acute coronary syndrome, BMI=body mass index, CABG=coronary artery bypass 
graft, DBP=diastolic blood pressure, HDL=high density lipoprotein, LBBB=left bundle 
branch block, LDL=low density lipoprotein, MI=myocardial infarction, PCI=percutaneous 
coronary intervention, SBP=systolic blood pressure 
Data presented as mean ± standard deviation or count (proportion).  Continuous 
variables were compared between groups by Student’s t-test.  Categorical variables 
were compared between groups by chi-squared test or Fisher’s exact test. 
* Measured at admission # Measured at discharge 
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Table 6.6:  Study population characteristics by CYP2J2 -50G>T genotype in all 
subjects 
Characteristic G/G G/T+T/T P-Value 
  N=587 N=94 
Age (years) 60.8 ± 12.6 58.7 ± 11.5 0.123   
Female gender (%) 210 (35.8%) 40 (42.6%) 0.206  
African-American race (%) 101 (17.2%) 23 (24.5%) 0.090 
ACS Classification Type   0.585 
 ST elevation MI/LBBB 168 (28.6%) 25 (26.6%) 
 Non ST elevation MI 185 (31.5%) 25 (26.6%)  
 Unstable angina 234 (39.9%) 44 (46.8%)   
History/Risk Factors  
 MI (%) 192 (32.7%) 31 (33.0%) 0.959 
 Hypertension (%) 387 (65.9%) 57 (60.6%) 0.317 
 Diabetes (%) 166 (28.3%) 22 (23.4%) 0.326 
 Hyperlipidemia (%) 358 (61.0%) 52 (55.3%) 0.297 
 Heart Failure (%) 48 (8.2%) 5 (5.3%) 0.337 
Smoking Status   0.455 
 Current 211 (36.0%) 33 (35.1%) 
 Former 208 (35.5%) 39 (41.5%) 
 Never 167 (28.5%) 22 (23.4%) 
BMI (kg/m2) * 29.7 ± 6.3 29.8 ± 6.9 0.960 
SBP (mmHg) * 137.0 ± 26.9 136.4 ± 24.0 0.844  
DBP (mmHg) * 74.2 ± 16.7 75.7 ± 14.9 0.393  
Total cholesterol (mg/dL) # 178.2 ± 41.5 182.8 ± 45.4 0.360  
LDL (mg/dL) # 102.2 ± 37.0 107.1 ± 37.5 0.288  
HDL (mg/dL) # 41.5 ± 14.5 45.4 ± 20.5 0.037  
Triglycerides (mg/dL) # 179.0 ± 126.9 171.5 ± 110.8 0.619  
Treatment Strategy   0.853 
 Medical Management 216 (36.8%) 37 (39.4%) 
 PCI 344 (58.6%) 54 (57.4%) 
 CABG 27 (4.6%) 3 (3.2%)  
Discharge Medications 
 Beta-blocker (%) 475 (81.1%) 73 (77.7%) 0.439 
 Statin (%) 436 (74.3%) 77 (81.9%) 0.111 
 Aspirin (%) 546 (93.2%) 89 (94.7%) 0.585 
ACS=acute coronary syndrome, BMI=body mass index, CABG=coronary artery bypass 
graft, DBP=diastolic blood pressure, HDL=high density lipoprotein, LBBB=left bundle 
branch block, LDL=low density lipoprotein, MI=myocardial infarction, PCI=percutaneous 
coronary intervention, SBP=systolic blood pressure 
Data presented as mean ± standard deviation or count (proportion).  Continuous 
variables were compared between groups by Student’s t-test.  Categorical variables 
were compared between groups by chi-squared test or Fisher’s exact test. 
* Measured at admission # Measured at discharge 
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Table 6.7:  Study population characteristics by CYP2J2 -50G>T genotype in 
Caucasians 
Characteristic G/G G/T+T/T P-Value 
  N=486 N=71 
Age (years) 62.2 ± 12.6 60.3 ± 11.6 0.222  
Female gender (%) 171 (35.2%) 25 (35.2%) 0.997  
ACS Classification Type   0.209 
 ST elevation MI/LBBB 154 (31.7%) 19 (26.8%) 
 Non ST elevation MI 161 (33.1%) 18 (25.4%)  
 Unstable angina 171 (35.2%) 34 (47.9%)   
History/Risk Factors  
 MI (%) 155 (31.9%) 24 (33.8%) 0.748 
 Hypertension (%) 308 (63.4%) 40 (56.3%) 0.253 
 Diabetes (%) 123 (25.3%) 12 (16.9%) 0.123 
 Hyperlipidemia (%) 309 (63.6%) 41 (57.7%) 0.342 
 Heart Failure (%) 28 (5.8%) 3 (4.2%) 0.785 
Smoking Status   0.517 
 Current 159 (32.8%) 23 (32.4%) 
 Former 182 (37.5%) 31 (43.7%) 
 Never 144 (29.7%) 17 (23.9%) 
BMI (kg/m2) * 29.6 ± 5.9 28.6 ± 5.9 0.167 
SBP (mmHg) * 134.3 ± 25.0 136.2 ± 21.5 0.554  
DBP (mmHg) * 72.1 ± 15.0 74.7 ± 14.3 0.170  
Total cholesterol (mg/dL) # 176.8 ± 40.3 182.1 ± 45.3 0.338  
LDL (mg/dL) # 101.0 ± 35.1 105.3 ± 35.2 0.388  
HDL (mg/dL) # 40.0 ± 13.5 44.9 ± 21.7 0.017  
Triglycerides (mg/dL) # 186.4 ± 132.9 182.6 ± 121.0 0.834  
Treatment Strategy   0.765 
 Medical Management 138 (28.4%) 22 (31.0%) 
 PCI 324 (66.7%) 47 (66.2%)  
 CABG 24 (4.9%) 2 (2.8%)  
Discharge Medications 
 Beta-blocker (%) 402 (82.7%) 54 (76.1%) 0.174 
 Statin (%) 381 (78.4%) 59 (83.1%) 0.363 
 Aspirin (%) 455 (93.6%) 70 (98.6%) 0.105 
ACS=acute coronary syndrome, BMI=body mass index, CABG=coronary artery bypass 
graft, DBP=diastolic blood pressure, HDL=high density lipoprotein, LBBB=left bundle 
branch block, LDL=low density lipoprotein, MI=myocardial infarction, PCI=percutaneous 
coronary intervention, SBP=systolic blood pressure 
Data presented as mean ± standard deviation or count (proportion).  Continuous 
variables were compared between groups by Student’s t-test.  Categorical variables 
were compared between groups by chi-squared test or Fisher’s exact test. 
* Measured at admission # Measured at discharge 
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Table 6.8:  Study population characteristics by CYP4F2 genotype in all subjects 
Characteristic No Variants Met433 Only -91C±Met433 P-Value 
  N=277 N=113  N=223 
Age (years) 60.2 ± 12.3 61.4 ± 12.7 61.1 ± 12.8 0.576   
Female gender (%) 102 (36.8%) 50 (44.2%) 74 (33.2%) 0.139  
African-American race (%) 45 (16.2%) 10 (8.8%) 54 (24.2%) 0.002 
ACS Classification Type    0.820 
 ST elevation MI/LBBB 78 (28.2%) 32 (28.3%) 64 (28.7%)  
 Non ST elevation MI 93 (33.6%) 35 (31.0%) 64 (28.7%) 
 Unstable angina 106 (38.3%) 46 (40.7%) 95 (42.6%)   
History/Risk Factors  
 MI (%) 98 (35.4%) 39 (34.5%) 65 (29.1%) 0.313 
 Hypertension (%) 179 (64.6%) 75 (66.4%) 145 (65.0%) 0.947 
 Diabetes (%) 83 (30.0%) 32 (28.3%) 52 (23.3%) 0.243 
 Hyperlipidemia (%) 170 (61.4%) 64 (56.6%) 132 (59.2%) 0.675 
 Heart Failure (%) 22 (7.9%) 8 (7.1%) 21 (9.4%) 0.729 
Smoking Status    0.647 
 Current 103 (37.2%) 44 (38.9%) 73 (32.7%)  
 Former 96 (34.7%) 41 (36.3%) 90 (40.4%)  
 Never 78 (28.2%) 28 (24.8%) 60 (26.9%) 
BMI (kg/m2) * 29.3 ± 6.0 30.4 ± 6.7 30.0 ± 6.9 0.252 
SBP (mmHg) * 136.0 ± 24.6 138.1 ± 27.9 137.1 ± 26.5 0.748  
DBP (mmHg) * 73.4 ± 16.0 73.1 ± 17.2 75.3 ± 15.5 0.340  
Total cholesterol (mg/dL) # 178.8 ± 44.5 184.2 ± 44.1 176.7 ± 40.0 0.357  
LDL (mg/dL) # 103.9 ± 40.2 104.8 ± 36.9 102.0 ± 35.4 0.814  
HDL (mg/dL) # 41.2 ± 12.3 41.8 ± 18.1 43.3 ± 17.8 0.413  
Triglycerides (mg/dL) # 174.7 ± 131.1 196.2 ± 117.1 166.5 ± 113.6 0.146  
Treatment Strategy      0.908 
 Medical Management 100 (36.1%) 43 (38.1%) 84 (37.7%) 
 PCI 162 (58.5%) 65 (57.5%) 132 (59.2%) 
 CABG 15 (5.4%) 5 (4.4%) 7 (3.1%)  
Discharge Medications 
 Beta-blocker (%) 226 (81.6%) 88 (77.9%) 181 (81.5%) 0.667 
 Statin (%) 220 (79.4%) 86 (76.1%) 159 (71.3%) 0.108 
 Aspirin (%) 267 (96.4%) 104 (92.0%) 203 (91.4%) 0.052 
ACS=acute coronary syndrome, BMI=body mass index, CABG=coronary artery bypass 
graft, DBP=diastolic blood pressure, HDL=high density lipoprotein, LBBB=left bundle 
branch block, LDL=low density lipoprotein, MI=myocardial infarction, PCI=percutaneous 
coronary intervention, SBP=systolic blood pressure 
Data presented as mean ± standard deviation or count (proportion).  Continuous 
variables were compared between groups by Student’s t-test.  Categorical variables 
were compared between groups by chi-squared test or Fisher’s exact test. 
* Measured at admission # Measured at discharge 
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Table 6.9:  Study population characteristics by CYP4F2 genotype in Caucasians 
Characteristic No Variants Met433 Only -91C±Met433 P-Value 
  N=232 N=103 N=169 
Age (years) 61.3 ± 12.4 62.5 ± 12.6 62.9 ± 12.9 0.397  
Female gender (%) 82 (35.3%) 45 (43.7%) 50 (29.6%) 0.061  
ACS Classification Type    0.484 
 ST elevation MI/LBBB 70 (30.2%) 29 (28.2%) 57 (33.7%)  
 Non ST elevation MI 84 (36.2%) 32 (31.1%) 49 (29.0%) 
 Unstable angina 78 (33.6%) 42 (40.8%) 63 (37.3%)   
History/Risk Factors  
 MI (%) 83 (35.8%) 34 (33.0%) 46 (27.2%) 0.192 
 Hypertension (%) 146 (62.9%) 66 (64.1%) 103 (60.9%) 0.860 
 Diabetes (%) 62 (26.7%) 29 (28.2%) 30 (17.8%) 0.063 
 Hyperlipidemia (%) 142 (61.2%) 61 (59.2%) 110 (65.1%) 0.582 
 Heart Failure (%) 14 (6.0%) 8 (7.8%) 8 (4.7%) 0.589 
Smoking Status    0.884 
 Current 78 (33.6%) 36 (35.0%) 51 (30.2%)  
 Former 85 (36.6%) 39 (37.9%) 69 (40.8%)  
 Never 69 (29.7%) 28 (27.2%) 49 (29.0%) 
BMI (kg/m2) * 29.1 ± 5.8 30.1 ± 6.1 29.4 ± 6.2 0.400 
SBP (mmHg) * 133.2 ± 23.2 136.5 ± 26.0 136.3 ± 25.4 0.342  
DBP (mmHg) * 71.4 ± 14.6 71.9 ± 16.1 73.9 ± 14.3 0.237  
Total cholesterol (mg/dL) # 176.4 ± 41.0 183.9 ± 45.3 176.0 ± 39.7 0.286  
LDL (mg/dL) # 101.7 ± 35.5 103.7 ± 37.3 102.0 ± 35.0 0.916  
HDL (mg/dL) # 40.1 ± 12.0 41.2 ± 18.3 41.4 ± 16.3 0.693  
Triglycerides (mg/dL) # 182.0 ± 138.1 202.9 ± 118.3 172.3 ± 121.0 0.202  
Treatment Strategy    0.202 
 Medical Management 68 (29.3%) 36 (35.0%) 42 (24.9%) 
 PCI 151 (65.1%) 63 (61.2%) 121 (71.6%) 
 CABG 13 (5.6%) 4 (3.9%) 6 (3.6%)  
Discharge Medications 
 Beta-blocker (%) 193 (83.2%) 79 (76.7%) 140 (82.8%) 0.330 
 Statin (%) 188 (81.0%) 80 (77.7%) 133 (78.7%) 0.736 
 Aspirin (%) 225 (97.0%) 94 (91.3%) 159 (94.1%) 0.079 
ACS=acute coronary syndrome, BMI=body mass index, CABG=coronary artery bypass 
graft, DBP=diastolic blood pressure, HDL=high density lipoprotein, LBBB=left bundle 
branch block, LDL=low density lipoprotein, MI=myocardial infarction, PCI=percutaneous 
coronary intervention, SBP=systolic blood pressure 
Data presented as mean ± standard deviation or count (proportion).  Continuous 
variables were compared between groups by Student’s t-test.  Categorical variables 
were compared between groups by chi-squared test or Fisher’s exact test. 
* Measured at admission # Measured at discharge 
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Figure Legends 
Figure 6.1:  Kaplan-Meier curves and mortality rates by EPHX2 Lys55Arg genotype in 
(A) all subjects and (B) Caucasians only.  
Figure 6.2:  Kaplan-Meier curves and mortality rates by CYP2J2 -50G>T genotype in 
(A) all subjects and (B) Caucasians only.  
Figure 6.3:  Kaplan-Meier curves and mortality rates by CYP4F2 genotype in (A) all 
subjects and (B) Caucasians only.  
Figure 6.4:  Kaplan-Meier curves and mortality rates by EPHX2 Arg287Gln genotype 
in (A) all subjects and (B) Caucasians only.  
Figure 6.5:  Kaplan-Meier curves and mortality rates by CYP2C8 Lys399Arg genotype 
in (A) all subjects and (B) Caucasians only.  
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Figure 6.1: Prognosis in ACS patients by EPHX2 Lys55Arg genotype 
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Figure 6.2:  Prognosis in ACS patients by CYP2J2 -50G>T genotype 
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Figure 6.3:  Prognosis in ACS patients by CYP4F2 genotype 
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Figure 6.4:  Prognosis in ACS patients by EPHX2 Arg287Gln genotype 
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Figure 6.5:  Prognosis in ACS patients by CYP2C8 Lys399Arg genotype 
 
 
  
0.75
0.8
0.85
0.9
0.95
1
0 1 2 3 4 5
S
u
rv
iv
a
l
Time (years)
Survival by Cyp2C8 Lys399Arg 
Genotype (Caucasians only)
Lys/Lys Arg399 Carrier
0.75
0.8
0.85
0.9
0.95
1
0 1 2 3 4 5
S
u
rv
iv
a
l
Time (years)
Survival by CYP2C8 Lys399Arg 
Genotype (All Subjects)
Lys/Lys Arg399 Carrier
! "
16.6%
14.5%
0%
10%
20%
30%
Lys/Lys Arg399 Carrier
M
o
rt
a
li
ty
 a
t 
5
-y
e
a
rs
 (
%
)
5-Year Mortality Rate 
(Caucasians only)
17.3%
15.3%
0%
10%
20%
30%
Lys/Lys Arg399 Carrier
M
o
rt
a
li
ty
 a
t 
5
-y
e
a
rs
 (
%
)
5-Year Mortality Rate 
(All Subjects) 
Log-rank 
P=0.573
Log-rank 
P=0.600
! "##!
References 
 
1. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, et al. (2011) Heart disease 
and stroke statistics--2011 update: a report from the American Heart Association. 
Circulation 123: e18-e209. 
2. Libby P, Ridker PM, Maseri A (2002) Inflammation and atherosclerosis. Circulation 
105: 1135-1143. 
3. Libby P, Ridker PM (2004) Inflammation and atherosclerosis: role of C-reactive 
protein in risk assessment. Am J Med 116 Suppl 6A: 9S-16S. 
4. Kavsak PA, Ko DT, Newman AM, Palomaki GE, Lustig V, et al. (2008) "Upstream 
markers" provide for early identification of patients at high risk for myocardial 
necrosis and adverse outcomes. Clin Chim Acta 387: 133-138. 
5. de Lemos JA, Morrow DA, Sabatine MS, Murphy SA, Gibson CM, et al. (2003) 
Association between plasma levels of monocyte chemoattractant protein-1 and 
long-term clinical outcomes in patients with acute coronary syndromes. 
Circulation 107: 690-695. 
6. Kavsak PA, Ko DT, Newman AM, Palomaki GE, Lustig V, et al. (2007) Risk 
stratification for heart failure and death in an acute coronary syndrome population 
using inflammatory cytokines and N-terminal pro-brain natriuretic peptide. Clin 
Chem 53: 2112-2118. 
7. Ridker PM, Rifai N, Pfeffer M, Sacks F, Lepage S, et al. (2000) Elevation of tumor 
necrosis factor-alpha and increased risk of recurrent coronary events after 
myocardial infarction. Circulation 101: 2149-2153. 
8. Zeldin DC (2001) Epoxygenase pathways of arachidonic acid metabolism. J Biol 
Chem 276: 36059-36062. 
9. Roman RJ (2002) P-450 metabolites of arachidonic acid in the control of 
cardiovascular function. Physiol Rev 82: 131-185. 
10. Seubert J, Yang B, Bradbury JA, Graves J, Degraff LM, et al. (2004) Enhanced 
postischemic functional recovery in CYP2J2 transgenic hearts involves 
mitochondrial ATP-sensitive K+ channels and p42/p44 MAPK pathway. Circ Res 
95: 506-514. 
11. Seubert JM, Sinal CJ, Graves J, DeGraff LM, Bradbury JA, et al. (2006) Role of 
soluble epoxide hydrolase in postischemic recovery of heart contractile function. 
Circ Res 99: 442-450. 
12. Motoki A, Merkel MJ, Packwood WH, Cao Z, Liu L, et al. (2008) Soluble epoxide 
hydrolase inhibition and gene deletion are protective against myocardial 
ischemia-reperfusion injury in vivo. Am J Physiol Heart Circ Physiol 295: H2128-
2134. 
! "#$!
13. Nithipatikom K, Gross ER, Endsley MP, Moore JM, Isbell MA, et al. (2004) Inhibition 
of cytochrome P450omega-hydroxylase: a novel endogenous cardioprotective 
pathway. Circ Res 95: e65-71. 
14. Gross ER, Nithipatikom K, Hsu AK, Peart JN, Falck JR, et al. (2004) Cytochrome 
P450 omega-hydroxylase inhibition reduces infarct size during reperfusion via 
the sarcolemmal KATP channel. J Mol Cell Cardiol 37: 1245-1249. 
15. Lv X, Wan J, Yang J, Cheng H, Li Y, et al. (2008) Cytochrome P450 omega-
hydroxylase inhibition reduces cardiomyocyte apoptosis via activation of ERK1/2 
signaling in rat myocardial ischemia-reperfusion. Eur J Pharmacol 596: 118-126. 
16. Yousif MH, Benter IF, Roman RJ (2009) Cytochrome P450 metabolites of 
arachidonic acid play a role in the enhanced cardiac dysfunction in diabetic rats 
following ischaemic reperfusion injury. Auton Autacoid Pharmacol 29: 33-41. 
17. Liu H, Zhao Y, Nie D, Shi J, Fu L, et al. (2008) Association of a functional 
cytochrome P450 4F2 haplotype with urinary 20-HETE and hypertension. J Am 
Soc Nephrol 19: 714-721. 
18. Fava C, Montagnana M, Almgren P, Rosberg L, Lippi G, et al. (2008) The V433M 
variant of the CYP4F2 is associated with ischemic stroke in male Swedes 
beyond its effect on blood pressure. Hypertension 52: 373-380. 
19. Ward NC, Tsai IJ, Barden A, van Bockxmeer FM, Puddey IB, et al. (2008) A single 
nucleotide polymorphism in the CYP4F2 but not CYP4A11 gene is associated 
with increased 20-HETE excretion and blood pressure. Hypertension 51: 1393-
1398. 
20. Gainer JV, Bellamine A, Dawson EP, Womble KE, Grant SW, et al. (2005) 
Functional variant of CYP4A11 20-hydroxyeicosatetraenoic acid synthase is 
associated with essential hypertension. Circulation 111: 63-69. 
21. Lee CR, North KE, Bray MS, Couper DJ, Heiss G, et al. (2007) CYP2J2 and 
CYP2C8 polymorphisms and coronary heart disease risk: the Atherosclerosis 
Risk in Communities (ARIC) study. Pharmacogenet Genomics 17: 349-358. 
22. Lee CR, North KE, Bray MS, Fornage M, Seubert JM, et al. (2006) Genetic variation 
in soluble epoxide hydrolase (EPHX2) and risk of coronary heart disease: The 
Atherosclerosis Risk in Communities (ARIC) study. Hum Mol Genet 15: 1640-
1649. 
23. Liu PY, Li YH, Chao TH, Wu HL, Lin LJ, et al. (2006) Synergistic effect of 
cytochrome P450 epoxygenase CYP2J2*7 polymorphism with smoking on the 
onset of premature myocardial infarction. Atherosclerosis. 
24. Spiecker M, Darius H, Hankeln T, Soufi M, Sattler AM, et al. (2004) Risk of coronary 
artery disease associated with polymorphism of the cytochrome P450 
epoxygenase CYP2J2. Circulation 110: 2132-2136. 
! "#$!
25. Cresci S, Jones PG, Sucharov CC, Marsh S, Lanfear DE, et al. (2008) Interaction 
between PPARA genotype and beta-blocker treatment influences clinical 
outcomes following acute coronary syndromes. Pharmacogenomics 9: 1403-
1417. 
26. Lanfear DE, Jones PG, Marsh S, Cresci S, McLeod HL, et al. (2005) Beta2-
adrenergic receptor genotype and survival among patients receiving beta-blocker 
therapy after an acute coronary syndrome. Jama 294: 1526-1533. 
27. Zineh I, Beitelshees AL, Welder GJ, Hou W, Chegini N, et al. (2008) Epithelial 
neutrophil-activating peptide (ENA-78), acute coronary syndrome prognosis, and 
modulatory effect of statins. PLoS ONE 3: e3117. 
28. Braunwald E (1989) Unstable angina. A classification. Circulation 80: 410-414. 
29. Marsh S, King CR, Garsa AA, McLeod HL (2005) Pyrosequencing of clinically 
relevant polymorphisms. Methods Mol Biol 311: 97-114. 
30. Storey JD, Tibshirani R (2003) Statistical significance for genomewide studies. Proc 
Natl Acad Sci U S A 100: 9440-9445. 
31. Deng Y, Theken KN, Lee CR (2010) Cytochrome P450 epoxygenases, soluble 
epoxide hydrolase, and the regulation of cardiovascular inflammation. J Mol Cell 
Cardiol 48: 331-341. 
32. Chen D, Whitcomb R, Macintyre E, Tran V, Do ZN, et al. (2011) Pharmacokinetics 
and Pharmacodynamics of AR9281, an Inhibitor of Soluble Epoxide Hydrolase, in 
Single- and Multiple-Dose Studies in Healthy Human Subjects. J Clin Pharmacol. 
33. Spiecker M, Zeldin DC, Mugge A, Tenderich G, Liao JK, et al. Reduced human 
myocardial mRNA expression of CYP2J2 in individuals with the G-50T promoter 
polymorphism; 2006 October 31, 2006; Chicago, USA. Circulation 691, II-117. 
pp. II-117. 
34. King LM, Gainer JV, David GL, Dai D, Goldstein JA, et al. (2005) Single nucleotide 
polymorphisms in the CYP2J2 and CYP2C8 genes and the risk of hypertension. 
Pharmacogenet Genomics 15: 7-13. 
35. Dai D, Zeldin DC, Blaisdell JA, Chanas B, Coulter SJ, et al. (2001) Polymorphisms in 
human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and 
arachidonic acid. Pharmacogenetics 11: 597-607. 
36. Lundblad MS, Stark K, Eliasson E, Oliw E, Rane A (2005) Biosynthesis of 
epoxyeicosatrienoic acids varies between polymorphic CYP2C enzymes. 
Biochem Biophys Res Commun 327: 1052-1057. 
37. Koerner IP, Jacks R, DeBarber AE, Koop D, Mao P, et al. (2007) Polymorphisms in 
the human soluble epoxide hydrolase gene EPHX2 linked to neuronal survival 
after ischemic injury. J Neurosci 27: 4642-4649. 
! "#$!
38. Przybyla-Zawislak BD, Srivastava PK, Vazquez-Matias J, Mohrenweiser HW, 
Maxwell JE, et al. (2003) Polymorphisms in human soluble epoxide hydrolase. 
Mol Pharmacol 64: 482-490. 
39. Sandberg M, Hassett C, Adman ET, Meijer J, Omiecinski CJ (2000) Identification 
and functional characterization of human soluble epoxide hydrolase genetic 
polymorphisms. J Biol Chem 275: 28873-28881. 
40. Stec DE, Roman RJ, Flasch A, Rieder MJ (2007) Functional polymorphism in human 
CYP4F2 decreases 20-HETE production. Physiol Genomics 30: 74-81. 
 
 
  
 
 
 
Chapter VII:  Discussion and Perspective 
Vascular inflammation is integral to the pathophysiology of atherosclerotic 
cardiovascular disease, from the initiation of plaque formation to progression to acute 
coronary syndromes (ACS) [1].  Consequently, novel pharmacologic agents that 
specifically modulate vascular inflammation may offer therapeutic potential for the 
treatment of atherosclerosis.  Accumulating evidence suggests that cytochrome P450 
(CYP)-derived eicosanoids are involved in the regulation of inflammation.  CYP 
epoxygenase-derived epoxyeicosatrienoic acids (EETs) possess potent anti-
inflammatory properties by attenuating cytokine-induced leukocyte adhesion to the 
vascular wall via inhibition of nuclear factor-!B (NF-!B) activation [2].  Conversely, 20-
hydroxyeicosatetraenoic acid (20-HETE), the product of "-hydroxylation of arachidonic 
acid, induces expression of cellular adhesion molecules and cytokines via NF-!B 
activation, thereby promoting inflammation [3].  Because of the divergent effects of the 
CYP epoxygenase and "-hydroxylase pathways in the regulation of inflammation, 
alterations in the functional balance between these parallel pathways may contribute to 
the pathogenesis and progression of inflammatory diseases, including atherosclerosis.  
The objectives of the work described in this doctoral dissertation were to characterize 
the effect of inflammation, metabolic dysfunction, and cardiovascular disease on the 
functional balance between the CYP epoxygenase and "-hydroxylase pathways, and 
explore the potential of modulating CYP-mediated eicosanoid metabolism as an anti-
inflammatory therapeutic strategy for the treatment of atherosclerotic cardiovascular 
disease. 
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It is well established that acute inflammatory stimuli alter hepatic CYP expression 
in vitro and in vivo [4,5,6], but the effect on CYP-mediated eicosanoid metabolism across 
tissues had not been rigorously evaluated.  Therefore, we first sought to determine the 
effect of systemic administration of lipopolysaccharide (LPS), a well-characterized acute 
inflammatory stimulus, on CYP epoxygenase and !-hydroxylase expression and 
metabolic activity in liver, kidney, lung, and heart [7] (Chapter II).  Acute activation of the 
innate immune response altered CYP expression and metabolic activity in a tissue-, 
isoform-, and time-dependent manner.  Moreover, the effect of LPS on the functional 
balance between the CYP epoxygenase and !-hydroxylase pathways varied by tissue, 
highlighting the relative differences in CYP-mediated eicosanoid metabolism across 
tissues under inflammatory conditions.  
These observations suggested that alteration of CYP-mediated eicosanoid 
metabolism is an important consequence of the acute inflammatory response in vivo and 
that modulating the pathways to increase EETs and decrease 20-HETE may have 
therapeutic potential, particularly in tissues where inflammatory stimuli tip the functional 
balance in favor of CYP !-hydroxylase-mediated 20-HETE biosynthesis, such as liver.  
We have recently shown that potentiation of the CYP epoxygenase pathway, via 
enhancement of CYP epoxygenase-mediated EET formation or inhibition of soluble 
epoxide hydrolase (sEH)-mediated EET hydrolysis, attenuates acute vascular 
inflammation in vivo [8].  Therefore, we sought to determine whether inhibition of the 
CYP !-hydroxylase pathway would have a similar anti-inflammatory effect following LPS 
administration, with the ultimate goal of investigating dual modulation of the pathways as 
a novel anti-inflammatory therapeutic strategy (Chapter III).  In contrast to our 
hypothesis, inhibition of 20-HETE biosynthesis or the putative 20-HETE receptor did not 
attenuate LPS-induced inflammatory gene expression, regardless of the tissue 
evaluated, inhibitor dose, or treatment regimen, demonstrating that the CYP !-
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hydroxylase pathway does not contribute to the acute inflammatory response following 
LPS administration.     
Although it is not a key regulator of LPS-induced acute inflammation in vivo, 20-
HETE stimulates the production of reactive oxygen species by NADPH oxidase [9] and 
endothelial nitric oxide synthase uncoupling via NF-!B activation [10,11] in endothelial 
cells, suggesting that the CYP "-hydroxylase pathway may be more relevant in the 
regulation of chronic vascular inflammation in the presence of cardiovascular disease.  
Consequently, inhibition of the CYP "-hydroxylase pathway may be an effective anti-
inflammatory strategy in models of vascular inflammation driven by overproduction of 20-
HETE.  For example, inhibition of the putative 20-HETE receptor lowered blood 
pressure, attenuated NF-!B activation, and improved endothelial function in a model of 
androgen-induced hypertension, which is mediated by elevated 20-HETE biosynthesis 
[12].  Thus, future studies investigating the therapeutic effect of inhibiting the CYP "-
hydroxylase pathway in other models of 20-HETE-dependent vascular inflammation are 
warranted. 
Chronic exposure to LPS has been associated with cardiovascular disease risk in 
humans [13]; however, the doses of LPS used in Chapters II and III are supra-
physiologic and stimulate an acute inflammatory response which more closely models 
septic shock, rather than the chronic inflammatory process that is observed in 
atherosclerosis.  Consequently, we also sought to evaluate the functional balance 
between the CYP epoxygenase and "-hydroxylase pathways in a model more relevant 
to cardiovascular disease, specifically high fat diet-induced metabolic syndrome 
(Chapter IV).  High fat diet-induced metabolic dysfunction suppressed hepatic CYP 
epoxygenase metabolic activity and induced renal CYP "-hydroxylase metabolic 
activity, thereby shifting the functional balance in favor of 20-HETE in both tissues.  Of 
note, alterations in CYP-mediated eicosanoid metabolism were apparent after only two 
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weeks of high fat diet, suggesting that the shift in the functional balance toward the CYP 
!-hydroxylase pathway contributes to the pathophysiologic consequences of long-term 
high fat diet feeding, such as insulin resistance, steatohepatitis, hypertension, and renal 
injury [14,15,16,17].  Thus, studies seeking to evaluate the therapeutic utility of 
modulating the CYP epoxygenase and !-hydroxylase pathways to increase EETs or 
decrease 20-HETE are warranted.  
Interestingly, enalapril reversed the high fat diet-induced alterations in hepatic 
CYP epoxygenase and renal CYP !-hydroxylase metabolic activity and restored the 
functional balance between the pathways, suggesting that the renin-angiotensin system 
regulates CYP-mediated eicosanoid metabolism in the presence of metabolic syndrome.  
Although we did not directly demonstrate that angiotensin II suppresses hepatic CYP 
epoxygenase metabolic activity and induces renal CYP !-hydroxylase metabolic activity, 
our findings, taken together with prior observations that angiotensin II regulates CYP-
mediated eicosanoid metabolism [18,19,20], strongly implicate angiotensin II in 
mediating the observed high fat diet-induced alterations in CYP-mediated eicosanoid 
metabolism.  A recent study has demonstrated that 20-HETE stimulates expression of 
ACE and the angiotensin II receptor [21], suggesting that 20-HETE may promote chronic 
vascular inflammation via renin-angiotensin system activation.  Further investigation of 
the interplay between the renin-angiotensin system and CYP-mediated eicosanoid 
metabolism is warranted.   
The studies described in Chapters II and IV demonstrate that systemic 
inflammation and high fat diet-induced metabolic syndrome alter CYP-mediated 
eicosanoid metabolism in mice.  However, few studies have directly measured CYP-
derived eicosanoids in humans, and the clinical factors that are associated with CYP 
epoxygenase, sEH, and CYP !-hydroxylase function in patients with established 
coronary artery disease (CAD) have not been described.  Therefore, we quantified 
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plasma levels of EETs, DHETs, and 20-HETE in a well-treated cohort of CAD patients 
and healthy individuals without risk factors for cardiovascular disease (Chapter V).  
Compared to healthy volunteers, CAD patients exhibited higher plasma EETs, lower 
plasma DHETs, and higher epoxide:diol ratios, indicative of lower sEH activity.  Further 
studies are needed to elucidate the mechanism underlying the observed suppression of 
sEH activity in CAD patients.  
Understanding the clinical factors that influence CYP-mediated eicosanoid 
metabolism may help identify subsets of the population that would derive the greatest 
benefit from therapies that modulate these pathways.  Although we identified several 
covariates that were associated with CYP epoxygenase and !-hydroxylase pathway 
function in CAD patients, our analysis was not comprehensive.  For example, we were 
unable to evaluate the effects of aspirin, statins, and beta-blockers on CYP-mediated 
eicosanoid metabolism due to the high use of these medications in CAD patients.  
Moreover, many of the clinical characteristics in CAD patients, such as serum lipid levels 
and blood pressure values, were influenced by drug therapy.  Future studies designed to 
characterize the effects of these clinical factors on CYP epoxygenase and !-
hydroxylase pathway function remain necessary. 
Although preclinical studies suggest that potentiation of CYP epoxygenase-
derived EETs and inhibition of CYP !-hydroxylase-derived 20-HETE may attenuate 
vascular inflammation and improve outcomes in CAD patients, investigation of this 
therapeutic strategy in humans has been limited by the lack of approved pharmacologic 
agents that specifically modulate CYP-mediated eicosanoid metabolism.  Therefore, we 
evaluated the association between functional genetic variants in the CYP epoxygenases 
(CYP2J2, CYP2C8), sEH (EPHX2), and the CYP !-hydroxylases (CYP4A11, CYP4F2) 
and survival in ACS patients in order to explore the effect of alterations in CYP-mediated 
eicosanoid metabolism on outcomes in patients with established CAD (Chapter VI).  
! "#$!
Consistent with our hypothesis, the EPHX2 Arg55 and CYP4F2 Met433 polymorphisms 
were associated with higher mortality in ACS patients.  In contrast, the CYP2J2 -50T 
variant allele was associated with lower mortality.  Additional studies are necessary to 
validate these relationships, as well as characterize the mechanism(s) underlying the 
observed associations.  Our results suggest that alterations in CYP-mediated eicosanoid 
metabolism influence prognosis in patients with established CAD, and support the 
development of drugs which specifically target the CYP epoxygenase and !-
hydroxylase pathways as a treatment strategy for atherosclerosis.   
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